Base editors and their construction methods and applications

By mutation screening of adenosine deaminase TadA-8e, new ABE, CBE and ACBE tools were constructed, solving the shortcomings of existing tools in terms of edit specificity, accuracy and volume, and achieving higher edit specificity and lower risk of off-targeting of RNA/DNA, improve the safety and application value of genome editing.

CN114045277BActive Publication Date: 2024-11-05FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111226226.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-10-21
Publication Date
2024-11-05
Estimated Expiration
2041-10-21

AI Technical Summary

Technical Problem

The existing ABE, CBE and ACBE tools have shortcomings in edit specificity, accuracy and volume, which limits their application prospects. In particular, the ability of ABE tools to mediate C·G--T·A mutations has reduced their specificity and Accuracy, the types of deaminases of CBE tools are limited, the ACBE tools are too large and the risk of RNA/DNA off-targeting is high.

Method used

By performing saturation mutation screening or systematic screening of the adenosine deaminase TadA-8e from E. coli-derived adenosine deaminase, new ABE, CBE and ACBE tools are constructed to reduce or eliminate the C·G--T·A mutation ability of the ABE tools and enhance the Its RNA/DNA off-target risk and reduces the volume of ACBE, improving its base editing accuracy and specificity.

Benefits of technology

ABE tools with higher edit specificity and low risk of RNA/DNA off-targeting, and CBE and ACBE tools with high editing accuracy and smaller size have been developed, which has improved the safety and application value of genome editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114045277B_ABST
    Figure CN114045277B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of gene editing technology, and in particular to a base editor and a construction method and application thereof, for mutation of specific bases at specific sites at the DNA level. The present invention constructs an ABE with higher editing specificity and low RNA / DNA off-target risk, a CBE with high editing accuracy and low RNA / DNA off-target risk, and a smaller ACBE tool. The ABE tool developed in the present invention has higher specificity when mediating A·T‑‑G·C mutations, and its ability to mediate C·G‑‑T·A mutations is significantly inhibited or even eliminated, and the off-target effects at the RNA and DNA levels are significantly reduced or even eliminated; the CBE tool developed in the present invention has higher accuracy when mediating C·G‑‑T·A mutations, and the off-target effects at the RNA and DNA levels are significantly reduced or even eliminated; the ACBE tool developed in the present invention only requires a single deaminase, is smaller in size, and has significantly reduced or even eliminated off-target effects at the RNA and DNA levels, and has higher application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene editing technology, and in particular to a base editor and a method for constructing the same. Background Art

[0002] The new gene editing technology represented by CRISPR / Cas9 has brought changes to biomedical research. This technology makes efficient and accurate gene editing possible. Since 2016, researchers have developed a variety of DNA base editing tools that can efficiently induce precise point mutations at the DNA level, and no DNA double-strand breaks will occur in the process. There are many types of base editors that have been reported, of which the two most important are cytosine base editors (CBE, which can mediate C·G--T·A mutations) and adenine base editors (ABE, which can mediate A·T--G·C mutations). Among them, CBE is a fusion of a specific cytidine deaminase with a mutant nuclease (such as spCas9 carrying D10A or mutations, called nspCas9) and a uracil glycosylase inhibitor (UGI). The resulting fusion protein can mediate C·G--T·A mutations under the guidance of sgRNA. ABE fuses the directed-evolved Escherichia coli-derived adenosine deaminase (ecTadA*) dimer or monomer with a mutant nuclease (such as spCas9 carrying D10A or mutation, called nCas9). The resulting fusion protein can mediate A·T--G·C mutation under the guidance of sgRNA. Based on ABE and CBE, the researchers also fused a specific cytidine deaminase, a directed-evolved adenosine deaminase from Escherichia coli (ecTadA*), a mutant nuclease (such as spCas9 carrying D10A or mutation, called nCas9), and a uracil glycosylase inhibitor (UGI) to construct ACBE. The resulting fusion protein can mediate the simultaneous occurrence of C·G--T·A mutation and A·T--G·C mutation in specific sites under the guidance of sgRNA (Nat Biotechnol, 2020.38(7):861-864; BMC Biol, 2020.18(1):131; Nat Biotechnol, 2020.38(7):856-860; Nat Biotechnol, 2020.38(7):865-869). Existing ABE, CBE and ACBE tools still have shortcomings, which limits their application prospects.

[0003] In addition to A·T--G·C mutations, existing ABE tools can also mediate C·G--T·A mutations to a certain extent, which reduces the specificity and accuracy of ABE editing and is not conducive to the application of ABE (Nat Biotechnol, 2021 (https: / / doi.org / 10.1038 / s41587-021-00943-2); Nat Biotechnol, 2019.37(10):1145-1148; Nat Commun, 2020.11(1):5827). Although some researchers have constructed CBE tools that can specifically mediate TC-TT mutations through point mutations based on the characteristics of ABE tools that can mediate C·G--T·A mutations, their activity is very low and their application scenarios are limited (Nat Biotechnol, 2021, https: / / doi.org / 10.1038 / s41587-021-00943-2). In addition, the deaminases currently suitable for ABE construction are all derived from the directed evolution of Escherichia coli-derived adenosine deaminase (ecTadA*), and the types of deaminases are very limited, which also limits the diversity of ABE base editing characteristics and is not conducive to the application and promotion of tools. In addition, there is currently a lack of ABE tools that can coordinately optimize multiple aspects such as RNA / DNA off-target effects and editing accuracy.

[0004] The deaminases in existing CBE tools all belong to the cytidine deaminase family. This type of tool currently has a series of problems in base editing accuracy (activity window specificity), RNA off-target effects, and DNA off-target effects. There is still a lack of CBE tools that can synergistically optimize multiple aspects such as RNA / DNA off-target effects and editing accuracy (Nat Biotechnol, 2020. 38(5): 620-628; Nat Commun, 2020. 11(1): 2052; Nat Methods, 2020. 17(6): 600-604).

[0005] Existing ACBE tools require the simultaneous fusion of two deaminases (cytidine deaminase and directed-evolved adenosine deaminase from Escherichia coli (ecTadA*)) on nCas9, which makes the ACBE tool too large and not conducive to application (Nat Biotechnol, 2020.38(7):861-864; BMC Biol, 2020.18(1):131; Nat Biotechnol, 2020.38(7):856-860; Nat Biotechnol, 2020.38(7):865-869). Summary of the invention

[0006] In order to optimize the deficiencies of base editors ABE, CBE and ACBE, and to develop ABE with higher editing specificity and low RNA / DNA off-target risk, CBE with high editing accuracy and low RNA / DNA off-target risk, and smaller ACBE tools, the purpose of the present invention is to provide a new base editor and a construction method and application thereof, which are used for mutation of specific bases at specific sites at the DNA level.

[0007] It can achieve the conversion of C·G base pairs to T·A base pairs at specific sites on the DNA level (C·G--T·A mutation, CBE), the mutation of A·T base pairs to G·C base pairs (A·T--G·C mutation, ABE), or simultaneously achieve the conversion of C·G base pairs to T·A base pairs and A·T base pairs to G·C base pairs at specific sites (C·G--T·A and A·T--G·C simultaneous mutation, ACBE).

[0008] The present invention provides a new method for constructing an adenine base editor (ABE), a cytosine base editor (CBE) and an ACBE, so as to develop an ABE with higher editing specificity and lower RNA / DNA off-target risk, a CBE with higher editing accuracy and lower RNA / DNA off-target risk, and an ACBE tool with smaller size.

[0009] The basic principle of the present invention is to perform saturation mutation screening on key amino acid sites of adenosine deaminase (TadA-8e) from Escherichia coli after directed evolution (Nat Biotechnol, 2020.38(7):883-891). Finally, through specific point mutations or point mutation combinations, the construction of ABE, CBE and ACBE and the conversion between various base editors are realized; or mutations and systematic screening are performed on various adenosine deaminase (TadA) in nature to find new functional TadA and construct diversified ABE, CBE and ACBE.

[0010] After directed protein evolution, adenosine deaminase (ecTadA) from Escherichia coli (called ecTadA* after evolution) has the ability to deaminate adenine (A) in single-stranded DNA and achieve A·T--G·C mutation. The base editor ABE constructed on this basis can achieve A·T--G·C mutation in the target site of the genome. The researchers also found that under certain conditions, ABE can deaminate cytosine (C) in single-stranded DNA, and to a certain extent can also mediate C·G--T·A mutation, and has certain CBE functions. This ability to mediate C·G--T·A mutations increases the off-target risk of ABE tools (Nat Biotechnol, 2019.37(10):1145-1148; Nat Commun, 2020.11(1):5827). Therefore, saturation mutation screening of specific sites of adenosine deaminase (TadA) or point mutation and systematic screening of naturally occurring adenosine deaminase (TadA) can construct new ABEs, CBEs, and ACBEs. Specific point mutations or combinations of point mutations can achieve the following goals:

[0011] (1) Reduce or eliminate the ability of ABE tools to mediate C·G--T·A mutations, improve RNA off-target effects and DNA off-target effects, and enhance their safety;

[0012] (2) Convert ABE to CBE to obtain new CBE tools, which have new features different from existing tools in terms of base editing accuracy (activity window specificity), RNA off-target effects, and DNA off-target effects;

[0013] (3) Convert ABE into ACBE and construct a new type of ACBE using a single deaminase to reduce the size of ACBE and improve its base editing accuracy (activity window specificity), RNA off-target effect, and DNA off-target effect.

[0014] After systematic research and saturation screening, the inventors discovered for the first time that one or more mutations in the amino acids at positions 28, 30, 46, 48, 49, 82, 84, 108, 110 or 111 in the deaminase TadA-8e have a significant effect on the deamination activity and base preference of TadA-8e. Different types of point mutations, or a combination of multiple point mutations, can significantly change the properties of the ABE tool based on TadA-8e. Through different point mutations at specific amino acid sites, or a combination of point mutations at multiple amino acid sites, ABE with higher editing specificity, CBE with high editing accuracy and low RNA / DNA off-target risk, and ACBE tools with smaller size are finally obtained, and the present invention is finally completed.

[0015] The purpose of the present invention can be achieved by the following technical solutions:

[0016] The first object of the present invention is to provide a base editor, which is a fusion protein formed by fusing a mutant TadA-8e to the N-terminus, C-terminus or internal fusion site of a Cas nuclease;

[0017] Mutant TadA-8e refers to a deaminase in which one or more amino acids are mutated at a distance of less than 5 angstroms from the adenine (A) analogue 8-azanebularine (8Az) in TadA-8e, and in particular, refers to a deaminase in which one or more amino acids are mutated at positions 28, 30, 46, 48, 49, 82, 84, 108, 110 or 111 in TadA-8e;

[0018] The amino acid sequence of TadA-8e is shown in SEQ ID NO.1.

[0019] In one embodiment of the present invention, the Cas nuclease is selected from the Cas9, Cas12, and Cas13 protein families; preferably, the Cas nuclease is selected from nSpCas9 and its mutants, SaCas9 and its mutants, Cas12a and its mutants, or Cas12f and its mutants, preferably nSpCas9.

[0020] In one embodiment of the present invention, the mutant TadA-8e refers to a deaminase obtained after one of the amino acids at the amino acid positions 28, 30, 46, 48, 49, 82, 84, 108, 110 or 111 in TadA-8e is mutated to one of the other 19 amino acids different from the original amino acid at the position;

[0021] Preferably, the mutant TadA-8e refers to a deaminase obtained by performing the following single-point mutations on the amino acids in TadA-8e: V28W, V28G, N46L, N46P, N46C, A48C, A48G, A48N, A48S, I49D, I49E, I49H, I49N, I49P, I49Q, I49V, I49W, I49Y, I49R, I49A, I49T, I49G, I49L, I49 S, I49M, I49C, I49F, I49K, V82G, V82A, V82T, V82C, V82S, V82D, F84M, N108H, N108M, N108C, N108D , N108F, N108Q, N108S, N108Y, V28A, V28D, V28E, V28K, V28M, V28R, V28L, V28Q, V30A, V30D, V30G, V 30W, V30E, V30N, V30Q, V30Y, V30T, V30S, N46H, N46K, N46Y, N46F, N46E, N46Q, N46D, N46G, N46M, N 46V, N46S, N46T, A48D, A48E, A48Y, A48W, A48F, A48Q, V82F, F84D, F84R, F84A, F84E, F84P, F84K, F8 4C, F84H, F84I, F84S, F84T, F84V, F84Q, F84N, F84G, F84Y, N108V, N108I, N108L, N108A, N108T, N10 8R, K110D, K110W, K110E, R111P, R111E, R111T, R111A, R111V, R111G, R111I, R111W, R111L, R111D.

[0022] In the above-mentioned expressions similar to “V28W”, 28 indicates the 28th amino acid site in TadA-8e, V indicates the amino acid before the 28th amino acid site in TadA-8e is mutated, and W indicates the amino acid after the 28th amino acid site in TadA-8e is mutated. V and W are abbreviations of amino acids, i.e., V28W indicates that the 28th amino acid site is mutated from valine to tryptophan; other expressions similar to “V28W” above or below are interpreted similarly, i.e., N46L indicates that the 46th amino acid site is mutated from asparagine to leucine.

[0023] The base editor obtained by the above single point mutation mediates C·G--T·A mutation.

[0024] In one embodiment of the present invention, the mutant TadA-8e refers to a deaminase obtained by performing the following double-point mutations on the amino acids in TadA-8e:

[0025] (1) a deaminase in which the amino acid at amino acid position 28 is mutated and one of the amino acids at positions 46, 48, 49, 82, 84, 108, 110 or 111 is mutated, or

[0026] (2) a deaminase in which the amino acid at position 46 is mutated and one of the amino acids at positions 28, 82, 84, and 108 is mutated, or

[0027] (3) a deaminase in which the amino acids at positions 48 and 108 are simultaneously mutated, or

[0028] (4) a deaminase in which the amino acid at position 49 is mutated and one of the amino acids at positions 82, 84, or 108 is mutated, or

[0029] (5) A deaminase in which the amino acid at amino acid position 108 is mutated and at the same time one of the amino acids at position 82 or 84 is mutated.

[0030] Preferably, the mutant TadA-8e refers to a deaminase obtained by performing the following double-point mutations on the amino acids in TadA-8e:

[0031] V28G-N108Y, V28G-N108C, V28G-N108H, V28G-N46L, V28G-N46C, V28G-N46P, V28W-N46L, V28W-N 46C, V28W-N46P, N46P-N108Y, N46P-N108S, N46P-N108Q, N46P-N108D, N46P-N108C, N46P-N108H , N46P-F84M, N46P-I49A, N46P-I49G, N46P-A48G, N46C-N108Y, N46C-N108S, N46C-N108Q, N46C- N108M, N46C-N108C, N46C-N108H, N46L-N108Y, N46L-N108Q, N46L-N108D, N46L-N108M, N46L-N1 08H, N46L-F84M, N46L-I49A, N46L-I49G, N46L-V82G, I49A-N108Y, V28G-A48G, V28G-I49A, V28G -I49G, V28G-V82T, V28G-F84Y, V28W-N108H, N46C-V82G, N46C-V82T, N46C-F84M, N46L-V82T, N4 6P-F84M, N46P-N108M, A48G-N108H, I49A-N108H, I49G-N108H, I49G-N108Y, I49G-V82G, I49G-V 82T, I49G-F84Y, V82G-N108Y, V82T-N108H, V82T-N108C, F84M-N108H, F84M-N108M, F84M-N108Q.

[0032] The V28G-N46C indicates that the 28th amino acid site is mutated from valine to glycine and the 46th amino acid site is changed from asparagine to cysteine. Other similar expressions above or below shall be interpreted similarly.

[0033] The base editor obtained by the above double point mutation mediates C·G--T·A mutation.

[0034] In one embodiment of the present invention, the mutant TadA-8e refers to a deaminase obtained by performing the following three point mutations on the amino acids in TadA-8e:

[0035] (1) a deaminase in which the amino acids at positions 28, 48 and 49 are simultaneously mutated, or

[0036] (2) a deaminase in which the amino acids at positions 28, 48 and 82 are simultaneously mutated, or

[0037] (3) a deaminase in which the amino acids at positions 28, 48 and 108 are simultaneously mutated, or

[0038] (4) a deaminase in which the amino acids at positions 28, 49 and 82 are simultaneously mutated, or

[0039] (5) a deaminase in which the amino acids at positions 28, 49 and 108 are simultaneously mutated, or

[0040] (6) deaminase in which the amino acids at positions 49, 82, and 108 are simultaneously mutated;

[0041] Preferably, the mutant TadA-8e refers to a deaminase obtained by performing the following three point mutations on the amino acids in TadA-8e:

[0042] I49A-V82T-N108Y, I49A-V82G1-N08Y, I49G-V82T-N108Y, I49G-V82G-N108Y, A48G-V82G-N108Y, A48G-I49G-N108 Y, V28G-V82G-N108Y, V28G-V82G-N108H, V28G-I49A-N108Y, V28G-I49A-N108H, V28G-I49G-N108H, V28G-A48G-N1 08Y, V28G-A48G-N108H, V28G-A48G-I49G, V28G-A48G-I49A, V28G-A48G-V82G, V28G-A48G-V82T, V28G-I49G-V82G , V28G-I49G-V82T, V28G-I49G-N108Y, V28G-I49A-V82G, V28G-I49A-V82T, I49G-V82G-N108H, I49G-V82T-N108H.

[0043] The V28G-A48G-I49G indicates that the 28th amino acid site mutates from valine to glycine, the 48th amino acid site mutates from alanine to glycine, and the 49th amino acid site mutates from isoleucine to glycine. Other similar expressions above or below shall be interpreted similarly.

[0044] The base editor obtained by the above three-point mutation mediates C·G--T·A mutation.

[0045] In one embodiment of the present invention, the mutant TadA-8e refers to a deaminase in which the amino acid at amino acid position 108 of TadA-8e is mutated and three other sites at amino acid positions 28, 48, 49, and 82 of TadA-8e are mutated;

[0046] Preferably, the mutant TadA-8e refers to a deaminase in which the amino acid position 108 of TadA-8e is mutated to N108Y or N108H, and three other positions of the amino acid positions 28, 48, 49, and 82 of TadA-8e are mutated as follows:

[0047] The amino acid position 28 in TadA-8e was mutated to V28G,

[0048] The amino acid position 48 in TadA-8e was mutated to A48G.

[0049] The amino acid position 49 in TadA-8e was mutated to I49A or I49G.

[0050] The amino acid position 82 in TadA-8e was mutated to V82T or V82G.

[0051] The V28G-I49G-V82T-N108Y indicates that the 28th amino acid mutates from valine to glycine, the 49th amino acid mutates from isoleucine to glycine, the 82nd amino acid mutates from valine to threonine, and the 108th amino acid mutates from asparagine to tyrosine. Other similar expressions above or below shall be interpreted similarly.

[0052] The base editor obtained by the above four-point mutation mediates C·G--T·A mutation.

[0053] In one embodiment of the present invention, the mutant TadA-8e refers to a deaminase in which the amino acids at positions 28, 48, 49, 82, and 108 of TadA-8e are simultaneously mutated;

[0054] Preferably, the mutant TadA-8e refers to a deaminase obtained by subjecting the amino acids in TadA-8e to the following five mutations:

[0055] While the amino acid position 108 in TadA-8e is mutated to N108Y or N108H, the amino acid positions 28, 48, 49, and 82 in TadA-8e are also mutated to the following deaminase;

[0056] The amino acid position 28 in TadA-8e was mutated to V28G,

[0057] The amino acid position 48 in TadA-8e was mutated to A48G.

[0058] The amino acid position 49 in TadA-8e was mutated to I49A or I49G.

[0059] The amino acid position 82 in TadA-8e was mutated to V82T or V82G.

[0060] The V28G-A48G-I49G-V82T-N108H means that the 28th amino acid mutates from valine to glycine, the 48th amino acid mutates from alanine to glycine, the 49th amino acid mutates from isoleucine to glycine, the 82nd amino acid mutates from valine to threonine, and the 108th amino acid mutates from asparagine to histidine. Other similar expressions above or below shall be interpreted similarly.

[0061] The base editor obtained by the above five-point mutation mediates C·G--T·A mutation.

[0062] In one embodiment of the present invention, various variants with different sequences are added to the 5' and 3' of the mutant TadA-8e and then placed at the N-terminus, C-terminus or internal fusion site of the Cas nuclease to form a fusion protein;

[0063] Preferably, after adding NLS sequence and linker sequence to 5' and 3' of mutant TadA-8e, respectively, NLS-mutant TadA-8e-linker is obtained, and NLS-mutant TadA-8e-linker is placed at the N-terminus, C-terminus or internal fusion site of Cas nuclease to form a fusion protein;

[0064] Wherein, NLS-mutant TadA-8e-linker means that one or more amino acids in TadA-8e are mutated relative to NLS-TadA-8e-linker, the amino acid sequence of NLS-TadA-8e-linker is shown in SEQ ID NO.4, and the amino acid sequence of NLS-mutant TadA-8e-linker is the amino acid sequence obtained by replacing TadA-8e with mutant TadA-8e in the amino acid sequence of NLS-TadA-8e-linker. The NLS sequence is PKKKRKV, and the linker sequence is SGGSSGGSSGSETPGTSESATPESSGGSSGGSSR.

[0065] In one embodiment of the present invention, when the Cas nuclease is selected as nSpCas9, the fusion sites inside the nSpCas9 include fusion sites 113, 203, 312, 459, 535, 583, 687, 701, 715, 730, 770, 793, 801, 895, 905, 919, 946, 1010, 1029, 1047, 1117, 1154, 1249, and 1282;

[0066] The preferred fusion site is position 1249.

[0067] The second object of the present invention is to provide a base editor, wherein an NLS sequence and a linker sequence are added to the 5' and 3' of TadA-8e to obtain an NLS-TadA-8e-linker, and the NLS-TadA-8e-linker is placed at the N-terminus, C-terminus or internal fusion site of the Cas nuclease to form a fusion protein;

[0068] The amino acid sequence of NLS-TadA-8e-linker is shown in SEQ ID NO.4;

[0069] The Cas nuclease is selected from the Cas9, Cas12, and Cas13 protein families. Preferably, the Cas nuclease is selected from nSpCas9 and its mutants, SaCas9 and its mutants, Cas12a and its mutants, or Cas12f and its mutants, and is further preferably nSpCas9.

[0070] In one embodiment of the present invention, when the Cas nuclease is selected as nSpCas9, the fusion sites inside the nSpCas9 include fusion sites 113, 203, 312, 459, 535, 583, 687, 701, 715, 730, 770, 793, 801, 895, 905, 919, 946, 1010, 1029, 1047, 1117, 1154, 1249, and 1282;

[0071] The preferred fusion site is position 1249.

[0072] The third object of the present invention is to provide a base editor, which is a fusion protein formed by fusing a mutant TadA-X to the N-terminus, C-terminus or internal fusion site of a Cas nuclease;

[0073] Mutant TadA-X refers to a deaminase in which the 106th and 108th homologous amino acids in TadA-X are mutated to valine and asparagine, respectively;

[0074] TadA-X refers to TadA from different sources; preferably, there are multiple groups of TadA-X, and the amino acid sequences of the mutants thereof are shown in any one of SEQ ID NO.5 to SEQ ID NO.57;

[0075] The Cas nuclease is selected from the Cas9, Cas12, and Cas13 protein families. Preferably, the Cas nuclease is selected from nSpCas9 and its mutants, SaCas9 and its mutants, Cas12a and its mutants, or Cas12f and its mutants, and is further preferably nSpCas9.

[0076] In one embodiment of the present invention, the mutant TadA-X refers to a deaminase in which the amino acids homologous to the 106th and 108th amino acids of ecTadA in Q2LYC0, F2G306, G0JN58, B5ZCW4, Q1AS41, E4TTF3, Q57LE3, Q99W51, ecTadA are mutated to valine and asparagine, respectively;

[0077] The amino acid sequences of Q2LYC0, F2G306, G0JN58, B5ZCW4, Q1AS41, E4TTF3, Q57LE3, Q99W51 or ecTadA mutants are SEQ ID NO.8, SEQ ID NO.14, SEQ ID NO.20, SEQ ID NO.22, SEQ ID NO.27, SEQ ID NO.43, SEQ ID NO.54, SEQ ID NO.55, and SEQ ID NO.58, respectively.

[0078] The base editor obtained above mediates A·T--G·C mutation.

[0079] In one embodiment of the present invention, the mutant TadA-X refers to a deaminase in which the amino acids 106 and 108 homologous to ecTadA in B3PCY2, A5WFT9, C1DXN9, B2UR34, R4K908, D5W8R4, and E1TAF4 are mutated to valine and asparagine, respectively;

[0080] The amino acid sequences of B3PCY2, A5WFT9, C1DXN9, B2UR34, R4K908, D5W8R4, and E1TAF4 mutants are SEQ ID NO.15, SEQ ID NO.19, SEQ ID NO.29, SEQ ID NO.32, SEQ ID NO.44, SEQ ID NO.49, and SEQ ID NO.57, respectively.

[0081] The base editor obtained above mediates C·G--T·A mutation.

[0082] In an embodiment of the present invention, mutant TadA-X refers to a deaminase in which the amino acids homologous to ecTadA 106 and 108 are mutated to valine and asparagine, respectively, at Q13XZ4, A8F050, E8WVH3, P44931, G0EXN4, E0TBL5, A1W869, D5X1Y1, and I3YB54;

[0083] The amino acid sequences of the Q13XZ4, A8F050, E8WVH3, P44931, G0EXN4, E0TBL5, A1W869, D5X1Y1, and I3YB54 mutants are SEQ ID NO.10, SEQ ID NO.18, SEQ ID NO.25, SEQ ID NO.28, SEQ ID NO.38, SEQ ID NO.46, SEQ ID NO.48, SEQ ID NO.50, and SEQ ID NO.53, respectively.

[0084] The base editors obtained above mediate A·T--G·C and C·G--T·A mutations.

[0085] In an embodiment of the present invention, an NLS sequence and a linker sequence are added to the 5' and 3' of the mutant TadA-X to obtain an NLS-mutant TadA-X-linker, and the NLS-mutant TadA-X-linker is placed at the N-terminus, C-terminus or internal fusion site of the Cas nuclease to form a fusion protein;

[0086] Among them, NLS-mutant TadA-X-linker means that TadA-8e is replaced by mutant TadA-X relative to NLS-TadA-8e-linker, and the amino acid sequence of NLS-TadA-8e-linker is shown in SEQ ID NO.4.

[0087] In an embodiment of the present invention, when the Cas nuclease is selected as nSpCas9, the fusion sites inside the nSpCas9 include fusion sites 113, 203, 312, 459, 535, 583, 687, 701, 715, 730, 770, 793, 801, 895, 905, 919, 946, 1010, 1029, 1047, 1117, 1154, 1249, and 1282;

[0088] The preferred fusion site is position 1249.

[0089] A fourth object of the present invention is to provide a method for constructing a base editor, characterized in that it comprises the following steps:

[0090] The base editors were constructed by fusing TadA-8e, mutant TadA-8e or mutant TadA-X to Cas nuclease at different sites;

[0091] The amino acid sequence of TadA-8e is shown in SEQ ID NO.1;

[0092] Mutant TadA-8e refers to a deaminase in which one or more of the amino acids at positions 28, 30, 46, 48, 49, 82, 84, 108, 110 or 111 in TadA-8e are mutated;

[0093] The mutant TadA-X refers to a deaminase in which the amino acids 106 and 108 homologous to ecTadA in TadA-X are mutated to valine and asparagine, respectively; there are multiple groups of TadA-X, and the amino acid sequences of the mutants are shown in any one of SEQ ID NO.5-SEQID NO.57.

[0094] In one embodiment of the present invention, NLS sequence and linker sequence may be added to the 5' and 3' ends of TadA-8e, mutant TadA-8e or mutant TadA-X, respectively.

[0095] A fifth object of the present invention is to provide an application of a base editor ABE, wherein the base editor ABE mediates A·T--G·C mutation;

[0096] Base editor ABE refers to a fusion protein formed by Q2LYC0, F2G306, G0JN58, B5ZCW4, Q1AS41, E4TTF3, Q57LE3, Q99W51, ecTadA and the 106th and 108th homologous amino acids of ecTadA being mutated to valine and asparagine respectively, and then being fused to the N-terminus and the 1249th fusion site of nSpCas9, wherein the amino acid sequences of Q2LYC0, F2G306, G0JN58, B5ZCW4, Q1AS41, E4TTF3, Q57LE3, Q99W51 or ecTadA mutants are SEQ ID NO.8, SEQ ID NO.14, SEQ ID NO.20, SEQ ID NO.22, SEQ ID NO.27, SEQ ID NO.43, SEQ ID NO.54, SEQ ID NO.55, and SEQ ID NO.58 respectively;

[0097] Base editor ABE also refers to a fusion protein formed by the following single point mutation or combination of point mutations in amino acids in TadA-8e, in which the deaminase is placed at the N-terminus of nSpCas9 and the 1249th fusion site. This type of fusion protein only has the obvious ability to mediate A·T--G·C mutations.

[0098] The sixth object of the present invention is to provide an application of a base editor CBE, wherein the base editor CBE mediates C·G--T·A mutation;

[0099] Base editor CBE refers to a fusion protein formed by mutating the amino acids homologous to positions 106 and 108 of B3PCY2, A5WFT9, C1DXN9, B2UR34, R4K908, D5W8R4, E1TAF4 and ecTadA to valine and asparagine, respectively, and then fused to the N-terminus and the 1249th fusion site of nSpCas9, wherein the amino acid sequences of the mutants of B3PCY2, A5WFT9, C1DXN9, B2UR34, R4K908, D5W8R4, and E1TAF4 are SEQ ID NO.15, SEQ ID NO.19, SEQ ID NO.29, SEQ ID NO.32, SEQ ID NO.44, SEQ ID NO.49, and SEQ ID NO.57, respectively;

[0100] Base editor CBE also refers to a fusion protein formed by fusion of the deaminase obtained by the following mutation of the amino acid in TadA-8e to the N-terminus of nSpCas9 and the 1249th fusion site,

[0101] Single point mutation: N46P

[0102] Double point mutations: V28G-N108Y, V28G-N108C, V28G-N108H, V28G-N46L, V28G-N46C, V28G-N46P, V28W-N46L, V28W-N46C, V28W-N46P, N46P-N108Y, N46P-N108S, N46P-N108Q, N46P-N108D, N46P-N108C, N46P-N108H, N46P-F84M, N46P-I49A, N46 P-I49G, N46P-A48G, N46C-N108Y, N46C-N108S, N46C-N108Q, N46C-N108M, N46C-N108C, N46C-N108H, N46L-N108Y, N46L-N108Q, N46L-N108D, N46L-N108M, N46L-N108H, N46L-F84M, N46L-I49A, N46L-I49G, N46L-V82G, I49A-N108Y

[0103] Three point mutations: I49A-V82T-N108Y, I49A-V82G1-N08Y, I49G-V82T-N108Y, I49G-V82G-N108Y, A48G-V82G-N108Y, A48G-I49G-N108Y, V28G-V82G-N108Y, V28G-V82G-N108H, V28G-I49A-N108Y, V28G-I49A-N108H, V28G-I49G-N108H, V28G-A48G-N108Y, V28G-A48G-N108H;

[0104] Four point mutations: V28G-A48G-I49A-N108Y, V28G-A48G-I49G-N108Y, V28G-A48G-V82T-N108Y, V28G-A48G-V82G-N108Y, V28G-I49A-V82T-N108Y, V28G-I49A-V82G-N1 08Y, V28G-I49G-V82T-N108Y, V28G-I49G-V82G-N108Y, A48G-I49A-V82T-N1 08Y, A48G-I49A-V82G-N108Y, A48G-I49G-V82T-N108Y, A48G-I49G-V82G-N10 8Y, V28G-A48G-I49A-N108H, V28G-A48G-I49G-N108H, V28G-A48G-V82T-N10 8H, V28G-A48G-V82G-N108H, V28G-I49A-V82T-N108H, V28G-I49A-V82G-N108 H. V28G-I49G-V82T-N108H, V28G-I49G-V82G-N108H, A48G-I49A-V82T-N108H , A48G-I49A-V82G-N108H, A48G-I49G-V82T-N108H, A48G-I49G-V82G-N108H.

[0105] Five point mutations: V28G-A48G-I49A-V82T-N108Y, V28G-A48G-I49 G-V82T-N108Y, V28G-A48G-I49A-V82G-N108Y, V28G-A48G-I49G-V82G-N108Y, V28G-A48G-I49G-V82G-N108Y, V28G-A48G-I49A-V82T-N108H, V28G-A48G-I49G-V82T-N108H, V28G-A48G-I49A-V82G-N108H, V28G-A48G-I49G-V82G-N108H.

[0106] The seventh object of the present invention is to provide an application of a base editor ACBE, wherein the base editor ACBE mediates A·T--G·C and C·G--T·A mutations;

[0107] Base editor ACBE refers to a fusion protein formed by the amino acids homologous to positions 106 and 108 of Q13XZ4, A8F050, E8WVH3, P44931, G0EXN4, E0TBL5, A1W869, D5X1Y1, and I3YB54 and ecTadA, which are mutated to valine and asparagine, respectively, and then placed at the N-terminus and the 1249th fusion site of nSpCas9, wherein the amino acid sequences of the mutants of Q13XZ4, A8F050, E8WVH3, P44931, G0EXN4, E0TBL5, A1W869, D5X1Y1, and I3YB54 are SEQ ID NO.10, SEQ ID NO.18, SEQ ID NO.25, SEQ ID NO.28, SEQ ID NO.38, SEQ ID NO.46, SEQ ID NO.48, SEQ ID NO.50, SEQ ID NO.53;

[0108] Base editor ACBE also refers to a fusion protein formed by fusion of the deaminase obtained by point mutation or combination of point mutations in amino acids in TadA-8e to the N-terminus of nSpCas9 and the 1249th fusion site. This type of fusion protein has the ability to mediate A·T--G·C and C·G--T·A mutations.

[0109] In a seventh aspect, the present invention provides a mutant TadA-8e protein, wherein the mutant protein is a non-natural protein, and the mutant TadA-8e protein refers to a deaminase in which one or more of the amino acids at positions 28, 30, 46, 48, 49, 82, 84, 108, 110 or 111 in TadA-8e are mutated;

[0110] Preferably, the mutant TadA-8e refers to a deaminase obtained by performing the following single-point mutation on the amino acid in TadA-8e:

[0111] V28W, V28G, N46L, N46P, N46C, A48C, A48G, A48N, A48S, I49D, I49E, I49H, I49N, I49P, I49Q, I49V, I49W, I49Y, I49R, I49A, I49T, I49G, I49L, I49S, I49M, I49C, I49F, I49K, V82G, V82A, V82T, V82C, V82S, V82D, F84M, N108H, N108M, N108C, N108D, N108F, N108Q, N108S, N108Y, V2 8A, V28D, V28E, V28K, V28M, V28R, V28L, V28Q, V30A, V30D, V30G, V30W, V30E, V30N, V30Q, V30 Y, V30T, V30S, N46H, N46K, N46Y, N46F, N46E, N46Q, N46D, N46G, N46M, N46V, N46S, N46T, A48 D. A48E, A48Y, A48W, A48F, A48Q, V82F, F84D, F84R, F84A, F84E, F84P, F84K, F84C, F84H, F84 I, F84S, F84T, F84V, F84Q, F84N, F84G, F84Y, N108V, N108I, N108L, N108A, N108T, N108R, K1 10D, K110W, K110E, R111P, R111E, R111T, R111A, R111V, R111G, R111I, R111W, R111L, R111D;

[0112] Alternatively, the mutant TadA-8e refers to a deaminase obtained by performing the following double-point mutations on the amino acids in TadA-8e:

[0113] V28G-N108Y, V28G-N108C, V28G-N108H, V28G-N46L, V28G-N46C, V28G-N46P, V28W-N46L, V28W-N 46C, V28W-N46P, N46P-N108Y, N46P-N108S, N46P-N108Q, N46P-N108D, N46P-N108C, N46P-N108H , N46P-F84M, N46P-I49A, N46P-I49G, N46P-A48G, N46C-N108Y, N46C-N108S, N46C-N108Q, N46C- N108M, N46C-N108C, N46C-N108H, N46L-N108Y, N46L-N108Q, N46L-N108D, N46L-N108M, N46L-N1 08H, N46L-F84M, N46L-I49A, N46L-I49G, N46L-V82G, I49A-N108Y, V28G-A48G, V28G-I49A, V28G -I49G, V28G-V82T, V28G-F84Y, V28W-N108H, N46C-V82G, N46C-V82T, N46C-F84M, N46L-V82T, N4 6P-F84M, N46P-N108M, A48G-N108H, I49A-N108H, I49G-N108H, I49G-N108Y, I49G-V82G, I49G-V 82T, I49G-F84Y, V82G-N108Y, V82T-N108H, V82T-N108C, F84M-N108H, F84M-N108M, F84M-N108Q;

[0114] Alternatively, the mutant TadA-8e refers to a deaminase obtained by performing the following three point mutations on the amino acids in TadA-8e:

[0115] I49A-V82T-N108Y, I49A-V82G1-N08Y, I49G-V82T-N108Y, I49G-V82G-N108Y, A48G-V82G-N108Y, A48G-I49G-N108 Y, V28G-V82G-N108Y, V28G-V82G-N108H, V28G-I49A-N108Y, V28G-I49A-N108H, V28G-I49G-N108H, V28G-A48G-N1 08Y, V28G-A48G-N108H, V28G-A48G-I49G, V28G-A48G-I49A, V28G-A48G-V82G, V28G-A48G-V82T, V28G-I49G-V82G , V28G-I49G-V82T, V28G-I49G-N108Y, V28G-I49A-V82G, V28G-I49A-V82T, I49G-V82G-N108H, I49G-V82T-N108H;

[0116] Or, the mutant TadA-8e refers to a deaminase obtained by performing the following four mutations on the amino acids in TadA-8e: V28G-A48G-I49A-N108Y, V28G-A48G-I49G-N108Y, V28G-A48G-V82T-N108Y, V28G-A48G-V82G-N108Y, V28G-I49A -V82T-N108Y, V28G-I49A-V82G-N108Y, V28G-I49G-V82T-N108Y, V28G-I49G-V82G -N108Y, A48G-I49A-V82T-N108Y, A48G-I49A-V82G-N108Y, A48G-I49G-V82T-N108Y , A48G-I49G-V82G-N108Y, V28G-A48G-I49A-N108H, V28G-A48G-I49G-N108H, V28G -A48G-V82T-N108H, V28G-A48G-V82G-N108H, V28G-I49A-V82T-N108H, V28G-I49A- V82G-N108H, V28G-I49G-V82T-N108H, V28G-I49G-V82G-N108H, A48G-I49A-V82T- N108H, A48G-I49A-V82G-N108H, A48G-I49G-V82T-N108H, A48G-I49G-V82G-N108H;

[0117] Or, the mutant TadA-8e refers to the deaminase obtained after the following five-point mutations in amino acids in TadA-8e: V28G-A48G-I49A-V82T-N108Y, V28G-A48G-I49 G-V82T-N108Y, V28G-A48G-I49A-V82G-N108Y, V28G-A48G-I49G-V82G-N108Y, V28G-A48G-I49G-V82G-N108Y, V28G-A48G-I49A-V82T-N108H, V28G-A48G-I49G-V82T-N108H, V28G-A48G-I49A-V82G-N108H, V28G-A48G-I49G-V82G-N108H.

[0118] In an eighth aspect, the present invention provides an adenine deaminase TadA mutant protein, wherein the adenine deaminase TadA mutant protein is a non-natural protein, and the adenine deaminase TadA mutant protein refers to a deaminase in which the amino acids 106 and 108 homologous to ecTadA in TadA-X are mutated to valine and asparagine, respectively;

[0119] TadA-X refers to TadA from different sources; preferably, there are multiple groups of TadA-X mutants, and their amino acid sequences are shown in any one of SEQ ID NO.5-SEQ ID NO.57.

[0120] Furthermore, the mutant TadA-8e protein or the adenine deaminase TadA mutant protein is a monomer or a dimer.

[0121] In the ninth aspect of the present invention, a polynucleotide is provided, encoding the fusion protein in the base editor.

[0122] Or, a polynucleotide encoding the mutant TadA-8e protein or the adenine deaminase TadA mutant protein.

[0123] The tenth aspect of the present invention provides a vector containing the polynucleotide.

[0124] In the eleventh aspect of the present invention, a host cell is provided, comprising the base editor, or the mutant TadA-8e protein or the adenine deaminase TadA mutant protein, or the vector.

[0125] In a twelfth aspect, the present invention provides a kit comprising reagents for constructing the base editor.

[0126] Compared with the prior art, the present invention has the following beneficial effects:

[0127] (1) The ABE tool developed in the present invention has higher specificity in mediating A·T--G·C mutation, and its ability to mediate C·G--T·A mutation is significantly inhibited or even eliminated.

[0128] (2) The CBE tool developed in the present invention has higher accuracy in mediating C·G--T·A mutation, and the off-target effects at the RNA and DNA levels are significantly reduced or even eliminated.

[0129] (3) The ACBE tool developed in the present invention only requires a single deaminase, which is smaller in size and has significantly reduced or even eliminated off-target effects at the RNA and DNA levels, thus having higher application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0130] Figure 1 Schematic diagram of the editing efficiency of various base editors ABEs for base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site when TadA-8e is fused to different positions of the nSpCas9 protein (including N-, C-, and internal fusion sites).

[0131] Figure 2 Schematic diagram of the editing efficiency of various base editors ABEs for base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site when NLS-TadA-8e-linker is fused to different positions of the nSpCas9 protein (including N-, C-, and internal fusion sites).

[0132] Figure 3 a is a schematic diagram of the editing efficiency (C·G--T·A mutation rate) of 1249-NLS-TadA-8e-linker and 1249-TadA-8e for the fourth base C (C4) and the sixth base C (C6) at the sgRNA-S1 site.

[0133] Figure 3 b is a schematic diagram of the spatial positions of V28, V30, N46, A48, I49, V82, F84, N108, K110, and R111 in the TadA-8e structure (PDB: 6VPC); the amino acid residues marked in the figure are located in the active pocket of TadA-8e.

[0134] Figure 3c is a single point mutation that enhances the C·G--T·A mutation ability and preference for cytosine (C) mediated by 1249-NLS-TadA-8e-linker. The bar graphs from left to right are the cytosine (C) preference of the 1249-NLS-TadA-8e-linker mutant (cytosine (C) preference = C·G--T·A mutation rate / A·T--G·C mutation rate), the relative editing activity of cytosine (C) (cytosine (C) relative editing activity = C·G--T·A mutation rate of mutant / non-mutant 1249-NLS-TadA-8e-linker) and the relative editing activity of adenine (A) (adenine (A) relative editing activity = A·T--G·C mutation rate of mutant / non-mutant 1249-NLS-TadA-8e-linker).

[0135] Figure 4 Schematic diagram of the change in the ability of TadA-8e in 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutation and C·G--T·A mutation at the sgRNA-S1 site after saturation mutation of V28 (A) and V30 (B);

[0136] The point mutations marked by the dark boxes in the figure can significantly enhance the C·G--T·A mutation ability and preference for cytosine (C) of 1249-NLS-TadA-8e-linker.

[0137] Figure 5 Schematic diagram of the change in the ability of TadA-8e in 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutation and C·G--T·A mutation at the sgRNA-S1 site after saturation mutation at N46 (A) and A48 (B);

[0138] The point mutations marked by the dark boxes in the figure can significantly enhance the C·G--T·A mutation ability and preference for cytosine (C) of 1249-NLS-TadA-8e-linker.

[0139] Figure 6 Schematic diagram of the change in the ability of TadA-8e in 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutation and C·G--T·A mutation at the sgRNA-S1 site after saturation mutation at I49 (A) and V82 (B);

[0140] The point mutations marked by the dark boxes in the figure can significantly enhance the C·G--T·A mutation ability and preference for cytosine (C) of 1249-NLS-TadA-8e-linker.

[0141] Figure 7Schematic diagram of the change in the ability of TadA-8e in 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutation and C·G--T·A mutation at the sgRNA-S1 site after saturation mutation of F84 (A) and N108 (B);

[0142] The point mutations marked by the dark boxes in the figure can significantly enhance the C·G--T·A mutation ability and preference for cytosine (C) of 1249-NLS-TadA-8e-linker.

[0143] Figure 8 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability of TadA-8e at the sgRNA-S1 site after saturation mutation of K110 (A) and R111 (B) in 1249-NLS-TadA-8e-linker.

[0144] Fig. 9 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the V28 site in 1249-NLS-TadA-8e-linker.

[0145] Fig.10 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the V30 site in 1249-NLS-TadA-8e-linker.

[0146] Fig.11 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the N46 site in 1249-NLS-TadA-8e-linker.

[0147] Fig.12 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the A48 site in 1249-NLS-TadA-8e-linker.

[0148] Fig.13Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the I49 site in 1249-NLS-TadA-8e-linker.

[0149] Fig.14 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the V82 site in 1249-NLS-TadA-8e-linker.

[0150] Fig.15 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the F84 site in 1249-NLS-TadA-8e-linker.

[0151] Fig.16 Schematic diagram of the editing efficiency (heat map) of bases A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the N108 site in 1249-NLS-TadA-8e-linker.

[0152] Fig.17 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the K110 site in 1249-NLS-TadA-8e-linker.

[0153] Fig.18 Schematic diagram of the editing efficiency (heat map) of base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-S1 site after saturation mutation of TadA-8e at the R111 site in 1249-NLS-TadA-8e-linker.

[0154] Fig.19 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of double point mutations V28G-X (a) and V28W-X (b) in TadA-8e in 1249-NLS-TadA-8e-linker; the V28G-X indicates that in addition to the mutation of the 28th amino acid from valine to glycine, there are mutations X at other amino acid sites.

[0155] The point mutation 1249-NLS-TadA-8e-linker marked by the dark box in the figure has almost no A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than the wild-type 1249-NLS-TadA-8e-linker.

[0156] Fig. 20 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of double point mutations N46P-X (a), N46C-X (b) and N46L-X (c) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0157] The point mutation 1249-NLS-TadA-8e-linker marked by the dark box in the figure has almost no A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than the wild-type 1249-NLS-TadA-8e-linker.

[0158] Fig.21 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of double point mutations A48G-X (a), I49G-X (b) and I49A-X (c) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0159] The point mutation 1249-NLS-TadA-8e-linker marked by the dark box in the figure has almost no A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than the wild-type 1249-NLS-TadA-8e-linker.

[0160] Fig. 22 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of V82G-X (a), V82T-X (b) and F84M / YX (c) double point mutations into TadA-8e in 1249-NLS-TadA-8e-linker;

[0161] The point mutation 1249-NLS-TadA-8e-linker marked by the dark box in the figure has almost no A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than the wild-type 1249-NLS-TadA-8e-linker.

[0162] Fig.23Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of N108Y-X (a), N108H-X (b) and N108M / C / D / Q / SX (C) double point mutations into TadA-8e in 1249-NLS-TadA-8e-linker;

[0163] The point mutation 1249-NLS-TadA-8e-linker marked by the dark box in the figure has almost no A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than the wild-type 1249-NLS-TadA-8e-linker.

[0164] Fig.24 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of double point mutations N108M-X (a), N108C-X (b), N108D-X (c), N108S-X (d) and N108Q-X (e) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0165] The point mutation 1249-NLS-TadA-8e-linker marked by the dark box in the figure has almost no A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than the wild-type 1249-NLS-TadA-8e-linker.

[0166] Fig.25 A summary of double-point mutations that can further enhance the editing ability and preference of 1249-NLS-TadA-8e-linker for cytosine (C) compared to single-point mutations.

[0167] Fig.26 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after introducing various three-point mutations into TadA-8e in 1249-NLS-TadA-8e-linker. The point mutation type 1249-NLS-TadA-8e-linker marked by the dark box has a significantly reduced A·T--G·C mutation ability, but its C·G--T·A mutation ability is still not weaker than that of the wild-type 1249-NLS-TadA-8e-linker.

[0168] Fig. 27Schematic diagram of the change in the ability of A·T--G·C mutation and C·G--T·A mutation at the sgRNA-S1 site after the introduction of three point mutations V28G-XY (A) and A48G-XY (B) into TadA-8e in 1249-NLS-TadA-8e-linker; V28G-XY indicates that on the basis of the mutation of amino acid valine to glycine at position 28, there are mutations X and Y at the other two amino acid sites;

[0169] The point mutations indicated by red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X and Y indicate amino acid mutations at other sites.

[0170] Fig.28 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of the three-point mutations I49A-XY (A) and I49G-XY (B) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0171] The point mutations indicated by red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X and Y indicate amino acid mutations at other sites.

[0172] Fig.29 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of the three-point mutations V82G-XY (A) and V82T-XY (B) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0173] The point mutations indicated by red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X and Y indicate amino acid mutations at other sites.

[0174] Fig.30 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of N108H-XY (A) and N108Y-XY (B) triple mutations into TadA-8e in 1249-NLS-TadA-8e-linker;

[0175] The point mutations indicated by red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X and Y indicate amino acid mutations at other sites.

[0176] Fig.31 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of four-point mutations V28G-XYZ (A) and A48G-XYZ (B) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0177] Schematically, the V28G-XYZ indicates that the amino acid at position 28 is mutated from valine to glycine and there are also mutations X, Y and Z;

[0178] The point mutations indicated by the red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X, Y and Z refer to amino acid mutations at other sites.

[0179] Fig.32 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of I49A-XYZ (A) and I49G-XYZ (B) four-point mutations into TadA-8e in 1249-NLS-TadA-8e-linker;

[0180] The point mutations indicated by the red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X, Y and Z refer to amino acid mutations at other sites.

[0181] Fig.33 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of four-point mutations V82G-XYZ (A) and V82T-XYZ (B) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0182] The point mutations indicated by the red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X, Y and Z refer to amino acid mutations at other sites.

[0183] Fig.34Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of four-point mutations N108H-XYZ (A) and N108Y-XYZ (B) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0184] The point mutations indicated by the red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X, Y and Z refer to amino acid mutations at other sites.

[0185] Fig.35 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after introducing five point mutations, V28G-XYZU (A), A48G-XYZU (B), I49A-XYZU (C) and I49G-XYZU (D), into TadA-8e in 1249-NLS-TadA-8e-linker;

[0186] Schematically, the V28G-XYZU indicates that the amino acid at position 28 is mutated from valine to glycine and there are also mutations X, Y, Z and U;

[0187] The point mutations indicated by the red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X, Y, Z and U refer to amino acid mutations at other sites.

[0188] Fig.36 Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after the introduction of four point mutations V82G-XYZU (A), V82T-XYZU (B), N108H-XYZU (C) and N108Y-XYZU (D) into TadA-8e in 1249-NLS-TadA-8e-linker;

[0189] The point mutations indicated by the red arrows in the figure can significantly enhance the C·G--T·A mutation ability of 1249-NLS-TadA-8e-linker, among which the dark red arrows are preferred point mutations. X, Y, Z and U refer to amino acid mutations at other sites.

[0190] Fig.37Schematic diagram of the changes in the A·T--G·C mutation ability and C·G--T·A mutation ability at the sgRNA-S1 site after introducing various four-point and five-point mutations into TadA-8e in 1249-NLS-TadA-8e-linker. The A·T--G·C mutation ability of the point mutant 1249-NLS-TadA-8e-linker marked by the dark box is significantly reduced, but its C·G--T·A mutation ability is still not weaker than that of the wild-type 1249-NLS-TadA-8e-linker.

[0191] Fig.38 Schematic diagram of the editing efficiency of various base editors ABEs for base A (A·T--G·C mutation) and C (C·G--T·A mutation rate) at the sgRNA-1, sgRNA-18, sgRNA-PT14, sgRNA-HPE6 and sgRNA-S5 sites when different types of TadA were fused to the 1249 site of the nSpCas9 protein (the experimental results are the average of two independent biological repeat experiments).

[0192] Fig.39 Schematic diagram of the off-target effects of different types of base editors at the RNA level and DNA level (non-Cas dependent).

[0193] a. Number of AI off-targets for each base editor at the RNA level.

[0194] b. Number of CU off-targets for each base editor at the RNA level.

[0195] c. AG off-target effects of each base editor at the DNA level (non-Cas9 dependent). A total of four off-target sites R-loop 1, 2, 3, and 4 were used for detection.

[0196] d. CT off-target effects of each base editor at the DNA level (non-Cas9 dependent). A total of four off-target sites R-loop 1, 2, 3, and 4 were used for detection.

[0197] * means P < 0.05; ** means P < 0.01; *** means P < 0.001. (The results are from three independent biological replicates).

[0198] Fig.40 A schematic diagram showing the activity window of the optimized base editor for mediating C·G--T·A mutation and A·T--G·C mutation, and the base preference when mediating C·G--T·A mutation;

[0199] The figure shows the activity window of 1249-NLS-TadA-8e-linker mediating C·G--T·A mutation and A·T--G·C mutation (a) and the base preference when mediating C·G--T·A mutation (b); the activity window of 1249-NLS-TadA-8e-linker (V28G) mediating C·G--T·A mutation and A·T--G·C mutation (c) and the base preference when mediating C·G--T·A mutation (d); the activity window of 1249-NLS-TadA-8e-linker (N108Y) mediating C·G--T·A mutation and A·T--G·C mutation (e) and the base preference when mediating C·G--T·A mutation (f).

[0200] Fig.41 A schematic diagram showing the activity window of the optimized base editor for mediating C·G--T·A mutation and A·T--G·C mutation, and the base preference when mediating C·G--T·A mutation;

[0201] The figure shows the activity window of 1249-NLS-TadA-8e-linker (N46L) for mediating C·G--T·A mutation and A·T--G·C mutation (a) and its base preference when mediating C·G--T·A mutation (b); the activity window of 1249-NLS-TadA-8e-linker (N46C) for mediating C·G--T·A mutation and A·T--G·C mutation (c) and its base preference when mediating C·G--T·A mutation (d); the activity window of 1249-NLS-TadA-8e-linker (N46P) for mediating C·G--T·A mutation and A·T--G·C mutation (e) and its base preference when mediating C·G--T·A mutation (f).

[0202] Fig.42 A schematic diagram showing the activity window of the optimized base editor for mediating C·G--T·A mutation and A·T--G·C mutation, and the base preference when mediating C·G--T·A mutation;

[0203] The figure shows the activity window of 1249-NLS-TadA-8e-linker (V28G-N46L) for mediating C·G--T·A mutation and A·T--G·C mutation (a) and its base preference when mediating C·G--T·A mutation (b); the activity window of 1249-NLS-TadA-8e-linker (V28G-N46C) for mediating C·G--T·A mutation and A·T--G·C mutation (c) and its base preference when mediating C·G--T·A mutation (d); the activity window of 1249-NLS-TadA-8e-linker (V28G-N46P) for mediating C·G--T·A mutation and A·T--G·C mutation (e) and its base preference when mediating C·G--T·A mutation (f).

[0204] Fig.43 A schematic diagram showing the activity window of the optimized base editor for mediating C·G--T·A mutation and A·T--G·C mutation, and the base preference when mediating C·G--T·A mutation;

[0205] The figure shows the activity window of 1249-NLS-TadA-8e-linker (N46C-N108Y) for mediating C·G--T·A mutation and A·T--G·C mutation (a) and its base preference when mediating C·G--T·A mutation (b); the figure shows the activity window of 1249-NLS-TadA-8e-linker (N46P-N108S) for mediating C·G--T·A mutation and A·T--G·C mutation (c) and its base preference when mediating C·G--T·A mutation (d).

[0206] Fig.44 A schematic diagram showing the activity window of the optimized base editor for mediating C·G--T·A mutation and A·T--G·C mutation, and the base preference when mediating C·G--T·A mutation;

[0207] The figure shows the activity window of 1249-NLS-TadA-8e-linker (F84M-N108Y) for mediating C·G--T·A mutation and A·T--G·C mutation (a) and its base preference when mediating C·G--T·A mutation (b); the figure shows the activity window of 1249-NLS-TadA-8e-linker (F84M-N108C) for mediating C·G--T·A mutation and A·T--G·C mutation (c) and its base preference when mediating C·G--T·A mutation (d).

[0208] Fig.45 A schematic diagram showing the activity window of the optimized base editor for mediating C·G--T·A mutation and A·T--G·C mutation, and the base preference when mediating C·G--T·A mutation;

[0209] The figure shows the activity window of 1249-NLS-Q13XZ4(VN)-linker for mediating C·G--T·A mutation and A·T--G·C mutation (a) and its base preference when mediating C·G--T·A mutation (b); the activity window of 1249-NLS-B3PCY2(VN)-linker for mediating C·G--T·A mutation and A·T--G·C mutation (c) and its base preference when mediating C·G--T·A mutation (d); the activity window of 1249-NLS-E8WVH3(VN)-linker for mediating C·G--T·A mutation and A·T--G·C mutation (e) and its base preference when mediating C·G--T·A mutation (f).

[0210] Fig.46 Schematic diagram of the activity window for optimizing base editors to mediate C·G--T·A mutation and A·T--G·C mutation;

[0211] The figure shows the activity window of 1249-NLS-B5ZCW4(VN)-linker mediated C·G--T·A mutation and A·T--G·C mutation (a); the activity window of 1249-NLS-Q57LE3(VN)-linker mediated C·G--T·A mutation and A·T--G·C mutation (b); the activity window of 1249-NLS-Q99W51(VN)-linker mediated C·G--T·A mutation and A·T--G·C mutation (c). DETAILED DESCRIPTION

[0212] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0213] Example 1

[0214] Construction of TadA-8e-based base editor ABE

[0215] It is known that ecTadA* can be placed at the N-terminus, C-terminus or internal fusion site of nSpCas9 (D10A) for the construction of functional ABE (Nat Commun, 2020.11(1):5827). In this embodiment, in order to obtain ABE tools with higher editing activity and more diverse editing windows, according to existing studies (Nat Commun, 2020.11(1):5827), TadA-8e (SEQ ID NO.1) was placed at the N-terminus, C-terminus (the C-terminus had an additional link sequence (SEQ ID NO.3)) and multiple internal fusion sites (Table 1) of SV40NLS-linker-nSpCas9-nucleoplasmin NLS (SEQ.ID NO.2, positions 2-17 in the sequence are the SV40NLS-linker sequence, positions 18-1384 correspond to the 2-1368 sequence of nSpCas9 (D10A), and positions 1385-1400 are the nucleoplasmin NLS sequence) to construct a variety of ABE tool expression vectors ABE-Internal-8e (simultaneously expressing EGFP through the 2A-EGFP element). In addition, considering that the protein linker may improve the conformation of the fusion protein after internal fusion, the applicant added NLS sequence and linker sequence to the 5' and 3' of TadA-8e to obtain NLS-TadA-8e-linker (SEQ ID NO.4), and placed them at the N-terminus and multiple internal fusion sites of nSpCas9, respectively, to construct a variety of ABE tool expression vectors ABE-Internal-8e (expressing EGFP simultaneously through the 2A-EGFP element). To evaluate the editing activity of ABE-Internal-8e, different ABE-Internal-8e were co-transfected with single guide RNA (sgRNA) (sgRNA simultaneously expressed uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double-positive cells expressing EGFP and mCherry were collected by FACS. The sgRNA used in this example is S1 (sequence is GAACACAAAGCATAGACTGC).

[0216] Table 1 nspCas9 fusion sites

[0217]

[0218]

[0219] The genome of the collected double-positive cells was extracted, and directional PCR was performed using primers that can specifically amplify the sgRNA-S1 site information. The PCR products were verified by Sanger sequencing to verify the editing efficiency of different ABE-Internal-8e at the S1 site. The results showed that compared with TadA-8e, NLS-TadA-8e-linker can enhance the editing activity of various ABE-Internal-8e and expand the editing window to a certain extent ( Figure 1-2 In addition, the results showed that 1249-TadA-8e and 1249-NLS-TadA-8e-linker constructed at the 1249th fusion site of nSpCas9 had certain C·G--T·A mutation activity, among which 1249-NLS-TadA-8e-linker had higher C·G--T·A mutation activity at the C4 site than 1249-TadA-8e( Figure 3 a).

[0220] Example 2

[0221] Screening for point mutations in TadA-8e using the 1249-NLS-TadA-8e-linker tool

[0222] In this example, according to the structural information of TadA-8e (PDB: 6VPC), any one of several amino acids (amino acids at positions 28, 30, 46, 48, 49, 82, 84, 108, 110 or 111) located in the active pocket of TadA-8e and adjacent to the reaction substrate was selected for saturation mutation ( Figure 3 b), analyze the effects of different point mutations on the base editing activity of 1249-NLS-TadA-8e-linker.

[0223] To evaluate the effect of different point mutations on the base editing activity of 1249-NLS-TadA-8e-linker, the 1249-NLS-TadA-8e-linker mutant (simultaneously expressing EGFP through the 2A-EGFP element) was co-transfected with a single guide RNA (sgRNA) (sgRNA simultaneously expressing uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1, FACS) or cells were directly collected (Scheme 2, NO.FACS). The sgRNA used in this example is S1 (sequence is GAACACAAAGCATAGACTGC).

[0224] The genome was extracted from the collected cells, and directional PCR was performed using primers that can specifically amplify the sgRNA-S1 site information. The PCR products were sequenced by Sanger to verify the changes in the base editing activity of each mutant of 1249-NLS-TadA-8e-linker.

[0225] In this example, the abilities of the base editors for A·T--G·C mutation and C·G--T·A mutation after single-point mutation of TadA-8e were analyzed.

[0226] The analysis indicators are: (1) after point mutation, the editing efficiency changes of the third adenine (A3), the fourth cytosine (C4), the fifth adenine (A5), the sixth cytosine (C6), and the seventh adenine (A7) (PAM is 21-23 sites) (relative efficiency = point mutation group / no mutation group, relative efficiency > 1 indicates that the ability of the mutant 1249-NLS-TadA-8e-linker A·T--G·C mutation or C·G--T·A mutation is enhanced);

[0227] (2) According to the editing of each base in the S1 site by 1249-NLS-TadA-8e-linker, its editing efficiency for A3, A5, A7, A8 and A9 is the highest and the efficiency of each site is close. Therefore, A5 is selected as the representative of the ability of 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutation. After point mutation, the change in the ratio of C4 mutation efficiency to A5 mutation efficiency (C4 / A5) and the change in the ratio of C6 mutation efficiency to A5 mutation efficiency (C6 / A5) can reflect the change in the preference of 1249-NLS-TadA-8e-linker for cytosine (C) and adenine (A). The relative efficiency of C4 / A5 = (point mutation group C4 / A5) / (no mutation group C4 / A5), the relative efficiency of C6 / A5 = (point mutation group C6 / A5) / (no mutation group C6 / A5), and the relative efficiency > 1 indicates that the mutant 1249-NLS-TadA-8e-linker has enhanced editing ability and preference for cytosine (C).

[0228] Combining the above two indicators, the applicant screened for point mutations that can promote the C·G--T·A mutation ability mediated by 1249-NLS-TadA-8e-linker and increase the preference for cytosine (C). The results showed that V28W, V28G, N46L, N46P, N46C, A48C, A48G, A48N, A48S, I49D, I49E, I49H, I49N, I49P, I49Q, I49V, I49W, I49Y, I49R, I49A, I49T, I49G, I49L, I49S, I49M, I49C, I49F, I49 K, V82G, V82A, V82T, V82C, V82S, V82D, F84M, N108H, N108M, N108C, N108D, N108F, N108Q, N108S, and N108Y point mutations can enhance the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations and its editing preference for cytosine (C) ( Figure 3 c). The effects of other point mutations on the function of 1249-NLS-TadA-8e-linker can be found in Figure 4-Figure 8 .

[0229] In addition, after analyzing the efficiency of 1249-NLS-TadA-8e-linker editing each base at the S1 site after point mutation (Scheme 1, FACS sorting part), it was found (efficiency heat map) that among the different point mutations at the V28 site, V28D, V28E, and V28K can effectively improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker. V28D and V28E mutations have obvious editing activity at the A5 site (PAM site numbered 21-23) (A·T--G·C mutation); the V28K mutation has obvious editing activity at A3-A7, among which A5-A7 has the highest editing efficiency (A·T--G·C mutation). In addition, V28M, V28R, V28D, V28Q, V28K, V28L, and V28E mutations can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (editing efficiency <10%). V28W, V28A, and V28G can significantly improve the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (increased by more than 20%), and V28G can also simultaneously inhibit the ability of 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutations and cause its activity window to narrow ( Fig. 9 ).

[0230] Among the different point mutations at the V30 site, V30D, V30G, V30W, V30E, V30N, V30Q, V30Y, V30T, and V30S can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker. The core activity window of V30D, V30W, and V30E is A5; the activity window of V30N, V30Q, and V30Y is A5-A7; and the activity window of V30T and V30S is A3-A7. In addition, V30A, V30D, V30T, V30G, V30P, V30W, V30E, V30K, V30N, V30Q, V30R, V30S, and V30Y could significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation (editing efficiency <10%), among which V30G, V30P, V30K, and V30R also simultaneously inhibited the ability of 1249-NLS-TadA-8e-linker to mediate A·T--G·C mutation ( Fig.10 ).

[0231] All 19 point mutations at the N46 site lead to a narrowing of the activity window of 1249-NLS-TadA-8e-linker. Among them, N46H, N46K, N46Y, and N46F have low editing activity only in A5 (~30%). The activity window of N46G and N46M is A5-A7, of which A5 is the core activity window (A5 editing efficiency ~60%, A7 about ~20%). The activity window of N46E, N46Q, and N46D is A3-A7. N46H, N46K, N46Y, N46F, N46G, N46M, N46E, N46Q, and N46D can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (<10% editing efficiency). Interestingly, N46P can only mediate C·G--T·A mutations at the C4-C6 site at the S1 site. The activity windows of N46A and N46V are located at C4-A5, among which N46A has lower activity (<20%); the activity window of N46L is located at C4-A5-C6; and the activity window of N46C is located at C4-A5-C6-A7. After the mutations of N46A, N46V, N46L, and N46C, 1249-NLS-TadA-8e-linker has a narrower activity window and has the ability to mediate both C·G--T·A mutations and A·T--G·C mutations. After the point mutations of N46A, N46R, and N46W, 1249-NLS-TadA-8e-linker has basically no editing activity. N46S and N46T have a narrower activity window and have the ability to mediate both C·G--T·A mutation and A·T--G·C mutation, but the ability of A·T--G·C mutation is significantly stronger than that of C·G--T·A mutation ( Fig.11 ).

[0232] Among the different point mutations at the A48 site, A48D and A48E can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located at A3-A7. A48Y, A48W, A48E, A48D, A48F, and A48Q can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (<10% editing efficiency). A48G, A48S, and A48N can significantly improve the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (increased by more than 20%). The A48L point mutation causes 1249-NLS-TadA-8e-linker to have basically no editing activity ( Fig.12 ).

[0233] Among the different point mutations at the I49 site, all 19 point mutations can improve the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation to a certain extent, and most point mutations can significantly improve the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation (increased by more than 20%). Fig.13 )

[0234] Among the different point mutations at the V82 site, V82F can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (<10% editing efficiency). V82K, V82W, V82R, and V82Y cause 1249-NLS-TadA-8e-linker to have basically no editing activity. V82A, V82T, V82C, V82S, and V82D can significantly improve the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (increased by more than 20%) ( Fig.14 ).

[0235] Among the different point mutations at the F84 site, F84D and F84R can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A5; F84A, F84E, and F84P can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A3-A7. In addition, F84K, F84C, F84H, F84I, F84S, F84T, F84V, F84Q, F84N, and F84G can narrow its active window. F84Y, F84E, and F84R can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (<10% editing efficiency). F84M can significantly enhance the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation (increased by more than 20%) Fig.15 ).

[0236] Among the different point mutations at the N108 site, except for N108V, all can cause the activity window of 1249-NLS-TadA-8e-linker to be significantly narrowed. N108I, N108L, N108A, and N108T can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A5. N108R can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A3-A7. N108I, N108L, N108R, N108A, and N108T can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (<10% editing efficiency). N108H, N108M, N108C, N108D, N108F, N108Q, N108S, and N108Y can significantly improve the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation (increased by more than 20%) Fig.16 ).

[0237] Among the different point mutations at the K110 site, K110D and K110W can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located at A2-A8. K110E and K110W can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutations (<10% editing efficiency) ( Fig.17 ).

[0238] Among the different point mutations at the R111 site, R111P, R111E, and R111T can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A5. R111A, R111V, R111G, R111I, and R111W can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A3-A7. R111L can significantly improve the base editing specificity and accuracy of 1249-NLS-TadA-8e-linker, and the active window is mainly located in A2-A7. R111P, R111D, R111L, R111E, R111I, R111T, and R111W can significantly inhibit the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation (<10% editing efficiency) ( Fig.18 ).

[0239] Example 3

[0240] Perform combined point mutation screening (double point mutation) on TadA-8e in the 1249-NLS-TadA-8e-linker tool

[0241] In this example, according to the structural information of TadA-8e (PDB: 6VPC), key point mutations V28G, V28W (preferably V28G), N46P, N46C, N46L, A48G, I49A, I49G, V82T, F84M, N108H, N108M, N108C, N108D, N108Q, N108S, N108Y (preferably N108H, N108Y) that can enhance the ability of TadA-8e to mediate C·G--T·A mutation are selected, as well as the V82G point mutation that can reduce the risk of RNA off-target, and a double-point mutation type 1249-NLS-TadA-8e-linker is constructed to analyze the effects of different double-point mutation combinations on the base editing activity of 1249-NLS-TadA-8e-linker.

[0242] To evaluate the effect of different point mutations on the base editing activity of 1249-NLS-TadA-8e-linker, 1249-NLS-TadA-8e-linker mutants (simultaneously expressing EGFP through the 2A-EGFP element) were co-transfected with single guide RNA (sgRNA) (sgRNA simultaneously expressing uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1), or all cells were directly collected (Scheme 2). The sgRNA used in this example is S1 (sequence is GAACACAAAGCATAGACTGC).

[0243] The collected cells were used to extract the genome, and directional PCR was performed using primers that can specifically amplify the sgRNA-S1 site information. The PCR products were sequenced by Sanger sequencing to verify the activity changes of each mutant of 1249-NLS-TadA-8e-linker.

[0244] The analysis indicators are: (1) changes in editing efficiency of the fourth cytosine (C4), the fifth adenine (A5), and the sixth cytosine (C6) after double point mutation (PAM is 21-23 sites) (relative efficiency = double point mutation group / no mutation group, when the relative efficiency of double point mutation > the relative efficiency of single point mutation, it indicates that compared with the single point mutation, the ability of the A·T--G·C mutation or C·G--T·A mutation of 1249-NLS-TadA-8e-linker after double point mutation is enhanced);

[0245] (2) After double point mutation, the relative efficiency of C4 / A5 = (double point mutation group C4 / A5) / (no mutation group C4 / A5), the relative efficiency of C6 / A5 = (double point mutation group C6 / A5) / (no mutation group C6 / A5). When the relative efficiency of double point mutation > the relative efficiency of single point mutation, it indicates that compared with the single point mutation, the editing ability and preference of 1249-NLS-TadA-8e-linker for cytosine (C) are enhanced after double point mutation.

[0246] Based on the above two indicators, the applicant screened for double-point mutations that can promote the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation ( Figure 19-24). Among them, the double point mutations V28G-N108Y, V28G-N108C, V28G-N108H, V28G-N46L, V28G-N46C, V28G-N46P, V28W-N46L, V28W-N46C, V28W-N46P, N46P-N108Y, N46P-N108S, N46P-N108Q, N46P-N108D, N46P-N108C, N46P-N108H, N46P-F84M, N46P-I49A, N46P-I49G, N46P-A48G, N46C-N108Y, N46C-N108S, N46C- N108Q, N46C-N108M, N46C-N108C, N46C-N108H, N46L-N108Y, N46L-N108Q, N46L-N108D, N46L-N108M, N46L-N108H, N46L-F84M, N46L-I49A, N46L-I49G, N46L-V82G, and I49A-N108Y can almost completely inhibit the A·T--G·C mutation ability of 1249-NLS-TadA-8e-linker, while maintaining the C·G--T·A mutation ability that is not weaker than that of 1249-NLS-TadA-8e-linker. In addition, compared with the corresponding single-point mutations, V28G-N46C, V28G-N46P, V28G-A48G, V28G-I49A, V28G-I49G, V28G-V82T, V28G-F84Y, V28W-N108H, V28W-N46P, V28W-N46C, N46C-V82G, N46C-V82T, N46C-F84M, N46L-A48G, N46L-V82T, N46L-F84M, N46P-F84M, N46P-N108H, N46P-N46P, and N46P-N108H. 08C, N46P-N108Q, N46P-N108S, A48G-N108H, I49A-N108H, I49G-N108H, I49G-N108Y, I49G-V82G, I49G-V82T, I49G-F84Y, V82G-N108Y, V82T-N108H, V82T-N108C, F84M-N108H, F84M-N108M, and F84M-N108Q double-point mutations can further enhance the editing ability and preference of 1249-NLS-TadA-8e-linker for cytosine (C) ( Fig.25 ).

[0247] Example 4

[0248] Perform point mutation combinatorial screening (three-point mutation) on TadA-8e in the 1249-NLS-TadA-8e-linker tool

[0249] In this example, according to the structural information of TadA-8e (PDB: 6VPC), as well as the results of single-point mutations and triple-point mutations, key point mutations V28G, A48G, I49A, I49G, V82T, N108H, and N108Y that can enhance the ability of TadA-8e to mediate C·G--T·A mutations, and V82G point mutations that can reduce the risk of RNA off-targets were selected, and a triple-point mutation type 1249-NLS-TadA-8e-linker was constructed to analyze the effects of different triple-point mutation combinations on the base editing activity of 1249-NLS-TadA-8e-linker.

[0250] To evaluate the effect of different point mutations on the base editing activity of 1249-NLS-TadA-8e-linker, 1249-NLS-TadA-8e-linker mutants (simultaneously expressing EGFP through the 2A-EGFP element) were co-transfected with single guide RNA (sgRNA) (sgRNA simultaneously expressing uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1), or all cells were directly collected (Scheme 2). The sgRNA used in this example is S1 (sequence is GAACACAAAGCATAGACTGC).

[0251] The collected cells were used to extract the genome, and directional PCR was performed using primers that can specifically amplify the sgRNA-S1 site information. The PCR products were sequenced by Sanger sequencing to verify the activity changes of each mutant of 1249-NLS-TadA-8e-linker.

[0252] The analysis indicators were: (1) changes in editing efficiency of the fourth cytosine (C4), the fifth adenine (A5), and the sixth cytosine (C6) after triple-point mutation (PAM was 21-23 sites) (relative efficiency = three-point mutation group / no mutation group, relative efficiency > single-point mutation group, indicating that compared with single-point mutation, the ability of A·T--G·C mutation or C·G--T·A mutation of 1249-NLS-TadA-8e-linker was enhanced after triple-point mutation);

[0253] (2) After triple-point mutation, the relative efficiency of C4 / A5 = (C4 / A5 in triple-point mutation group) / (C4 / A5 in non-mutation group), the relative efficiency of C6 / A5 = (C6 / A5 in triple-point mutation group) / (C6 / A5 in non-mutation group), and the relative efficiency > single-point mutation group indicated that compared with single-point mutation, the ability of C·G--T·A mutation of 1249-NLS-TadA-8e-linker was enhanced after triple-point mutation.

[0254] Combining the above two indicators, we found that the three point mutations that significantly inhibited the A·T--G·C mutation ability of 1249-NLS-TadA-8e-linker while maintaining or enhancing the C·G--T·A mutation ability all contained N108Y or N108H point mutations. These three-point mutations include I49A-V82T-N108Y, I49A-V82G1-N08Y, I49G-V82T-N108Y, I49G-V82G-N108Y, A48G-V82G-N108Y, A48G-I49G-N108Y, V28G-V82G-N108Y, V28G-V82G-N108H, V28G-I49A-N108Y, V28G-I49A-N108H, V28G-I49G-N108H, V28G-A48G-N108Y, V28G-A48G-N108H ( Fig.26 ).

[0255] The analysis indicators were: (1) changes in editing efficiency of the fourth cytosine (C4), the fifth adenine (A5), and the sixth cytosine (C6) after triple-point mutation (PAM was 21-23 sites) (triple / single relative efficiency = triple-point mutation group / corresponding single-point mutation group, relative efficiency > 1 indicated that compared with the single-point mutation, the ability of the A·T--G·C mutation or C·G--T·A mutation of 1249-NLS-TadA-8e-linker was enhanced after triple-point mutation);

[0256] (2) After triple-point mutation, the triple / single relative efficiency of C4 / A5 = (triple-point mutation group C4 / A5) / (corresponding single-point mutation group C4 / A5), and the triple / single relative efficiency of C6 / A5 = (triple-point mutation group C6 / A5) / (corresponding single-point mutation group C6 / A5). The relative efficiency > 1 indicates that compared with the single-point mutation, the ability of the C·G--T·A mutation of 1249-NLS-TadA-8e-linker is enhanced after triple-point mutation.

[0257] Combining the above two indicators, the applicant screened for three point mutations that could promote the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation ( Figure 27-30). The results showed that V28G-A48G-I49G, V28G-A48G-I49A, V28G-A48G-V82G, V28G-A48G-V82T, V28G-A48G-N108H, V28G-A48G-N108Y, V28G-I49G-V82G, V28G-I49G-V82T, V28G-I49G-N108H, V28G-I49G-N108Y, V28G-I49G-V82G. The triple-point mutations 9A-V82G, V28G-I49A-V82T, V28G-I49A-N108H, V28G-I49A-N108Y, I49G-V82G-N108H, I49G-V82G-N108Y, I49G-V82T-N108H, and I49G-V82T-N108Y can further enhance the C·G--T·A mutation ability mediated by 1249-NLS-TadA-8e-linker.

[0258] Example 5

[0259] Perform point mutation combinatorial screening on TadA-8e in the 1249-NLS-TadA-8e-linker tool (four point mutations)

[0260] In this example, according to the structural information of TadA-8e (PDB: 6VPC), as well as the results of single-point mutation, double-point mutation and triple-point mutation, the key point mutations V28G, A48G, I49A, I49G, V82T, N108H, N108Y that can enhance the ability of TadA-8e to mediate C·G--T·A mutation, and the V82G point mutation that can reduce the risk of RNA off-target are selected, and the four-point mutation expression vector of 1249-NLS-TadA-8e-linker is constructed to analyze the effects of different four-point mutation combinations on the base editing activity of 1249-NLS-TadA-8e-linker.

[0261] To evaluate the effect of different point mutations on the base editing activity of 1249-NLS-TadA-8e-linker, 1249-NLS-TadA-8e-linker mutants (simultaneously expressing EGFP through the 2A-EGFP element) were co-transfected with single guide RNA (sgRNA) (sgRNA simultaneously expressing uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1), or all cells were directly collected (Scheme 2). The sgRNA used in this example is S1 (sequence is GAACACAAAGCATAGACTGC).

[0262] The collected cells were used to extract the genome, and directional PCR was performed using primers that can specifically amplify the sgRNA-S1 site information. The PCR products were sequenced by Sanger sequencing to verify the activity changes of each mutant of 1249-NLS-TadA-8e-linker.

[0263] The analysis indicators were: (1) changes in editing efficiency of the fourth cytosine (C4), the fifth adenine (A5), and the sixth cytosine (C6) after four-point mutation (PAM was 21-23 sites) (four / single relative efficiency = four-point mutation group / corresponding single-point mutation group, relative efficiency > 1 indicated that compared with the single-point mutation, the ability of the A·T--G·C mutation or C·G--T·A mutation of 1249-NLS-TadA-8e-linker was enhanced after four-point mutation);

[0264] (2) After four-point mutation, the four / single relative efficiency of C4 / A5 = (four-point mutation group C4 / A5) / (corresponding single-point mutation group C4 / A5), and the four / single relative efficiency of C6 / A5 = (four-point mutation group C6 / A5) / (corresponding single-point mutation group C6 / A5). The relative efficiency > 1 indicates that compared with the single-point mutation, the ability of the C·G--T·A mutation of 1249-NLS-TadA-8e-linker is enhanced after four-point mutation.

[0265] Combining the above two indicators, the applicant screened for four point mutations that could promote the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation ( Figure 31-34 The results showed that the four-point mutations V28G-I49G-V82T-N108Y, A48G-I49A-V82T-N108H, and A48G-I49G-V82G-N108H could further enhance the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation.

[0266] Example 6

[0267] Perform point mutation combinatorial screening on TadA-8e in the 1249-NLS-TadA-8e-linker tool (five point mutations)

[0268] In this example, according to the structural information of TadA-8e (PDB: 6VPC), as well as the results of single-point mutation, two-point mutation, three-point mutation and four-point mutation, the key point mutations V28G, A48G, I49A, I49G, V82T, N108H, N108Y that can enhance the ability of TadA-8e to mediate C·G--T·A mutation, and the V82G point mutation that can reduce the risk of RNA off-target are selected. By constructing a five-point mutation expression vector of 1249-NLS-TadA-8e-linker, the effects of different five-point mutation combinations on the base editing activity of 1249-NLS-TadA-8e-linker are analyzed.

[0269] To evaluate the effect of different point mutations on the base editing activity of 1249-NLS-TadA-8e-linker, 1249-NLS-TadA-8e-linker mutants (simultaneously expressing EGFP through the 2A-EGFP element) were co-transfected with single guide RNA (sgRNA) (sgRNA simultaneously expressing uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1), or all cells were directly collected (Scheme 2). The sgRNA used in this example is S1 (sequence is GAACACAAAGCATAGACTGC).

[0270] The collected cells were used to extract the genome, and directional PCR was performed using primers that can specifically amplify the sgRNA-S1 site information. The PCR products were sequenced by Sanger sequencing to verify the activity changes of each mutant of 1249-NLS-TadA-8e-linker.

[0271] The analysis indicators were: (1) changes in editing efficiency of the fourth cytosine (C4), the fifth adenine (A5), and the sixth cytosine (C6) after five-point mutation (PAM was 21-23 sites) (five / single relative efficiency = five-point mutation group / corresponding single-point mutation group, relative efficiency > 1 indicated that compared with the single-point mutation, the ability of the A·T--G·C mutation or C·G--T·A mutation of 1249-NLS-TadA-8e-linker was enhanced after five-point mutation);

[0272] (2) After the five-point mutation, the five-point / single relative efficiency of C4 / A5 = (five-point mutation group C4 / A5) / (corresponding single-point mutation group C4 / A5), and the five-point / single relative efficiency of C6 / A5 = (five-point mutation group C6 / A5) / (corresponding single-point mutation group C6 / A5). The relative efficiency > 1 indicates that compared with the single-point mutation, the ability of the C·G--T·A mutation of 1249-NLS-TadA-8e-linker is enhanced after the five-point mutation.

[0273] Combining the above two indicators, the applicant screened five mutations that could promote the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation ( Figure 35-36 The results showed that the five-point mutations V28G-A48G-I49G-V82T-N108H, V28G-A48G-I49G-V82T-N108Y, V28G-A48G-I49A-V82T-N108H, and V28G-A48G-I49A-V82T-N108Y could further enhance the ability of 1249-NLS-TadA-8e-linker to mediate C·G--T·A mutation.

[0274] In addition, we further analyzed the data of four-point mutations and five-point mutations and calculated two indicators respectively:

[0275] (1) Changes in editing efficiency of the fourth cytosine (C4), the fifth adenine (A5), and the sixth cytosine (C6) after multiple point mutations (PAM is 21-23 sites) (relative efficiency = multiple point mutation group / no point mutation group).

[0276] (2) After multiple point mutations, the relative efficiency of C4 / A5 = (multiple point mutation group C4 / A5) / (no point mutation group C4 / A5), and the relative efficiency of C6 / A5 = (multiple point mutation group C6 / A5) / (no point mutation group C6 / A5).

[0277] Combining the above two indicators, we found that the four / five point mutations that significantly inhibited the A·T--G·C mutation ability of 1249-NLS-TadA-8e-linker, while maintaining or enhancing the C·G--T·A mutation ability, all contained N108Y or N108H point mutations. This indicates that the point mutation at the N108 site is critical to changing the base editor's preference for editing cytosine (C) and adenine (A). The N108Y / H point mutation can significantly enhance the 1249-NLS-TadA-8e-linker's preference for editing cytosine (C). Except for A48G-I49A-V82T-N108H, all four-point mutations and five-point mutations containing N108Y / H (various four-point mutations and five-point mutation combinations of V28G, A48G, I49A / G, V82T / G and N108H / Y) can significantly inhibit the A·T--G·C mutation ability of 1249-NLS-TadA-8e-linker. ( Fig.37 ).

[0278] Example 7

[0279] Screening of other types of TadA in nature and construction of base editors

[0280] In this embodiment, dozens of different types of TadA were screened in nature, and the amino acid sites corresponding to the 106th and 108th amino acids of ecTadA were mutated to valine and asparagine (TadA-X, SEQ ID NO.5-SEQ ID NO.57), respectively. The wild-type ecTadA (SEQ ID NO.58) with mutations at the A106V and D108N sites was used as a control. Then, TadA-8e in 1249-NLS-TadA-8e-linker was replaced with mutant TadA-X, and the 1249-TadA-X expression vector was constructed to analyze the base editing ability and characteristics of 1249-TadA-X.

[0281] To evaluate the base editing ability of 1249-TadA-X, 1249-TadA-X (which simultaneously expresses EGFP through the 2A-EGFP element) was co-transfected with a single guide RNA (sgRNA) (sgRNA simultaneously expresses uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double-positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1).The sgRNAs used in Scheme 1 of this embodiment are S1 (sequence: GAACACAAAAGCATAGACTGC), S18 (ACACACACACTTAGAATCTG), PT14 (sequence: TCCAAACCCATATATACAGC), HPE6 (sequence: GTATAATCCAAAGATGGTCA), S5 (GATGAGATAATGATGAGTCA) and PT14 (TCCAAACCCATATATACAGC). The results show that 1249-NLS-Q2LYC0(VN)-linker, 1249-N LS-Q13XZ4(VN)-linker, 1249-NLS-F2G306(VN)-linker, 1249-NLS-B3PCY2(VN)-linker, 1249-NLS-A8F050(N)-linker, 1249-NLS-A 5WFT9(VN)-linker,1249-NLS-G0JN58(VN)-linker,1249-NLS-B5ZCW4(VN)-linker,1249-NLS-E8WVH3(VN)-linker,1249-NLS-Q1AS 41(VN)-linker, 1249-NLS-P44931(VN)-linker, 1249-NLS-C1DXN9(VN)-linker, 1249-NLS-B2UR34(VN)-linker, 1249-NLS-G0EXN4 (VN)-linker, 1249-NLS-E4TTF3(VN)-linker, 1249-NLS-R4K908(VN)-linker, 1249-NLS-E0TBL5(VN)-linker, 1249-NLS-A1W869(VN )-linker, 1249-NLS-D5W8R4(VN)-linker, 1249-NLS-D5X1Y1(VN)-linker, 1249-NLS-I3YB54(VN)-linker, 1249-NLS-Q57LE3(VN)-linker, 1249-NLS-Q99W51(VN)-linker, 1249-NLS-E1TAF4(VN)-linker, 1249-NLS-ecTadA(VN)-linker have significant base editing activity (>10%) at at least one site.In terms of base editing specificity, 1249-NLS-B3PCY2(VN)-linker, 1249-NLS-A5WFT9(VN)-linker, 1249-NLS-C1DXN9(VN)-linker, 1249-NLS-B2UR34(VN)-linker, 1249-NLS-R4K908(VN)-linker, 1249-NLS-D5W8R4(VN)-linker, 1249-NLS-E1TAF4 (VN)-linker mainly mediates C·G--T·A mutations and is mainly used as a CBE tool; 1249-NLS-Q13XZ4(VN)-linker, 1249-NLS-A8F050(N)-linker, 1249-NLS-E8WVH3(VN)-linker, 1249-NLS-P44931(VN)-linker, 1249-NLS-G0EXN4(VN)-linker, 1249-NLS-E0TBL5(VN) -linker, 1249-NLS-A1W869(VN)-linker, 1249-NLS-D5X1Y1(VN)-linker, 1249-NLS-I3YB54(VN)-linker have the same ability to mediate A·T--G·C and C·G--T·A mutations, and have the potential to be ACBE, 1249-NLS-Q2LYC0(VN)-linker, 1249-NLS-F2G306(VN)-linker, 1249-NLS- G0JN58(VN)-linker, 1249-NLS-B5ZCW4(VN)-linker, 1249-NLS-Q1AS41(VN)-linker, 1249-NLS-E4TTF3(VN)-linker, 1249-NLS-Q57LE3(VN)-linker, 1249-NLS-Q99W51(VN)-linker, 1249-NLS-ecTadA(VN)-linker are mainly used as ABE tools (. Fig.38 ).

[0282] Example 8

[0283] Preferred tools for off-target effect analysis at the RNA level

[0284] In this embodiment, 1249-NLS-TadA-8e-linker, 1249-NLS-TadA-8e-linker (V28G), 1249-NLS-TadA-8e-linker (N46L), 1249-NLS-TadA-8e-linker (N46C), 1249-NLS-TadA-8e-linker (N46P), 1249-NLS-TadA-8e-linker (N108Y), 1249-NLS-TadA-8e-linker (V28G-N46L), 1249-NLS-TadA-8e-linker (V28G-N46P), 1249-NLS-TadA-8e-linker (V28G-N46C), 1249-NLS-TadA-8e-linker (N46C- N108Y), 1249-NLS-TadA-8e-linker (N46P-N108S), 1249-NLS-TadA-8e-linker (F84M-N108Y), 1249-NLS-TadA-8e-linker(F84M-N108C), 1249-NLS-Q13XZ4(VN)-linker, 1249-NLS-B3PCY2(V N)-linker, 1249-NLS-B5ZCW4(VN)-linker, 1249-NLS-E8WVH3(VN)-linker, 1249-NLS-Q57LE3(VN)-linker, 1249-NLS-Q99W51(VN)-linker, 1249-NLS-ecTadA(VN)-linker to analyze its off-target effects at the RNA level. Among them, 1249-NLS-TadA-8e-linker(8E) was used as a positive control; nCas9-D10A was used as a negative control.

[0285] To evaluate the off-target effects of each preferred tool at the RNA level, each preferred expression vector (expressing EGFP simultaneously through the 2A-EGFP element) was co-transfected with a single guide RNA (sgRNA) (sgRNA simultaneously expressed the uracil glycosylase inhibitor UGI and 2A-puromycin) into cultured 293T cells. Puromycin was added 24 hours after transfection to select positive cells. After 48 hours of puromycin treatment, cells were collected to extract total RNA for RNA-seq experiments. The sgRNA used in this protocol is sg-RNF (sequence GTCATCTTAGTCATTACCTG).

[0286] RNA editing refers to the process of changing genetic information at the mRNA level. Specifically, it refers to the deletion, insertion or chemical modification of nucleotides in mRNA molecules. This modification affects gene expression, the production of different amino acids and the formation of open reading frames. In mammalian cells, there are two main types of RNA editing, namely AI editing and CU editing. This RNA editing is mediated by RNA-dependent adenine deaminase.

[0287] We first analyzed the AI ​​editing results and found that the TadA-8e* point mutation significantly reduced the off-target effect of 1249-NLS-TadA-8e-linker at the RNA level. After the point mutation, the off-target effect at the RNA level was similar to that of the background (NC, transfection of sgRNA only) and the negative control group (Cas9-D10A+sgRNA). In addition, among other newly screened functional TadA-based base editors, the off-target effects of 1249-NLS-B5ZCW4(VN)-linker and 1249-NLS-B3PCY2(VN)-linker at the RNA level were similar to those of the background and negative controls, while the off-target effects of 1249-NLS-Q13XZ4(VN)-linker, 1249-NLS-ecTadA(VN)-linker, 1249-NLS-Q57LE3(VN)-linker and 1249-NLS-E8WVH3(VN)-linker at the RNA level were slightly higher than those of the background and negative controls, but significantly lower than those of 1249-NLS-TadA-8e-linker. The off-target effect of 1249-NLS-Q99W51(VN)-linker at the RNA level was significantly higher than that of 1249-NLS-TadA-8e-linker( Fig.39 a).

[0288] The results of CU editing at the RNA level showed that each sample group was similar to the background (NC, transfected with sgRNA only) and the negative control group (Cas9-D10A+sgRNA), with no significant increase ( Fig.39 b).

[0289] Example 9

[0290] Analysis of off-target effects of some tools at the DNA level (non-Cas-dependent off-target effects)

[0291] In this embodiment, 1249-NLS-TadA-8e-linker (V28G), 1249-NLS-TadA-8e-linker (N46L), 1249-NLS-TadA-8e-linker (N46C), 1249-NLS-TadA-8e-linker (N46P), 1249-NLS-TadA-8e-linker (N108Y), 1249-NLS-TadA-8e-linker (V28G-N46L), 1249-NLS-TadA-8e-linker (V28G-N46P), 1249-NLS-TadA-8e-linker (V28G-N46C), 1249-NLS-TadA-8e-linker (N46C-N108Y) are preferred. , 1249-NLS-TadA-8e-linker(N46P-N108S), 1249-NLS-TadA-8e-linker(F84M-N108Y), 1249-NLS-TadA-8e-linker(F84M-N108C), 1249-NLS-Q13XZ4(VN)-linker, 1249-NLS-B3PCY2(VN)-linker, 1249-NLS-B5ZCW4(VN)-linker, 1249-NLS-E8WVH3(VN)-linker, 1249-NLS-Q57LE3(VN)-linker, 1249-NLS-Q99W51(VN)-linker to analyze their off-target effects at the DNA level (non-Cas-dependent off-target effects). 1249-NLS-TadA-8e-linker (8e) was also selected as a control.

[0292] Off-target effects at the DNA level (non-Cas-dependent off-target effects) are analyzed by R-Loop experiments [8]. The basic principle is that dSaCas9 and sasgRNA (sasgRNA-X) targeting a specific genomic site (site X) are co-expressed in cells, inducing the formation of a single-stranded DNA (ssDNA) region at site X; at this time, the co-expressed base editor (ABE or CBE) in the cell may bind to ssDNA and mediate C·G--T·A (CBE) or A·T--G·C (ABE) mutations due to its own affinity for ssDNA.

[0293] After the human HEK293T cell line was revived and cultured, it was plated in 12-well plates at a density of 30%-50%. After 24 hours, liposomes were used to co-transfect the preferred expression vectors of the base editor (simultaneously expressing EGFP through the 2A-EGFP element) and the inactivated SaCas9 (dSaCas9)-sasgRNA co-expression vector (simultaneously expressing red fluorescent protein). After 72 hours of culture, the cells were harvested by trypsin digestion, double-positive cells were sorted by flow cytometry, and the genome was extracted by lysing the cells with lysis buffer. After that, primers were designed for directional amplification of the sasgRNA site. The amplified products were purified and deeply sequenced, and data analysis was performed to understand the AG and CT mutation frequencies at the sasgRNA site. In the study, four different sasgRNA off-target sites (sasgRNA-1~6) were selected for off-target effect analysis at the DNA level (non-Cas-dependent off-target effects).

[0294] The results of AG mutation efficiency showed that the base editing efficiency of 1249-NLS-TadA-8e-linker (8e) at the four sites of sasgRNA-1, 2, 4, and 6 was <8% (the editing efficiency is the sum of the AG mutation frequencies of all off-target sites), indicating that its off-target effect at the DNA level (non-Cas-dependent off-target effect) is very low. Compared with 1249-NLS-TadA-8e-linker (8e), 1249-NLS-TadA-8e-linker (V28G), 1249-NLS-TadA-8e-linker (N46L), 1249-NLS-TadA-8e-linker (N46C), 1249-NLS-TadA-8e-linker (N46P), 1249-NLS-TadA-8e-linker (N108 Y), 1249-NLS-TadA-8e-linker (V28G-N46L), 1249-NLS-TadA-8e-linker (V28G-N46P), 1249-NLS-TadA-8e- linker(V28G-N46C), 1249-NLS-TadA-8e-linker(N46C-N108Y), 1249-NLS-TadA-8e-linker(N46P-N108S), 1 249-NLS-TadA-8e-linker(F84M-N108Y), 1249-NLS-TadA-8e-linker(F84M-N108C), 1249-NLS-Q13XZ4(VN) -linker, 1249-NLS-B3PCY2(VN)-linker, 1249-NLS-B5ZCW4(VN)-linker, 1249-NLS-E8WVH3(VN)-linker, 1 Point mutations such as 249-NLS-Q57LE3(VN)-linker and 1249-NLS-Q99W51(VN)-linker can significantly reduce the off-target effects at the DNA level of the four sites of sasgRNA-1, 2, and 4 (non-Cas-dependent off-target effects); at the sasgRNA-6 site, the off-target effects at the DNA level of the above base editors (non-Cas-dependent off-target effects) are also lower than 8e, and the AG base editing efficiencies at the four off-target sites 1, 2, 4, and 6 are all <4% ( Fig.39 c).

[0295] Analysis of CT mutation efficiency showed that except for V28G-N46C at the sasgRNA-6 site, which had a mutation efficiency of nearly 4%, the CT mutation efficiencies of the other base editors at the four sites were all <2% ( Fig.39 d).

[0296] The results of DNA off-target effect analysis showed that base editors constructed with point mutations and new TadA deaminase had a low level of non-Cas-dependent off-target effects and significantly improved safety.

[0297] Example 10 Preferred base editor activity window and base preference

[0298] In this embodiment, 1249-NLS-TadA-8e-linker, 1249-NLS-TadA-8e-linker(V28G), 1249-NLS-TadA-8e-linker(N46L), 1249-NLS-TadA-8e-linker(N46C), 1249-NLS-TadA-8e-linker(N46P), 1249-NLS -TadA-8e-linker(N108Y)、1249-NLS-TadA-8e-linker(V28G-N46L)、1249-NLS-TadA-8e-linke r(V28G-N46P), 1249-NLS-TadA-8e-linker(V28G-N46C), 1249-NLS-TadA-8e-linker(N46C-N10 8Y), 1249-NLS-TadA-8e-linker (N46P-N108S), 1249-NLS-TadA-8e-linker (F84M-N108Y), 1249 -NLS-TadA-8e-linker(F84M-N108C), 1249-NLS-Q13XZ4(VN)-linker, 1249-NLS-B3PCY2(VN)-l Inker, 1249-NLS-B5ZCW4(VN)-linker, 1249-NLS-E8WVH3(VN)-linker, 1249-NLS-Q57LE3(VN)-linker, and 1249-NLS-Q99W51(VN)-linker were used to analyze their activity window and base preference, and 1249-NLS-TadA-8e-linker (8e) was selected as a control.

[0299] In order to systematically analyze the activity window and base preference of base editors, 12 sgRNAs (S18 sequence: ACACACACACTTAGAATCTG; HEK4 sequence: GGCACTGCGGCTGGAGGTGG; ZSCAN2 sequence: GTGCGGCAAGAGCTTCAGCC; AAVS1 sequence: GACCCTCAGCCGTGCTGCTC; FAN3 sequence: CGCCGTCTCCAAGGTGAAAG; EMX sequence: GAGTCCGAGCAGAAGAAGAA; MSKC sequence: CGTCGCCGATCTTCACAGGG; PT14 sequence: TCCAAACCCATATATACAGC; RNF sequence: GTCATCTTAGTCATTACCTG; S1 sequence: GAACACAAAGCATAGACTGC; sgB sequence: AGAGCCCCCCCTCAAAGAGA; UBE3A sequence: GTACAGTTAGTACTCAGCAG) were selected for related research. The 1249-NLS-TadA-8e-linker mutant (which simultaneously expresses EGFP through the 2A-EGFP element) was co-transfected with a single guide RNA (sgRNA) (which simultaneously expresses the uracil glycosylase inhibitor UGI and 2A-mCherry) into cultured 293T cells. After 72 hours of cell culture, double-positive cells expressing both EGFP and mCherry were collected by FACS (Scheme 1).

[0300] The cell-extracted genome was collected and directional PCR was performed using primers that can specifically amplify the target sgRNA site information. The PCR products were sequenced by amplicon to analyze the activity window and base preference of the preferred base editor (n = 3 biological replicates).

[0301] The results showed that 1249-NLS-TadA-8e-linker has the ability to mediate C·G--T·A mutation (CBE activity) and A·T--G·C mutation (ABE activity), but its ABE activity is significantly higher than its CBE activity. The ABE activity window of 1249-NLS-TadA-8e-linker is A2-A14 (PAM is 21-23), and the CBE activity window is (C4-C7) ( Fig.40 a). The CBE activity of 1249-NLS-TadA-8e-linker showed base preference, and its preference for different base sites was CA≈CT>CG≈CC, AC≈TC>GC≈CC( Fig.40 b).

[0302] Different point mutations of TadA-8e have an impact on its base editing activity and base preference. For single point mutations, after the V28G point mutation, the CBE activity of 1249-NLS-TadA-8e-linker (V28G) is higher than the ABE activity, and the CBE activity window is (C4-C7), and the ABE activity window is A5 ( Fig.40 c). Its preference for different base sites is CA≈CT>CG≈CC, AC≈TC>CC>GC( Fig.40 d). The CBE activity of 1249-NLS-TadA-8e-linker (N108Y) is similar to the ABE activity, where the CBE activity window is (C4-C7) and the ABE activity window is (A5-A7) ( Fig.40 e). Its preference for different base sites is CT≈CA≈CC>CG, TC>AC>CC≈GC ( Fig.40 f). 1249-NLS-TadA-8e-linker (N46L) has almost no ABE activity, and its CBE activity window is (C4-C8) ( Fig.41 a). Its preference for different base sites is CG>CA≈CC≈CT, CC≈TC>GC≈AC( Fig.41 b). The CBE activity of 1249-NLS-TadA-8e-linker (N46C) is similar to the ABE activity, where the CBE activity window is (C4-C8) and the ABE activity window is (A5-A7) ( Fig.41 c). Its preference for different base sites is CT≈CA≈CC>CG, CC≈TC>GC≈AC ( Fig.41 d). 1249-NLS-TadA-8e-linker (N46P) has only CBE activity, and the activity window is (C4-C8) ( Fig.41 e). Its preference for different base sites is CC≈TC>GC≈AC( Fig.41 f).

[0303] For the double-point mutation, the ABE activity of 1249-NLS-TadA-8e-linker (V28G-N46L) is very low, and the CBE activity window is (C4-C8) ( Fig.42 a), its preference for different base sites is CG≈CT≈CA>CC, TC≈CC>GC≈AC( Fig.42 b). The ABE activity of 1249-NLS-TadA-8e-linker (V28G-N46C) is very low, and the CBE activity window is (C4-C9) ( Fig.42 c), its preference for different base sites is TC≈CC≈AC>GC( Fig.42d). The ABE activity of 1249-NLS-TadA-8e-linker (V28G-N46P) is very low, and the CBE activity window is (C4-C8) ( Fig.42 e), its preference for different base sites is CT≈CG≈CA>CC, TC≈CC>GC≈AC( Fig.42 f). The ABE and CBE activities of 1249-NLS-TadA-8e-linker (N46C-N108Y) are both very low, with the ABE activity window at A5 and the CBE activity window at C4-C6 ( Fig.43 a). Its preference for different base sites is CA≈CT>CC≈CG, AC≈TC>CC≈GC( Fig.43 b). The CBE activity of 1249-NLS-TadA-8e-linker (N46P-N108S) is significantly higher than the ABE activity. The ABE activity window is A5, and the CBE activity window is C4-C9 ( Fig.43 c), which has no obvious base preference ( Fig.43 d). The ABE activity of 1249-NLS-TadA-8e-linker (F84M-N108Y) is similar to that of CBE. The activity window of ABE is A5-A7, while that of CBE is C4-C7 ( Fig.44 a), its preference for different base sites is CT≈CA≈CC>CG, TC≈AC>CC≈GC( Fig.44 b). The activity of ABE of 1249-NLS-TadA-8e-linker (F84M-N108C) is significantly higher than that of CBE. The activity window of ABE is A5-A7, while that of CBE is C4-C7 ( Fig.44 c). Its preference for different base sites is CA≈CT>CC≈CG, AC≈TC>CC≈GC ( Fig.44 d).

[0304] In summary, different point mutations in TadA-8e will significantly change the base editing activity and preference of 1249-NLS-TadA-8e-linker, and the effects of different point mutations on ABE and CBE activities are significantly different.

[0305] For base editors derived from TadA homologous proteins, the CBE activity of 1249-NLS-Q13XZ4(VN)-linker is significantly higher than the ABE activity. The CBE activity window is C4-6, and the ABE activity window is A5, A7 ( Fig.45 a). Its preference for different base sites is CA≈CT>CC≈CG, AC≈TC>CC≈GC( Fig.45b). The ABE activity of 1249-NLS-B3PCY2(VN)-linker is very low, and the CBE activity window is C4-7 ( Fig.45 c). Its preference for different base sites is that it has high editing activity at CT / AC sites and very low editing activity at CG / GC sites ( Fig.45 d). 1249-NLS-E8WVH3(VN)-linker has similar ABE and CBE activities, with the CBE activity window being C4-6 and the ABE activity window being A3-7 ( Fig.45 e). Its preference for different base sites is CA≈CT>CC>CG, AC>TC≈CC≈GC( Fig.45 f). The CBE activity of 1249-NLS-B5ZCW4(VN)-linker is very low, and the ABE activity window is A5-7 ( Fig.46 a) The CBE activity of 1249-NLS-Q57LE3(VN)-linker is very low, and the ABE activity window is A5. Fig.46 b), the CBE and ABE activities of 1249-NLS-Q99W51(VN)-linker are both very low, with the CBE activity window at C5 and the ABE activity window at A3 and A5 ( Fig.46 c)

[0306] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention. Sequence Listing <110> Fudan University <120> Base editors and their construction methods and applications <160> 58 <170> SIPOSequenceListing 1.0 <210> 1 <211> 167 <212> PRT <213> Escherichia coli <400> 1 Met Ser Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu 1 5 10 15 Thr Leu Ala Lys Arg Ala Arg Asp Glu Arg Glu Val Pro Val Gly Ala 20 25 30 Val Leu Val Leu Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Ala 35 40 45 Ile Gly Leu His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg 50 55 60 Gln Gly Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu 65 70 75 80 Tyr Val Thr Phe Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His 85 90 95 Ser Arg Ile Gly Arg Val Val Phe Gly Val Arg Asn Ser Lys Arg Gly 100 105 110 Ala Ala Gly Ser Leu Met Asn Val Leu Asn Tyr Pro Gly Met Asn His 115 120 125 Arg Val Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu 130 135 140 Leu Cys Asp Phe Tyr Arg Met Pro Arg Gln Val Phe Asn Ala Gln Lys 145 150 155 160 Lys Ala Gln Ser Ser Ile Asn 165 <210> 2 <211> 1400 <212> PRT <213> Artificial Sequence <400> 2 Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val 20 25 30 Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe 35 40 45 Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile 50 55 60 Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu 65 70 75 80 Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys 85 90 95 Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser 100 105 110 Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys 115 120 125 His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr 130 135 140 His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp 145 150 155 160 Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His 165 170 175 Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro 180 185 190 Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr 195 200 205 Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala 210 215 220 Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn 225 230 235 240 Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn 245 250 255 Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe 260 265 270 Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp 275 280 285 Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp 290 295 300 Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp 305 310 315 320 Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser 325 330 335 Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys 340 345 350 Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe 355 360 365 Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser 370 375 380 Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp 385 390 395 400 Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg 405 410 415 Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 420 425 430 Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe 435 440 445 Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile 450 455 460 Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp 465 470 475 480 Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu 485 490 495 Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr 500 505 510 Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser 515 520 525 Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys 530 535 540 Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln 545 550 555 560 Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr 565 570 575 Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp 580 585 590 Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly 595 600 605 Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp 610 615 620 Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr 625 630 635 640 Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala 645 650 655 His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr 660 665 670 Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp 675 680 685 Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe 690 695 700 Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe 705 710 715 720 Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu 725 730 735 His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly 740 745 750 Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly 755 760 765 Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln 770 775 780 Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile 785 790 795 800 Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro 805 810 815 Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu 820 825 830 Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg 835 840 845 Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys 850 855 860 Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg 865 870 875 880 Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys 885 890 895 Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys 900 905 910 Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp 915 920 925 Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr 930,935,940 Lys Tyr Asp Ser Arg Met Asn Thr Lys Tyr Asp 945 950 955 960 Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Lys Ser 965,970,975 Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg 980,985,990 Glu Ile Asn Asn Tyr His Ala His Asp Ala Tyr Leu Asn Ala Val 995 1000 1005 Val Gly Thr Ala Leu Ile Lys Tyr Pro Lys Leu Glu Ser Glu Phe 1010 1015 1020 Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala Lys 1025 1030 1035 1040 Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser 1045 1050 1055 Asn With Asn Phe Phe Lys Thr Glu With Thr Leu Ala Asn Glu 1060 1065 1070 Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile 1075 1080 1085 Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser 1090 1095 1100 Met Pro Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly 1105 1110 1115 1120 Phe Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile 1125 1130 1135 Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser 1140 1145 1150 Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu Lys Gly 1155 1160 1165 Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile 1170 1175 1180 Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala 1185 1190 1195 1200 Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys 1205 1210 1215 Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser 1220 1225 1230 Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr 1235 1240 1245 Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser 1250 1255 1260 Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His 1265 1270 1275 1280 Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val 1285 1290 1295 Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys 1300 1305 1310 His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu 1315 1320 1325 Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp 1330 1335 1340 Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp 1345 1350 1355 1360 Ala Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile 1365 1370 1375 Asp Leu Ser Gln Leu Gly Gly Asp Lys Arg Pro Ala Ala Thr Lys Lys 1380 1385 1390 Ala Gly Gln Ala Lys Lys Lys Lys 1395 1400 <210> 3 <211> 95 <212> PRT <213> Artificial Sequence <400> 3 Glu Leu Gly Gly Gly Gly Thr Gly Gly Gly Gly Ser Ala Glu Tyr Val 1 5 10 15 Arg Ala Leu Phe Asp Phe Asn Gly Asn Asp Glu Glu Asp Leu Pro Phe 20 25 30 Lys Lys Gly Asp Ile Leu Arg Ile Arg Asp Lys Pro Glu Glu Gln Trp 35 40 45 Trp Asn Ala Glu Asp Ser Glu Gly Lys Arg Gly Met Ile Leu Val Pro 50 55 60 Tyr Val Glu Lys Tyr Ser Gly Asp Tyr Lys Asp His Asp Gly Asp Tyr 65 70 75 80 Lys Asp His Asp Ile Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe 85 90 95 <210> 4 <211> 211 <212> PRT <213> Artificial Sequence <400> 4 Thr Ser Gly Ser Pro Lys Lys Lys Arg Lys Val Ser Glu Val Glu Phe 1 5 10 15 Ser His Glu Tyr Trp Met Arg His Ala Leu Thr Leu Ala Lys Arg Ala 20 25 30 Arg Asp Glu Arg Glu Val Pro Val Gly Ala Val Leu Val Leu Asn Asn 35 40 45 Arg Val Ile Gly Glu Gly Trp Asn Arg Ala Ile Gly Leu His Asp Pro 50 55 60 Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln Gly Gly Leu Val Met 65 70 75 80 Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr Val Thr Phe Glu Pro 85 90 95 Cys Val Met Cys Ala Gly Ala Met Ile His Ser Arg Ile Gly Arg Val 100 105 110 Val Phe Gly Val Arg Asn Ser Lys Arg Gly Ala Ala Gly Ser Leu Met 115 120 125 Asn Val Leu Asn Tyr Pro Gly Met Asn His Arg Val Glu Ile Thr Glu 130 135 140 Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu Cys Asp Phe Tyr Arg 145 150 155 160 Met Pro Arg Gln Val Phe Asn Ala Gln Lys Lys Ala Gln Ser Ser Ile 165 170 175 Asn Ser Gly Gly Ser Ser Gly Gly Ser Ser Gly Ser Glu Thr Pro Gly 180 185 190 Thr Ser Glu Ser Ala Thr Pro Glu Ser Ser Gly Gly Ser Ser Gly Gly 195 200 205 Ser Ser Arg 210 <210> 5 <211> 169 <212> PRT <213> Artificial Sequence <400> 5 Glu His Thr Val Lys Ile Thr Gly Glu His Lys Asp Leu Tyr Arg Gly 1 5 10 15 Ser Phe Arg Asp Thr Pro Asp Glu Lys Ile Met Arg Lys Ala Leu Cys 20 25 30 Leu Ala His Ala Ala Gly Glu Lys Gly Glu Ile Pro Val Gly Ala Val 35 40 45 Ile Ala Asp Val Asn Gly Lys Thr Ile Ala Glu Gly Phe Asn Lys Arg 50 55 60 Glu Glu Ser Lys Asp Pro Thr Asp His Ala Glu Ile Ile Ala Ile Arg 65 70 75 80 Lys Ala Ser Gln Met Leu Lys Asp Trp Arg Leu Ser Gly Leu Thr Leu 85 90 95 Phe Val Thr Met Glu Pro Cys Thr Met Cys Ala Gly Ala Ile Val Thr 100 105 110 Ser Arg Ile Ser Arg Val Val Phe Gly Val Phe Asn Asn Lys Thr Gly 115 120 125 Ser Val Gly Ser Arg Ile Asp Ile Leu Arg Asp Glu Ile Leu Asn Thr 130 135 140 Asn Ile Glu Val Val Ser Gly Val Leu Ile Ser Glu Cys Glu Gly Val 145 150 155 160 Leu Ala Lys Phe Phe Ala Asp Leu Arg 165 <210> 6 <211> 243 <212> PRT <213> Artificial Sequence <400> 6 Thr Leu Thr Ser Pro Pro Leu Pro Pro Ala Ala Ile Ala Trp Leu Ala 1 5 10 15 Glu Leu Asp Ile His Thr Arg Gln Gln Leu His Ala Arg Gly Val Val 20 25 30 Thr Ala Phe Leu Gln Leu Lys Ala Ala Gly His Thr Ala Thr Arg Arg 35 40 45 Leu Leu Phe Ala Leu Glu Ala Ala Ala Arg Gly Ile His Trp Arg Gln 50 55 60 Leu Glu Glu Glu Asp Lys Ala Leu Leu Leu Arg Arg Leu Ser Asp His 65 70 75 80 Pro Pro Val Ala Leu Pro Pro Asp Ala Asp Asp Arg Leu Arg Tyr Met 85 90 95 Arg Gln Ala Arg Asp Leu Ala Gln Gln Ala Ala Ala Glu Gly Glu Val 100 105 110 Pro Val Gly Ala Leu Val Val Lys Asp Gly Glu Ile Ile Gly Arg Gly 115 120 125 Tyr Asn Gln Pro Ile Gly Arg His Asp Pro Ser Ala His Ala Glu Met 130 135 140 Gln Ala Leu Arg Asp Ala Ala Ala Arg Leu Arg Asn Tyr Arg Leu Asp 145 150 155 160 Gly Cys Asp Leu Tyr Val Thr Leu Glu Pro Cys Pro Met Cys Ser Gly 165 170 175 Ala Ile Leu His Ala Arg Val Ala Arg Val Ile Tyr Gly Val Ala Asn 180 185 190 Ala Lys Thr Gly Ala Ala Gly Ser Thr Val Asp Leu Phe Ala Asp Pro 195 200 205 Arg Leu Asn His His Ala Ala Val Phe Gly Gly Val Glu Ala Glu Ala 210 215 220 Cys Ala Ala Gln Leu Ser Ala Phe Phe Arg Gln Arg Arg Gln Ser Ala 225 230 235 240 Gly Glu Asp <210> 7 <211> 195 <212> PRT <213> Artificial Sequence <400> 7 Val Val Ile Leu Ile Glu Thr Ser His Ser Phe Gln Ala Phe Pro Ala 1 5 10 15 Arg His Pro His Pro Ser Glu Ala Gly Thr Ala Pro Thr Gly Thr Met 20 25 30 Gly Ala Val Pro Ile Pro Thr Ala Gln Tyr Glu Pro Trp Met Arg Arg 35 40 45 Ala Leu Lys Leu Ala Thr Thr Leu Pro Asp Pro Gly Ala Asp Asp Pro 50 55 60 Pro Val Gly Ala Val Ile Tyr Gly Pro Asp Gly Thr Glu Ile Ala Ala 65 70 75 80 Ala His His Asp Arg Glu Arg Thr Ala Asp Pro Thr Ala Tyr Ala Glu 85 90 95 Ile Leu Ala Leu Arg Gln Ala Ala Gln Ala Leu Gly Thr Trp Arg Leu 100 105 110 Thr Asp Cys Thr Leu Val Thr Thr Leu Glu Pro Gly Thr Met Ser Ala 115 120 125 Gly Ala Ile Val Leu Ala Arg Ile Pro Arg Leu Ile Ile Gly Val Trp 130 135 140 Asn Lys Tyr Asn Gly Ala Val Cys Ser Leu Trp Asp Val Val Arg Asp 145 150 155 160 Arg Arg Leu Asn His Phe Val Glu Val Ile Pro Asp Val Leu Lys Asp 165 170 175 Glu Cys Asp Ala Leu Leu Asp Ser Tyr Leu Asp Ser Pro Ser Asn Leu 180 185 190 Ala Arg Gly 195 <210> 8 <211> 186 <212> PRT <213> Artificial Sequence <400> 8 Asp Thr Glu Asn Gly Ser Ala Glu Ser Asp Arg Asn Pro Gly Phe Pro 1 5 10 15 Ser Gly Ala Ser Glu Thr Glu Arg Asp His Asp Glu Arg Trp Met Arg 20 25 30 Leu Ala Leu Glu Glu Ala Arg Leu Ala Ala Ser Glu Gly Glu Val Pro 35 40 45 Ile Gly Ala Val Ile Val Arg Glu Asn Glu Val Ile Ala Arg Ser His 50 55 60 Asn Met Pro Val Asp Arg His Asp Pro Thr Ala His Ala Glu Ile Leu 65 70 75 80 Ala Ile Arg Glu Ala Ala Glu Lys Met Lys Asn Tyr Arg Leu Thr Gly 85 90 95 Met Thr Leu Tyr Val Thr Leu Glu Pro Cys Ile Met Cys Ala Gly Ala 100 105 110 Ile Leu Gln Ala Arg Leu Lys Arg Leu Val Tyr Gly Val Gly Asn Pro 115 120 125 Lys Gly Gly Ala Val Asp Ser Leu Tyr Arg Leu Leu Gln Asp Ser Arg 130 135 140 Leu Asn His Phe Val Glu Val Thr Gly Gly Val Leu Gln Ala Ser Cys 145 150 155 160 Ala Glu Ile Leu Ser Gly Phe Phe Arg Glu Lys Arg Val Thr Ser Pro 165 170 175 Leu Leu Lys Ser Glu Gly Gln Val Lys Ser 180 185 <210> 9 <211> 202 <212> PRT <213> Artificial Sequence <400> 9 Gly Ser Glu His Ser Pro Leu Trp Trp His Ile Lys Val Val Ala His 1 5 10 15 Gln Thr Met Arg Ser Ala Lys Ser Leu Thr Met Gln Ser Pro Ile Glu 20 25 30 Leu Ser Pro Gln Lys Met Gln Ala Trp Met Gly Ile Leu Ile Glu Arg 35 40 45 Ala Arg Arg Phe Gly Glu Arg Gly Glu Val Pro Val Ser Ala Val Val 50 55 60 Leu Asp His His Gly Arg Cys Ile Gly His Gly Ile Asn Gln Arg Glu 65 70 75 80 Leu His His Asp Pro Leu Gly His Ala Glu Leu Met Ala Val Arg Gln 85 90 95 Ala Cys Arg Leu Arg Gly Asp Trp Arg Leu Asn Asp Cys Thr Leu Leu 100 105 110 Val Thr Leu Glu Pro Cys Pro Met Cys Ala Gly Ala Leu Val Gln Ala 115 120 125 Arg Val Gly Gln Val Ile Phe Ala Val Thr Asn Pro Lys Arg Gly Ala 130 135 140 Met Gly Ser Thr Ile Asn Leu Ala Thr His Ile Ser Ala His His Arg 145 150 155 160 Met Thr Val Ile Gly Gly Val Leu Gly Glu Glu Ala Lys Glu Met Leu 165 170 175 Ser Ser Trp Phe Lys Gln Arg Arg Arg Arg Ser Asp Gly Thr Gly Ala 180 185 190 Ala Pro Phe Gln Thr Gly Ser Thr Thr Cys 195 200 <210> 10 <211> 194 <212> PRT <213> Artificial Sequence <400> 10 Glu Ala Ala Ala Gly Ser Val Pro Gly Asp Ser Pro Ala Ser Ser Ala 1 5 10 15 Val Leu Glu Arg Asp Arg Arg Phe Met Ala Leu Ala Gln Ala Ala Ala 20 25 30 Glu Glu Ala Arg Ala Ile Gly Glu Val Pro Val Gly Ala Val Leu Val 35 40 45 Arg Gly Asp Glu Val Ile Ala Lys Gly Phe Asn His Pro Ile Gly Ala 50 55 60 His Asp Pro Ser Ala His Ala Glu Met Val Ala Leu Arg Ala Ala Ala 65 70 75 80 Gln Ala Val Glu Asn Tyr Arg Leu Pro Gly Cys Glu Leu Tyr Val Thr 85 90 95 Leu Glu Pro Cys Leu Met Cys Ala Gly Ala Ile Met His Ala Arg Ile 100 105 110 Ala Arg Val Val Phe Gly Val Arg Asn Pro Lys Thr Gly Ala Cys Gly 115 120 125 Ser Val Val Asp Ala Phe Ala Asn Pro Gln Leu Asn His His Thr Thr 130 135 140 Val Thr Gly Gly Val Leu Glu Ser Glu Cys Gly Ala Ala Leu Lys Ala 145 150 155 160 Phe Phe Ala Glu Arg Arg Arg Ala Ser Arg Glu Ala Arg Val Ser Ala 165 170 175 Arg Ala Glu Ala Gly Ala Asp Ala Gly Ala Asp Ala Gly Pro Ala Lys 180 185 190 Ala Pro <210> 11 <211> 238 <212> PRT <213> Artificial Sequence <400> 11 Leu Thr Thr Pro Pro Leu Ala Pro Lys Thr Val Ala Ala Leu His Arg 1 5 10 15 Leu Gly Ile Arg Thr Leu Glu Glu Leu Arg Gln Thr Gly Ala Val Gln 20 25 30 Thr Phe Leu Leu Leu Lys Ala Ser Gly Leu Thr Leu Thr Lys Ser Thr 35 40 45 Leu Trp Gln Leu Glu Ser Leu Leu Asp Gly Thr Pro Pro Gln Glu Met 50 55 60 Ser Gln Ala His Lys Ala Arg Leu Leu Ala Glu Leu Lys Asn His Pro 65 70 75 80 Pro Val Ala Ala Phe Pro Pro Gln Gly Glu Met Ala His Phe Met Gly 85 90 95 Leu Ala Leu Glu Gln Ala Lys Leu Ser Ala Leu Met Gly Glu Ile Pro 100 105 110 Val Gly Ala Val Ile Val Ser Asp Gly Lys Ile Ile Ala Ser Ala His 115 120 125 Asn Thr Cys Ile Ala Asp Cys Asn Val Ser Arg His Ala Glu Ile Asn 130 135 140 Ala Leu Ala Gln Ala Gly Ser Lys Ile Gln Asn Tyr Arg Leu Asp Gly 145 150 155 160 Cys Asp Ile Tyr Ile Thr Leu Glu Pro Cys Ala Met Cys Ala Ser Ala 165 170 175 Leu Ile Gln Ala Arg Val Lys Arg Val Ile Tyr Gly Val Gly Asn Pro 180 185 190 Lys Thr Gly Ala Ala Gly Ser Ile Val Asn Leu Phe Ala Asp Lys Arg 195 200 205 Leu Asn Thr His Thr Ala Ile Arg Gly Gly Ile Leu Gln Glu Glu Cys 210 215 220 Arg Ala Val Leu Ser Arg Phe Phe Gln Asn Lys Arg Lys Gly 225 230 235 <210> 12 <211> 150 <212> PRT <213> Artificial Sequence <400> 12 Leu Glu Glu Ala Ile Leu Arg Thr Ala Leu Ala Ala Ala Tyr Ser Glu 1 5 10 15 Ala Glu Leu Ala Phe Ala Glu Asn Glu Val Pro Val Gly Ala Val Val 20 25 30 Val Trp Asn Asn Glu Ile Ile Ala Arg Asp His Asn Arg Ile Val Gln 35 40 45 Ser Ala Asn Ala Leu Arg His Ala Glu Leu Ser Val Leu Glu Arg Ala 50 55 60 Ala Gly Val Val Lys Asn Glu Arg Leu Ile Asp Cys His Leu Val Thr 65 70 75 80 Thr Leu Glu Pro Cys Met Met Cys Ser Gly Ala Ile Val His Ser Arg 85 90 95 Val Ala Ser Val His Phe Leu Val Glu Asn Glu Arg Ala Pro Gly Leu 100 105 110 Lys Gln Leu Leu Ala Leu Pro Asn Val Asn His Lys Pro Gln Leu Tyr 115 120 125 Arg His Arg Ser Glu Asp Trp Asp Ser Ala Ala Leu Leu Arg Arg Phe 130 135 140 Phe Gln Met Arg Arg Gln 145 150 <210> 13 <211> 143 <212> PRT <213> Artificial Sequence <400> 13 Asp Lys Lys Phe Met Glu Leu Ala Met Ser Val Ala Arg Gln Ser Asp 1 5 10 15 Cys Glu Val Pro Val Gly Ala Val Leu Val Arg Gln Gly Ala Val Ile 20 25 30 Ala Ser Ser Gly Asn Arg Val Phe Arg Asp Ser Asp Pro Thr Ala His 35 40 45 Ala Glu Met Phe Val Ile Arg Glu Ala Ile Gln Arg Leu Gly Val Lys 50 55 60 Phe Leu Val Asp Phe Glu Leu Tyr Val Thr Leu Glu Pro Cys Pro Met 65 70 75 80 Cys Met Tyr Ala Met Ser Leu Ser Arg Val Gly Thr Leu Cys Phe Ala 85 90 95 Val Tyr Asn Glu Lys Arg Gly Ala Ile Ser Asn Gly Cys Leu Gly Thr 100 105 110 Gly Thr Tyr Phe His Val Pro Ile Ile Tyr Glu Gly Leu Met Glu Asp 115 120 125 Glu Ala Lys Glu Leu Leu Ser Ser Phe Phe Arg Ile Leu Arg Asn 130 135 140 <210> 14 <211> 222 <212> PRT <213> Artificial Sequence <400> 14 Ser Asp Glu Asn Asn Asn Pro Ser Pro Met Pro Ser Glu Leu Asn His 1 5 10 15 Gln Gln Ser Val Arg Arg Asp Arg Ser Gln Ser Gly Ser Asp Val Ala 20 25 30 Asn Ile Lys Ser Leu Ser His Met His Glu Ser Asp Val Ser Asn Val 35 40 45 Ala Val Ser Asp Glu Glu Leu Glu Gln His Ile Arg Trp Met Lys His 50 55 60 Ala Leu Ala Leu Ala Asp Ser Ala Glu Ser Ile Gly Glu Val Pro Val 65 70 75 80 Gly Ala Cys Val Val Leu Asn Gly Glu Leu Ile Gly Glu Gly Tyr Asn 85 90 95 Thr Pro Ile Ser Asp His Asp Pro Ser Ala His Ala Glu Leu Arg Ala 100 105 110 Val Lys Gln Ala Ala Ser Lys Val Gln Asn Tyr Arg Leu Ile Asp Ala 115 120 125 Thr Leu Tyr Val Thr Leu Glu Pro Cys Ser Met Cys Ala Gly Met Leu 130 135 140 Val His Ala Arg Val Lys Arg Val Val Phe Gly Val Lys Asn Ala Lys 145 150 155 160 Thr Gly Ala Ala Gly Ser Val Met Asn Leu Leu Gln His Pro Ala Leu 165 170 175 Asn His Gln Val Asp Ile Val Ser Gly Val Leu Ala Ser Thr Cys Ala 180 185 190 Asn Lys Leu Ser Asp Phe Phe Arg Lys Arg Arg Glu Glu Ile Lys Ala 195 200 205 Ala Lys Lys Ala Lys Lys Arg Leu Glu Gly Lys Met Pro Asp 210 215 220 <210> 15 <211> 200 <212> PRT <213> Artificial Sequence <400> 15 Val Pro Leu Ser Asp Arg Gln Asp Asp Ser Tyr Trp Met Arg Arg Ala 1 5 10 15 Ile Ala Leu Ala Ser Gln Gly Glu Ala Leu Gly Glu Val Pro Val Gly 20 25 30 Ala Val Ile Val Arg Glu Gly Ile Ala Ile Gly Glu Gly Phe Asn Gln 35 40 45 Pro Ile Thr Ser Arg Asp Pro Ser Ala His Ala Glu Ile Val Ala Leu 50 55 60 Arg Gln Ala Ala Ala His Leu Gln Asn Tyr Arg Leu Pro Gly Ala Thr 65 70 75 80 Leu Tyr Val Thr Leu Glu Pro Cys Thr Met Cys Val Gly Ala Leu Val 85 90 95 His Ala Arg Ile Thr Arg Leu Val Tyr Gly Val Ala Asn Pro Lys Ala 100 105 110 Gly Ala Val Thr Ser Arg Ala Arg Leu Leu Asp Ala Asp Tyr Val Asn 115 120 125 His Arg Val Ser Tyr Glu Gly Gly Leu Met Ala Ala Glu Cys Gln His 130 135 140 Gln Leu Ser His Phe Phe Gln Gln Arg Arg Leu Gln His Lys Gln Ala 145 150 155 160 Arg Gly Ala Gly Thr Thr Asn Gln Gly Ile Ile Ala Val Glu Gln Ser 165 170 175 Phe Asp Glu Lys Gln Leu Glu Asp Asp Gly Leu Pro Gly Ile Gly Glu 180 185 190 Phe Gly Lys Asn Thr Pro Leu Lys 195 200 <210> 16 <211> 161 <212> PRT <213> Artificial Sequence <400> 16 His Asp Ser Asp Lys Tyr Phe Met Lys Cys Ala Ile Phe Leu Ala Lys 1 5 10 15 Ile Ser Glu Met Ile Gly Glu Val Pro Val Gly Ala Val Leu Val Phe 20 25 30 Asn Asn Thr Ile Ile Gly Lys Gly Leu Asn Ser Ser Ile Leu Asn His 35 40 45 Asp Pro Thr Ala His Ala Glu Ile Lys Ala Leu Arg Asn Gly Ala Lys 50 55 60 Phe Leu Lys Asn Tyr Arg Leu Leu His Thr Thr Leu Tyr Val Thr Leu 65 70 75 80 Glu Pro Cys Ile Met Cys Tyr Gly Ala Ile Ile His Ser Arg Ile Ser 85 90 95 Arg Leu Val Phe Gly Val Lys Tyr Lys Asn Leu Gln Lys Tyr Ile Cys 100 105 110 Cys Lys Asn His Phe Phe Ile Asn Lys Asn Phe Arg Lys Ile Ser Ile 115 120 125 Thr Gln Glu Val Leu Glu Ser Glu Cys Ser Asn Leu Leu Ser Ser Phe 130 135 140 Phe Lys Arg Lys Arg Lys Ile Ala Thr Lys Tyr Phe Asn Asn Asn Ile 145 150 155 160 Ile <210> 17 <211> 197 <212> PRT <213> Artificial Sequence <400> 17 Trp Leu Arg Ser Trp Ala Ser Thr Arg Ser Ser Pro Thr Cys Trp Thr 1 5 10 15 Pro Thr Cys Leu Thr Thr Arg Thr Met Thr Thr Glu Pro Gly Ser Pro 20 25 30 Ala Gln Pro Asp Arg Leu Ile Gly Gly Gly Leu Pro Arg Gln Gly Gly 35 40 45 His Val Ala Asp Glu Glu Leu Met Arg Gln Ala Ile Asp Val Ala Cys 50 55 60 Ser Thr Pro Pro Gly Asp Val Pro Val Gly Ala Leu Val Val Asp Ala 65 70 75 80 Asp Gly Thr Val Leu Ala Thr Ala Thr Asn Arg Arg Glu Gln Asp Ala 85 90 95 Asp Pro Leu Ala His Ala Glu Val Leu Ala Leu Arg Gln Ala Val Arg 100 105 110 Ala Leu Gly Asp Ser Trp Arg Leu Glu Arg Cys Thr Leu Val Val Thr 115 120 125 Leu Glu Pro Cys Ala Met Cys Ala Gly Ala Ala Leu Gly Ala Arg Val 130 135 140 Gly Arg Ile Val Phe Gly Val Tyr Asn Pro Arg Thr Gly Ala Cys Gly 145 150 155 160 Ser Val Trp Asp Leu Pro Arg Glu Ala Leu Leu His Lys Ala Glu Val 165 170 175 Arg Gly Gly Val Leu Gln Pro Glu Cys Glu Gln Leu Leu Arg Gly Phe 180 185 190 Phe Glu Lys Leu Arg 195 <210> 18 <211> 199 <212> PRT <213> Artificial Sequence <400> 18 Asn Leu Leu Leu Asp Lys Glu Thr Ser Phe Asn Asn Phe Phe Met Gln 1 5 10 15 Gln Ala Leu Lys Gln Ala Arg Ile Ala Phe Asp Lys Asn Glu Val Pro 20 25 30 Val Gly Ala Val Ile Val Asp Arg Leu Asn Gln Lys Ile Ile Ala Ser 35 40 45 Ser Tyr Asn Asn Thr Glu Glu Lys Asn Asn Ala Leu Tyr His Ala Glu 50 55 60 Ile Ile Thr Ile Asn Glu Ala Cys Asn Ile Ile Ser Cys Lys Asn Leu 65 70 75 80 Asn Asp Tyr Asp Ile Tyr Val Thr Leu Glu Pro Cys Ala Met Cys Ala 85 90 95 Ala Ala Ile Ser His Ser Arg Leu Lys Arg Leu Phe Tyr Gly Val Ser 100 105 110 Asn Pro Lys His Gly Ala Val Glu Ser Asn Leu Arg Tyr Phe Asn Ser 115 120 125 Ser Ala Cys Phe His Arg Pro Glu Ile Tyr Ser Gly Ile Leu Ala Glu 130 135 140 Asp Ser Gly Leu Leu Met Lys Glu Phe Phe Lys Lys Ile Arg Thr Thr 145 150 155 160 Ile Pro Asn His Gly Arg Ala Leu Leu Arg Asn Ser Asn Asp Val Ile 165 170 175 Pro Val Lys Val Gly Asp Cys Cys Met Ala Arg Lys Ile Ala Gln Met 180 185 190 Ser Phe Gln Arg Lys Cys Glu 195 <210> 19 <211> 189 <212> PRT <213> Artificial Sequence <400> 19 Thr Val Thr Ala Val Asn Leu Leu Thr Pro His Ser Ala Leu Leu Ser 1 5 10 15 Glu Ala Tyr Pro Gly Asp Leu Thr Ala Ala Asn Tyr Trp Leu Leu Ser 20 25 30 Asp Val Gly Phe Met Arg Arg Ala Leu Ala Leu Ala Gln Gln Gly Ala 35 40 45 Ser Gln Glu Glu Val Pro Val Gly Ala Val Leu Val Cys Asp Asn Lys 50 55 60 Ile Ile Gly Glu Gly Phe Asn Gln Pro Ile Thr Thr Ser Asp Pro Thr 65 70 75 80 Ala His Ala Glu Val Val Ala Leu Arg Cys Ala Cys Gln Thr Leu Gln 85 90 95 Asn Tyr Arg Leu Pro Pro Asn Thr Thr Leu Tyr Val Thr Leu Glu Pro 100 105 110 Cys Thr Met Cys Leu Gly Ala Leu Ile His Ala Arg Leu Ala Arg Leu 115 120 125 Val Phe Ala Val Phe Asn Pro Arg Ala Gly Met Val Gly Ser Gln Leu 130 135 140 Asn Leu Thr Glu Met Asp Phe Tyr Asn His Lys Met Gln Ala Tyr Ser 145 150 155 160 Gly Leu Leu Gln Gln Gln Ser Gln Thr Gln Leu Arg Ser Phe Phe Arg 165 170 175 Ala Arg Arg Gly Lys Lys Lys Pro Gln Lys Gln Ser Asp 180 185 <210> 20 <211> 187 <212> PRT <213> Artificial Sequence <400> 20 Ile Leu Thr Glu Ala Asp Gly His Cys Arg Asp Leu Ala Trp Met Thr 1 5 10 15 Leu Ala Leu Asp Tyr Ala Ala Arg Gly Ala Val Gln Gly Glu Val Pro 20 25 30 Val Gly Ala Val Leu Leu Gly Ala Asp Gly His Leu Leu Ala Ala Ala 35 40 45 His Asn Thr Pro Val Gln Ser His Asp Pro Ser Ala His Ala Glu Met 50 55 60 Leu Val Leu Arg Gln Ala Ala Leu Val Leu Gln Asn Tyr Arg Leu Thr 65 70 75 80 Gly Ala Thr Leu Tyr Val Thr Leu Glu Pro Cys Val Met Cys Ile Gly 85 90 95 Ala Met Leu His Ala Arg Val Ala Arg Leu Val Tyr Ala Val Ser Asn 100 105 110 Pro Lys Thr Gly Ala Val Glu Ser Leu Tyr His Leu Leu Glu Asp Asp 115 120 125 Arg Phe Asn His Arg Ile Val Thr Glu Gly Gly Val Leu Ala Ala Pro 130 135 140 Ser Ala Thr Leu Leu Arg Asn Phe Phe Arg Ala Arg Arg Arg Gly Lys 145 150 155 160 Gly Ala Gly Glu Ala Asp Val Ala Thr Ala Glu Thr Gly Val Glu Thr 165 170 175 Gly Gln Arg Ser Gly Asp Ala Ala Leu Gln Ser 180 185 <210> 21 <211> 172 <212> PRT <213> Artificial Sequence <400> 21 Gly Lys Glu Met Thr Ala Gln Gly Gly Asp Glu Arg Leu Ser Arg Asp 1 5 10 15 Tyr Tyr Phe Met Gly Leu Ala Leu Glu Lys Ala Lys Glu Ala Phe Asp 20 25 30 Asn Gly Glu Val Pro Val Gly Ala Val Ile Val Arg Gly Glu Glu Ile 35 40 45 Leu Gly Phe Gly Arg Asn Arg Val Glu Arg His Arg Asp Val Thr Ala 50 55 60 His Ala Glu Met Glu Ala Ile Arg Gln Ser Gln Gln Arg Val Gly Asp 65 70 75 80 Trp Arg Leu Asp Ser Thr Thr Leu Tyr Val Thr Lys Glu Pro Cys Leu 85 90 95 Met Cys Trp Gly Ala Val Phe Leu Ser Arg Ile Glu Arg Val Val Phe 100 105 110 Gly Val Ser Asn Pro Lys Gln Ala Asp Phe Cys Cys Ile Lys Asp Phe 115 120 125 Phe Thr Ala Arg Lys Lys Pro Glu Ile Leu Pro Gly Val Arg Ser Gln 130 135 140 Glu Ser Leu Glu Leu Met His Gln Phe Phe Phe Ile Leu Arg Asn Lys 145 150 155 160 Lys Arg Glu Leu Pro Arg Cys Asn Ile Gly Ile Ser 165 170 <210> 22 <211> 177 <212> PRT <213> Artificial Sequence <400> 22 Thr Asn Gly Ala Ala Arg Gly Gln Ala Gly Asp Gly Pro Met Ala Leu 1 5 10 15 Ala Leu Ala Glu Ala Arg Ala Ala Ala Ala Arg Gly Glu Val Pro Val 20 25 30 Gly Ala Val Leu Leu Gly Pro Asp Gly Thr Ile Leu Ala Arg Ala Gly 35 40 45 Asn Gln Val Glu Ala Gly His Asp Ala Ala Ala His Ala Glu Met Leu 50 55 60 Val Met Arg Ala Ala Ala Arg Ile Leu Gly Ser Pro Arg Leu Thr Gly 65 70 75 80 Cys Thr Leu Val Val Thr Leu Glu Pro Cys Pro Met Cys Ala Ala Ala 85 90 95 Ser Val His Phe Arg Val Gly Arg Ile Val Phe Gly Val Tyr Asn Pro 100 105 110 Lys Gly Gly Gly Val Glu His Gly Pro Arg Leu Leu Ala Arg Pro Asp 115 120 125 Cys Leu His Arg Pro Glu Trp Val Gly Gly Val Arg Glu Arg Glu Ala 130 135 140 Ala Ala Leu Leu Arg Asp Phe Phe Ala Ala Leu Arg Gly Arg Pro Glu 145 150 155 160 Gly Gly Pro Pro Glu Gly Asp Gly Lys Gly Asp Leu Arg Glu Ala Ser 165 170 175 Ser <210> 23 <211> 173 <212> PRT <213> Artificial Sequence <400> 23 Val His Arg Ile Ser Tyr Gln Gln His Cys Glu Trp Met Glu Gln Ala 1 5 10 15 Ile Ala Leu Ala Glu Gln Ala Gly Ala Ala Gly Glu Val Pro Val Gly 20 25 30 Ala Ile Val Val Ser Pro Gln Gly Glu Leu Leu Gly Thr Gly Glu Asn 35 40 45 Arg Arg Glu Arg Asp Gly Asp Pro Thr Ala His Ala Glu Ile Leu Ala 50 55 60 Leu Arg Ala Ala Gly Gln Lys Leu Gln Thr Trp Tyr Leu Lys Asn Cys 65 70 75 80 Thr Leu Tyr Val Asn Leu Glu Pro Cys Pro Met Cys Ala Gly Ala Ile 85 90 95 Leu Gln Ala Arg Ile Gly Leu Leu Val Tyr Gly Val Asp Asn Ala Lys 100 105 110 Thr Gly Ala Ile Arg Thr Val Leu Asn Leu Pro Asp Ser Arg Cys Ser 115 120 125 Phe His Arg Leu Thr Thr Leu Gly Gly Ile Leu Glu Thr Thr Cys Arg 130 135 140 Gln Gln Leu Gln Thr Trp Phe Ala Arg Lys Arg Gly Asp Ser Leu Ser 145 150 155 160 Pro Ala Leu Val Asp Arg Asp Pro Lys Leu Pro Leu Val 165 170 <210> 24 <211> 629 <212> PRT <213> Artificial Sequence <400> 24 Asp Phe Gly Asp Phe Asn Val Tyr His Ile Phe Thr Met Gly Phe Ala 1 5 10 15 Gly Ala Glu Glu Tyr Gln Glu Gln Cys Gly Gln Thr Lys His Arg Leu 20 25 30 Trp Lys Ile Glu Asn Leu Leu Glu Tyr Leu Lys Lys Leu Gly Ile Asn 35 40 45 Thr Ile Leu Leu Gly Pro Leu Phe Ser Ser Val Ser His Gly Tyr Asp 50 55 60 Thr Thr Asp Tyr Tyr Thr Val Asp Arg Arg Leu Gly Thr Asn Glu Asp 65 70 75 80 Leu Ala Ala Leu Met Asn Lys Leu His Asp Ser Gly Phe Lys Val Val 85 90 95 Leu Asp Cys Val Phe Asn His Val Gly Arg Asp Phe Phe Ala Phe Gln 100 105 110 Asp Met Lys Gln Asn Arg Glu Asn Ser Arg Tyr Lys Asp Trp Phe Leu 115 120 125 Gly Val Asn Phe Trp Gly Asn Asn Ser Phe Asn Asp Gly Leu Ser Tyr 130 135 140 Glu Asn Trp Ala Gly His Asp Asn Leu Val Lys Leu Asn Leu Tyr Asn 145 150 155 160 Pro Glu Val Lys Asp Tyr Leu Lys Glu Val Met Arg Phe Trp Ile Glu 165 170 175 Thr Phe His Ile Asp Gly Val Arg Met Asp Ala Ala Asn Val Met Asn 180 185 190 Thr Glu Phe Leu Arg Glu Leu Ser Asp Phe Ser Lys Asn Leu Lys Gln 195 200 205 Asp Phe Trp Phe Val Gly Glu Ser Val His Gly Asp Tyr Asn Val Leu 210 215 220 Val Gln Glu Gly His Leu Asp Ser Val Thr Asn Tyr Glu Asp Tyr Lys 225 230 235 240 Gly Leu Tyr Ser Ser Leu Asn Thr Lys Asn Tyr Phe Glu Ile Ser Phe 245 250 255 Ser Leu Asn Arg Leu Phe Gly Glu Tyr Gly Ile Tyr Lys Ser Phe Tyr 260 265 270 Thr Phe Asn Phe Val Asp Asn His Asp Val Asp Arg Val Ala Ser Thr 275 280 285 Leu Thr Arg Glu Ala Trp Leu Tyr Pro Leu Tyr Leu Met Leu Tyr Thr 290 295 300 Met Pro Gly Ile Pro Ser Ile Tyr Tyr Gly Ser Glu Gln Gly Ala Lys 305 310 315 320 Gly Val Lys Gly Asn Gly Thr Asp Ala Pro Leu Arg Pro Asn Tyr Glu 325 330 335 Ser Met His Phe Asp Glu His Cys Asp Leu Tyr Gln Lys Ile Cys Arg 340 345 350 Met Ala Ala Val Arg Arg Ala Ser Arg Ala Ile Arg Tyr Gly Asp Tyr 355 360 365 Lys Glu Leu Phe Val Lys Ser Gln Gln Met Gly Phe Met Arg Arg Phe 370 375 380 Glu Asn Glu Gln Val Tyr Ala Leu Phe Asn Ser Glu Glu Asn Ser Val 385 390 395 400 Arg Val Glu His His Asp Leu Arg Gly Lys Phe Arg Asp Leu Tyr Asn 405 410 415 Asp Glu Ile Val Glu Cys Asp Gly Ser Val Glu Ile Pro Gly Asp Ser 420 425 430 Gly Arg Val Leu Ala Ala Glu Ser Cys Gly Leu Val Val Glu Glu Ile 435 440 445 Thr Glu Gln Pro Ser Ser Ser Gln Ala Glu Glu Gln Ser Ala Gly Glu 450 455 460 Ile Lys Ser Arg Glu Glu Lys Cys Asp Gln Thr Leu Glu Ile Pro Ile 465 470 475 480 Gly Met Thr Met Gln Asp Ile Met Ser Lys Ala Ile Glu Glu Ala Glu 485 490 495 Arg Gly Ile Glu Glu Gly Glu Val Pro Val Gly Ala Val Ile Leu His 500 505 510 Asn Gly Glu Ile Ile Ala Ala Ala His Asn Gln Lys Glu Thr Leu Gln 515 520 525 Asp Pro Thr Ala His Ala Glu Met Leu Val Ile Arg Glu Ala Ser Lys 530 535 540 Lys Leu Gly Arg Trp Arg Leu Asp Asp Cys Glu Leu Tyr Val Thr Ala 545 550 555 560 Glu Pro Cys Pro Met Cys Met Gly Ala Val Ile Gln Ser Arg Ile Arg 565 570 575 Lys Leu Val Tyr Gly Thr Trp Glu Thr Arg Phe Gly Gly Val Glu Thr 580 585 590 Thr Ala Glu Leu Gly Lys His Pro Met Leu Ser Asn Ala Thr Glu Ile 595 600 605 Tyr Ser Gly Ile Cys Glu Glu Lys Cys Gln Glu Leu Leu Glu Arg Phe 610 615 620 Phe Gln Asn Asn Arg 625 <210> 25 <211> 291 <212> PRT <213> Artificial Sequence <400> 25 Thr Pro Asp Glu Gln Phe Leu Arg Glu Ala Ile Ala Glu Ala Arg Ala 1 5 10 15 Ala Glu Gln Ala Gly Glu Val Pro Val Gly Ala Val Leu Val Leu Asn 20 25 30 Asn Glu Ile Ile Ala Arg Gly Arg Asn Arg Val Ile Leu Asp Ser Asp 35 40 45 Pro Thr Ala His Ala Glu Ile Val Ala Leu Arg Glu Ala Gly Arg Ile 50 55 60 Leu Gly Asn Tyr Arg Leu Glu Asn Cys Asp Leu Tyr Thr Thr Leu Glu 65 70 75 80 Pro Cys Ala Met Cys Ala Gly Ala Ile Leu His Ala Arg Ile Arg Arg 85 90 95 Leu Ile Tyr Ala Val Ala Asn Pro Lys Ala Gly Ala Cys Gly Ser Ala 100 105 110 Leu Asp Val Met Asn His Pro Arg Leu Asn His Arg Met Glu Val Ala 115 120 125 Val Gly Leu Leu Ala Glu Glu Cys Gly Glu Met Leu Thr Ser Phe Phe 130 135 140 Arg Thr Arg Arg Leu Lys Asn Lys Glu Asn Ala Ala Ser Ala Ile Gly 145 150 155 160 Ile Glu Ala Leu Met Thr Thr Val Lys Lys Ser Ala Ala Pro Lys Lys 165 170 175 Ser Ala Ala Lys Thr Thr Ala Lys Lys Thr Ala Ala Lys Pro Pro His 180 185 190 Lys Trp Ser Ala Lys Val Thr Thr Asp Ser Thr His Pro Asp Glu Gly 195 200 205 Leu Phe Asn Glu Asp Ala Gln Thr Ile Ala Lys Lys Leu Ala Ser Lys 210 215 220 Lys Val Ser Pro Lys Gly Pro Ala Ser Gly Met Gln Met Leu Asn Phe 225 230 235 240 Tyr Ile Asn Arg Ala Gly Lys Asn Leu Pro Lys Ala Arg Gln Ala Glu 245 250 255 Leu Glu Lys Ala Lys Asp Ile Leu Ser Gln Ile Ile Ala Asp Ala Lys 260 265 270 Pro Lys Ala Pro Ala Lys Lys Ala Gly Arg Lys Thr Pro Ala Lys Lys 275 280 285 Thr Ala Asn 290 <210> 26 <211> 180 <212> PRT <213> Artificial Sequence <400> 26 Thr Asn Asp Cys Pro Phe Asp Lys Ile Tyr Pro Ser Glu Leu Asn Arg 1 5 10 15 Asn Glu Asp Tyr Phe Met Ala His Ala Phe Asn Glu Ala Ile Glu Ala 20 25 30 Trp Lys Lys Asp Glu Val Pro Ile Gly Ala Val Ile Glu Tyr Glu Gly 35 40 45 Arg Ile Ile Ala Ser Ala His Asn Gln Ser Arg Ser Thr Asn Asp Pro 50 55 60 Thr Ala His Ala Glu Ile Leu Ala Ile Ser Gln Ala Ala Asn Thr Leu 65 70 75 80 Gly Asp Trp Arg Leu Asn Glu Cys Arg Leu Tyr Val Thr Lys Glu Pro 85 90 95 Cys Pro Met Cys Ser Gly Ala Leu Val Ile Ala Arg Ile Gly Lys Val 100 105 110 Tyr Tyr Gly Val Pro Asn Glu Lys Met Gly Cys Val Gly Gly Ala Val 115 120 125 Asp Leu Gly Ala Leu Pro Arg Ser Asn His His Phe Glu Ser Ile Gly 130 135 140 Gly Val Met Glu Asp Ala Asn His Ala Ile Leu Lys Ala Phe Phe Glu 145 150 155 160 Lys Lys Arg Ala Ile Asn Ala Ala Lys Lys Glu Ala Ala Arg Leu Glu 165 170 175 Asp Pro Lys Glu 180 <210> 27 <211> 166 <212> PRT <213> Artificial Sequence <400> 27 Ala Val His Glu Pro Gly Ala Gln Asn Pro Pro Cys Ala Gly Arg Arg 1 5 10 15 Asp Leu Arg Met Met Arg Leu Ala Leu Arg Ala Ala Arg Glu Ala Ala 20 25 30 Gly Arg Gly Glu Val Pro Val Gly Ala Val Val Ala Arg Gly Glu Glu 35 40 45 Val Leu Ala Leu Ala Ser Asn Glu Arg Glu Ala Thr Gly Asp Pro Thr 50 55 60 Ala His Ala Glu Leu Leu Ala Ile Arg Arg Ala Ala Ala Ala Leu Gly 65 70 75 80 Gly Trp Arg Leu Thr Gly Cys Thr Leu Tyr Ser Thr Leu Glu Pro Cys 85 90 95 Pro Met Cys Ala Gly Ala Ala Trp Ala Ala Arg Leu Ser Arg Ile Val 100 105 110 Tyr Ala Val Pro Asn Pro Lys Ala Gly Tyr Ala Gly Thr Leu His Asn 115 120 125 Thr Pro Ser Asp Arg Arg Leu Asn His Thr Ala Ser Val Leu Gly Gly 130 135 140 Leu Leu Ala Gln Glu Ser Ala Thr Leu Leu Arg Asp Phe Phe Arg Glu 145 150 155 160 Arg Arg Leu Lys Arg Ala 165 <210> 28 <211> 172 <212> PRT <213> Artificial Sequence <400> 28 Asp Ala Ala Lys Val Arg Ser Glu Phe Asp Glu Lys Met Met Arg Tyr 1 5 10 15 Ala Leu Glu Leu Ala Asp Lys Ala Glu Ala Leu Gly Glu Ile Pro Val 20 25 30 Gly Ala Val Leu Val Asp Asp Ala Arg Asn Ile Ile Gly Glu Gly Trp 35 40 45 Asn Leu Ser Ile Val Gln Ser Asp Pro Thr Ala His Ala Glu Ile Ile 50 55 60 Ala Leu Arg Asn Gly Ala Lys Asn Ile Gln Asn Tyr Arg Leu Leu Asn 65 70 75 80 Ser Thr Leu Tyr Val Thr Leu Glu Pro Cys Thr Met Cys Ala Gly Ala 85 90 95 Ile Leu His Ser Arg Ile Lys Arg Leu Val Phe Gly Val Ser Asn Tyr 100 105 110 Lys Thr Gly Ala Ile Gly Ser Arg Phe His Phe Phe Asp Asp Tyr Lys 115 120 125 Met Asn His Thr Leu Glu Val Thr Ser Gly Val Leu Ala Glu Glu Cys 130 135 140 Ser Gln Lys Leu Ser Thr Phe Phe Gln Lys Arg Arg Glu Glu Lys Lys 145 150 155 160 Ile Glu Lys Ala Leu Leu Lys Ser Leu Ser Asp Lys 165 170 <210> 29 <211> 156 <212> PRT <213> Artificial Sequence <400> 29 Lys Glu Ile Asn Thr Lys Phe Ile Glu Leu Ala Ile Lys Glu Ala Glu 1 5 10 15 Lys Ala Leu Lys Lys Gly Glu Val Pro Val Gly Ala Val Leu Val Lys 20 25 30 Asp Asp Lys Val Val Ser Lys Gly Tyr Asn Leu Arg Ile Ser Lys Lys 35 40 45 Asn Ala Leu Tyr His Ala Glu Ile Val Ala Ile Glu Arg Ala Cys Lys 50 55 60 Lys Leu Lys Ser Trp Arg Leu Asp Asp Thr Val Leu Tyr Thr Thr Leu 65 70 75 80 Glu Pro Cys Leu Met Cys Ala Gly Ala Ile Met Gln Ala Arg Ile Lys 85 90 95 Lys Val Val Phe Leu Val Lys Asn Glu Lys Gly Gly Ala Val Leu Ser 100 105 110 Asn Tyr Thr Val Phe Asp Asp Lys Lys Leu Pro Phe Lys Val Glu Tyr 115 120 125 Ser Tyr Ile Pro Asp Glu Arg Ala Glu Lys Leu Leu Lys Asp Phe Phe 130 135 140 Lys Ile Leu Arg Glu Ala Lys His His Asp Lys Val 145 150 155 <210> 30 <211> 157 <212> PRT <213> Artificial Sequence <400> 30 Glu Asn His Glu Pro Phe Leu Arg Glu Ala Ile Ala Leu Ser Arg Ser 1 5 10 15 Ala Ile Glu Gln Gly Gly Gly Glu Pro Phe Gly Ser Val Leu Val Lys 20 25 30 Asn Gly Glu Val Ile Leu Arg Ala Glu Asn Ser Val Phe Ser Gly His 35 40 45 Asp Met Thr Asn His Ala Glu Met Asn Leu Val Lys Leu Ala Ala Gln 50 55 60 His Tyr Asp Thr Ala Phe Leu Ala Asp Cys Thr Leu Tyr Thr Ser Thr 65 70 75 80 Glu Pro Cys Ala Met Cys Ser Gly Ala Ile Tyr Trp Ser Gly Ile Gly 85 90 95 His Met Val Phe Ala Cys Ser Glu Thr Arg Leu Gly Glu Ile Ala Gly 100 105 110 Ile Gly Leu Asn Val Pro Ser Arg Pro Val Leu Gln Thr Gly Ala Arg 115 120 125 Leu Val Thr Val Val Gly Pro Thr Ser Leu Glu Asp Glu Ala Ala Glu 130 135 140 Val His Gln Glu Phe Trp Pro Lys His Leu Gly Lys Ala 145 150 155 <210> 31 <211> 173 <212> PRT <213> Artificial Sequence <400> 31 Pro Asp Ala Pro Arg Asp Leu Gln Tyr Met Glu Arg Ala Leu Gln Leu 1 5 10 15 Ala Ala Tyr Ala Gly Glu Met Gly Glu Val Pro Ile Gly Ala Val Val 20 25 30 Val Ala Gly Gly Lys Ile Leu Gly Glu Gly Cys Asn Leu Arg Glu Met 35 40 45 Trp Asn Asp Pro Thr Ala His Ala Glu Met Val Ala Leu Arg Gln Ala 50 55 60 Ala Gln Ala Val Gly Gly Trp Arg Leu Ser Gly Thr Thr Leu Tyr Val 65 70 75 80 Thr Leu Glu Pro Cys Ala Met Cys Val Gly Ala Ala Val Leu Ala Arg 85 90 95 Val Glu Arg Val Val Phe Gly Val Pro Asn Pro Lys Ala Gly Ala Cys 100 105 110 Gly Ser Val Leu Gln Val Ala Asp Ala Pro Leu Asn His Arg Leu Lys 115 120 125 Val Glu Gly Gly Val Leu Gln Gln Ser Cys Ser His Leu Leu Lys Gln 130 135 140 Phe Phe Arg Glu Leu Arg Met Arg Lys Arg Pro Gln Ala Gly Arg Ser 145 150 155 160 Ser Val Leu Ser Phe Asp Asp Pro Ser Arg Arg Asp Val 165 170 <210> 32 <211> 180 <212> PRT <213> Artificial Sequence <400> 32 Ile Thr Ser Val Met Met Glu Met Pro Gly Ser Asp Glu Trp Phe Met 1 5 10 15 Arg Gln Ala Met Lys Glu Ser Arg Lys Ala Leu Val Lys Gly Glu Val 20 25 30 Pro Val Gly Ala Ile Val Val Lys Asp Gly Arg Val Ile Gly Arg Gly 35 40 45 Trp Asn Gln Val Glu Thr Leu Lys Asp Ala Thr Ala His Ala Glu Met 50 55 60 Ile Ala Leu Thr Ala Ala Gln Glu Ala Leu Gly Asp Trp Arg Leu Glu 65 70 75 80 Gly Cys Thr Leu Tyr Val Thr Lys Glu Pro Cys Pro Met Cys Ala Gly 85 90 95 Ala Ile Val His Cys Arg Pro Asp Arg Val Val Phe Gly Val Pro Asn 100 105 110 Ala Lys Thr Gly Ala Ala Gly Gly Trp Ile Asn Leu Leu Asp Ser Asn 115 120 125 Pro Pro Leu Asn His Lys Cys Glu Val Arg Pro Gly Val Leu Gly Asp 130 135 140 Glu Cys Leu Leu His Leu Gln Glu Phe Phe Arg Ala Ala Arg Leu Ala 145 150 155 160 Ala Lys Glu Arg Lys Lys Leu Ser Ala Arg Leu Ser Ser Pro Pro Asp 165 170 175 Glu Asn Gly Glu 180 <210> 33 <211> 160 <212> PRT <213> Artificial Sequence <400> 33 Lys Tyr Glu Lys Asp Lys Asn Trp Met Lys Ile Ala Leu Lys Tyr Ala 1 5 10 15 Tyr Tyr Ala Lys Glu Lys Gly Glu Ile Pro Ile Gly Ala Ile Leu Val 20 25 30 Phe Lys Glu Arg Ile Ile Gly Ile Gly Trp Asn Ser Ser Ile Ser Lys 35 40 45 Asn Asp Pro Thr Ala His Ala Glu Ile Ile Ala Leu Arg Gly Ala Gly 50 55 60 Lys Lys Ile Lys Asn Tyr Arg Leu Leu Asn Thr Thr Leu Tyr Val Thr 65 70 75 80 Leu Gln Pro Cys Ile Met Cys Cys Gly Ala Ile Ile Gln Ser Arg Ile 85 90 95 Lys Arg Leu Val Phe Gly Val Asn Cys Asn Ser Ser Asp His Arg Phe 100 105 110 Ser Leu Lys Asn Leu Phe Cys Asp Pro Gln Lys Asp Tyr Lys Leu Asp 115 120 125 Ile Lys Lys Asn Val Met Gln Arg Glu Cys Ser Asp Ile Leu Ile Asn 130 135 140 Phe Phe Gln Lys Lys Arg Lys Asn Lys Ile His Ile Cys Lys Lys Ile 145 150 155 160 <210> 34 <211> 365 <212> PRT <213> Artificial Sequence <400> 34 Arg Val Pro Val Pro Gly Thr Arg Ala Val Ala Lys Gln Thr Ser Thr 1 5 10 15 Gly Pro Thr Pro Val Ala Met Glu Asp Asn Gln Ala Ser Ala Gln Leu 20 25 30 Arg Ile Val Pro Ala Thr Ala Ala Asp Ile Asp Ala Leu Ser Ala Leu 35 40 45 Leu Val Glu Thr Val Ala Ser Asn Gly Ser Val Gly Phe Met His Pro 50 55 60 Leu Pro Met Glu Gln Ala Arg Ala Phe Trp Thr Ala Ala Leu Glu Glu 65 70 75 80 Ala Gly Gln Gly Arg Arg Val Val Leu Cys Ala Trp Arg Asp Gly Glu 85 90 95 Leu Leu Ala Thr Gly Ser Leu Ala Leu Val Gln Ala Pro Ser Gln Pro 100 105 110 His Arg Ala Glu Leu Thr Lys Val Met Thr Ala Pro Ala Ala Arg Gly 115 120 125 Ala Gly Val Gly Ala Ile Leu Val Arg Ala Leu Glu Gln Val Ala Arg 130 135 140 Glu Arg Gly Arg Arg Leu Leu Thr Leu Asp Ala Ser Leu Val Glu Gly 145 150 155 160 Ala Thr Ser Phe Tyr Arg Arg Leu Gly Tyr His Thr Thr Gly Asp Ile 165 170 175 Pro Glu Tyr Ala Tyr Lys Pro Leu Gly Gly Leu Gly Ala Thr Arg Ile 180 185 190 Met Trp Lys Leu Leu Asp Ala Arg Glu Pro Met Arg Val Thr Ala Val 195 200 205 Asp Arg Ala Ile Asp Glu Arg His Met Cys His Ala Leu Asp Leu Ala 210 215 220 Glu Arg Ala Glu Lys Glu Phe Asp Glu Ile Pro Val Gly Ala Val Val 225 230 235 240 Val Ser Ala Ala Gly Glu Val Ile Gly Glu Gly Trp Asn Arg Asn Ile 245 250 255 Leu Asp His Asp Pro Ser Ala His Ala Glu Ile Met Ala Met Arg Gln 260 265 270 Ala Gly Gln Ala Leu Ser Asn His Arg Leu Val Gly Ala Thr Leu Tyr 275 280 285 Val Thr Leu Glu Pro Cys Ala Met Cys Ala Met Ala Leu Val His Ala 290 295 300 Arg Ile Ala Arg Val Val Tyr Gly Val Ala Asn Pro Lys Thr Gly Ala 305 310 315 320 Cys Gly Ser Val Phe Asp Val Ile Gly Asp Pro Arg His Asn His Arg 325 330 335 Val Gln Val Gln Gly Gly Val Leu Gly Glu Glu Ala Gly Arg Arg Leu 340 345 350 Thr Asn Tyr Phe Arg Ala Lys Arg Gly Lys Pro Leu Val 355 360 365 <210> 35 <211> 168 <212> PRT <213> Artificial Sequence <400> 35 Arg Leu Ser Asp Tyr Asp Tyr Leu Ala Leu Ala Phe Glu Glu Ala Asn 1 5 10 15 Gln Ala Phe Glu Glu Gly Thr Tyr Pro Ile Gly Ala Val Ile Val Asp 20 25 30 Asp Asp Gly Asn Ile Val Ser Lys Gly Arg Asn Arg Val Phe Thr Glu 35 40 45 Ser Asp Cys Thr Ala His Ala Glu Val Asp Ala Ile Arg Lys Ala Gly 50 55 60 His Lys Leu Leu Asp Ile Pro Asn Lys Arg Phe Val Lys Asn Asn Leu 65 70 75 80 Thr Leu Tyr Thr Thr Cys Glu Pro Cys Pro Met Cys Thr Cys Thr Ile 85 90 95 Leu Leu Ser Gly Ile Lys Arg Val Val Trp Ala Val Asp Asn Asp Glu 100 105 110 Tyr Gly Gly Ile Arg Lys Phe Lys Glu Gly Pro His Phe Ile Asn Leu 115 120 125 Phe Asp Thr Ile Thr Tyr Thr Ala Ser Pro Tyr Asp Asp Leu Glu Asn 130 135 140 Lys Gln Arg Asp Leu Leu Ala Arg Trp Asn Ile Gly Arg Gly Ile Leu 145 150 155 160 Asn Thr Glu Trp Glu Lys Pro Lys 165 <210> 36 <211> 239 <212> PRT <213> Artificial Sequence <400> 36 Leu Phe Gly Met Ile Cys Cys Ser Trp Ile Leu Ser Ala Val Ile Leu 1 5 10 15 Ser Gln Phe Asp Tyr Phe Asp Ser Ile Val Ser Ile Asn Ile Glu Val 20 25 30 Ser Leu Glu Arg Gly Phe Trp Ile Ser Ala Met Phe Phe Gly Arg Cys 35 40 45 Ala Ser Leu Trp Leu Tyr Leu Ala Ala Phe Leu Phe Gln Leu Pro Leu 50 55 60 Lys Asn Pro Gly Asp Ser Phe Ala Tyr Thr Met Ile Asp Thr Asp Tyr 65 70 75 80 Met Phe Glu Ala Leu Ala Gln Ala Ala Leu Ala Glu Ala Ala Gly Glu 85 90 95 Val Pro Val Gly Ala Val Val Val Lys Asp Gly Gln Ile Ile Gly Arg 100 105 110 Gly Tyr Asn Ala Pro Ile Ser Leu His Asp Pro Ser Ala His Ala Glu 115 120 125 Met Gln Ala Leu Arg Ala Ala Ala Gln Tyr Leu Gly Asn Tyr Arg Leu 130 135 140 Val Gly Cys Glu Leu Phe Val Thr Leu Glu Pro Cys Val Met Cys Ala 145 150 155 160 Gly Ala Ile Met His Ala Arg Ile Arg Arg Leu Val Tyr Gly Val Ser 165 170 175 Asn Phe Lys Thr Gly Val Cys Gly Ser Leu Leu Asp Leu Phe Ala Glu 180 185 190 Gln Arg Leu Asn His His Thr Glu Val Ala Gly Gly Val Leu Ala Glu 195 200 205 Ala Cys Gly Ala Thr Leu Ser Arg Phe Phe Ser Leu Arg Arg Glu Gln 210 215 220 Lys Lys Ile Asn Glu Asn Lys His Ile His Gln Asn Ser Ala Ala 225 230 235 <210> 37 <211> 168 <212> PRT <213> Artificial Sequence <400> 37 Thr Asn Ile Ile Thr Arg Gly Thr Pro Pro Ala Asn Pro Pro Gln Gly 1 5 10 15 Gln Thr Trp Arg Ser Met Met Asp Thr Ala Ile Arg Glu Ala Phe Lys 20 25 30 Ala Arg Arg His Glu Glu Val Pro Ile Gly Ala Ala Leu Phe Thr Ala 35 40 45 Glu Gly Glu Leu Leu Ala Thr Gly Asn Asn Thr Pro Leu Thr Gln Asn 50 55 60 Asp Pro Thr Gly His Ala Glu Val Asn Cys Ile Arg Asn Ala Cys Lys 65 70 75 80 Asn Leu Asp Asn Tyr Arg Leu Pro Arg Gly Thr Ile Leu Val Val Thr 85 90 95 Leu Glu Pro Cys Ile Met Cys Leu Gly Ala Ile Ile His Ala Arg Val 100 105 110 Gly Gly Val Val Phe Gly Val Pro Asn Pro Lys Ala Gly Ala Val Val 115 120 125 Ser Asn Leu Glu Gly Thr Asp Leu Ser Phe Ala Asn His Lys Phe Trp 130 135 140 Thr Ile Gly Gly Val Cys Glu Asn Glu Cys Lys Glu Ile Leu Gln Ser 145 150 155 160 Phe Phe Leu His Lys Arg Lys Lys 165 <210> 38 <211> 199 <212> PRT <213> Artificial Sequence <400> 38 Thr Glu Thr Pro Pro Leu Pro Leu Arg Ala Leu Arg Ala Leu Pro Glu 1 5 10 15 Asp Pro Val Glu Ala Ala Glu Arg Asp Ala Arg Tyr Met Arg Ala Ala 20 25 30 Leu Glu Glu Ala Arg Leu Ala Glu Ala Ala Gly Glu Val Pro Val Gly 35 40 45 Ala Val Val Val Trp Asn Asp Thr Ile Ile Ala Arg Gly His Asn Leu 50 55 60 Pro Ile Arg Ser Val Asp Pro Ser Ala His Ala Glu Met Gln Ala Leu 65 70 75 80 Arg Ala Ala Ala Gln Val Ile Gly Asn Tyr Arg Met Pro Glu Cys Glu 85 90 95 Leu Tyr Val Thr Leu Glu Pro Cys Val Met Cys Ser Gly Ala Ile Leu 100 105 110 His Ala Arg Leu Arg His Val Val Phe Gly Val Thr Asn Pro Lys Thr 115 120 125 Gly Ala Ala Gly Ser Val Leu Asn Leu Phe Glu Gln Ala Gln Leu Asn 130 135 140 His Gln Thr Thr Ile Ala Gly Gly Val Leu Ala Asp Thr Cys Gly Gln 145 150 155 160 Met Leu Lys Asp Phe Phe Gly Ala Arg Arg Arg Ala Gln Lys Ala Ala 165 170 175 Gln Lys Ala Ala Gln Gln Asp Ala Ala Ala Pro Val Thr Asp Pro Asp 180 185 190 Lys Asn Asn Asp Ile Glu Ala 195 <210> 39 <211> 170 <212> PRT <213> Artificial Sequence <400> 39 Ile Ile Gln Lys Thr Val Phe Asp Asp Lys Lys Ile Gln Lys Asn Leu 1 5 10 15 Leu Lys Ile Asp Lys Glu Lys Gly Asp Lys Leu Met Tyr Ile Tyr Asn 20 25 30 Val Met Lys Thr Leu Ile Glu Tyr Ala Ser Arg Ser Asn Asp Ile Pro 35 40 45 Val Ala Ala Ala Val Val Lys Asn Gly Lys Ile Ile Ser Ile Lys Arg 50 55 60 Asn Asp Ser Lys Lys Ala Ile Tyr His Ala Glu Ile Leu Ala Ile Ile 65 70 75 80 Asp Ala Thr Ser Lys Leu Ser Thr Lys Asp Leu Arg Ser Cys Glu Met 85 90 95 Phe Val Thr Lys Glu Pro Cys Pro Met Cys Met Ser Ala Ile Val Leu 100 105 110 Ser Lys Val Lys Arg Leu Tyr Phe Gly Val Arg Asn Phe Lys Met Gly 115 120 125 Ala Ala Glu Ser Cys Phe Asn Leu Ser Gln Asn Pro Phe Leu Asn His 130 135 140 Lys Val Glu Val Ile Gly Gly Ile Cys Glu Asp Glu Cys Arg Leu Leu 145 150 155 160 Leu Lys Arg Phe Phe Glu Glu Lys Arg Arg 165 170 <210> 40 <211> 206 <212> PRT <213> Artificial Sequence <400> 40 Leu Gln Pro His Arg Pro Lys Glu Pro Ala Thr Ala Thr Arg Ala Ala 1 5 10 15 Ser Gly Ser Pro Arg Gly Pro Glu Ala Ser Gln Asp Glu Ala Leu Ala 20 25 30 Ala Pro Ala Ala Arg Pro Ala Pro Asp Asp Pro Asp Val Leu Tyr Met 35 40 45 Ala Glu Ala Leu Ala Glu Ala Arg Arg Ala Leu Ala Leu Gly Glu Val 50 55 60 Pro Val Gly Ala Val Ala Val His Asp Gly Arg Ile Ile Ala Arg Gly 65 70 75 80 His Asn Leu Arg Glu Arg Leu Gly Asp Pro Thr Ala His Ala Glu Ile 85 90 95 Leu Val Leu Arg Glu Ala Ala Ala Arg Leu Gly Gly Trp Arg Leu Glu 100 105 110 Gly Val Thr Leu Tyr Val Thr Leu Glu Pro Cys Pro Met Cys Ala Gly 115 120 125 Ala Ile Val Leu Ala Arg Val Pro Arg Leu Val Tyr Gly Val Pro Asn 130 135 140 Pro Lys Ala Gly Ala Ala Gly Ser Leu Met Asn Leu Val Gln His Asp 145 150 155 160 Lys Leu Asn His Arg Val Glu Leu Arg Ala Gly Val Leu Ala Glu Ala 165 170 175 Ser Ala Ala Leu Leu Arg Gly Phe Phe Arg Gln Leu Arg Gly Ala Gly 180 185 190 Asp Pro Ala Pro Ala Pro Gly Pro Ala Glu Thr Gly Asp Pro 195 200 205 <210> 41 <211> 164 <212> PRT <213> Artificial Sequence <400> 41 Phe Leu Trp Gln Leu Asp Cys Phe Ala Lys Gly Gly Ser His Ile Lys 1 5 10 15 Lys Asn Leu Gln Glu Met Met Glu Gln Ala Ile Ile Ile Ala Lys Gln 20 25 30 Gly Glu Ala Lys Gly Glu Val Pro Ile Gly Ala Leu Val Val Cys Gln 35 40 45 Gly Glu Val Ile Ala Arg Ala His Asn Gln Lys Glu Thr Leu Ala Asp 50 55 60 Pro Thr Ala His Ala Glu Met Leu Val Ile Arg Glu Ala Ala Lys Lys 65 70 75 80 Leu Gly Arg Trp Arg Leu Asp Asp Cys Gln Leu Phe Val Thr Ala Glu 85 90 95 Pro Cys Val Met Cys Met Gly Ala Ile Ile Gln Ala Arg Ile Pro Phe 100 105 110 Leu Val Tyr Gly Val Thr Asn Lys Lys Phe Gly Gly Val Glu Ser Thr 115 120 125 Ala Tyr Leu Cys Gln His Pro Met Leu Pro Lys Gln Met Glu Ile Tyr 130 135 140 Ala Gly Ile Cys Glu Gln Gln Cys Glu Ala Leu Leu Lys Asn Phe Phe 145 150 155 160 Ser Ser Lys Arg <210> 42 <211> 162 <212> PRT <213> Artificial Sequence <400> 42 Cys Asp His Val Val His Glu Gln Glu Lys Gln Ile Met Arg Gln Ala 1 5 10 15 Ile Glu Phe Ser Arg Glu Lys Met Ile Ala Gly Phe Gly Gly Pro Phe 20 25 30 Gly Ala Val Ile Ser Arg Asn Gly Glu Val Ile Ala Thr Gly Phe Asn 35 40 45 Gln Val Thr Ser Ala Asn Asp Pro Thr Ala His Ala Glu Val Ser Ala 50 55 60 Ile Arg Ala Ala Cys Gln Val Leu Asn Thr Phe Asp Leu Ser Gly Cys 65 70 75 80 Glu Ile Tyr Thr Ser Cys Glu Pro Cys Pro Met Cys Leu Ser Ala Ile 85 90 95 Tyr Trp Ala Arg Leu Asp Arg Ile Tyr Tyr Ala Asn Ser Arg Gln Asp 100 105 110 Ala Ala Asp Ile Gly Phe Asp Asp Ala Phe Leu Tyr Glu Glu Ile Ala 115 120 125 Lys Asp Ile Pro Asp Arg Gln Ile Pro Thr Ile Arg Leu Leu Glu Lys 130 135 140 Glu Ala Ile Leu Pro Phe Asn Glu Trp Arg Ala Lys Pro Asp Lys Ile 145 150 155 160 Ala Tyr <210> 43 <211> 151 <212> PRT <213> Artificial Sequence <400> 43 Glu Leu Thr Val Asn Ser Asp Glu His Phe Met Arg Glu Ala Leu Arg 1 5 10 15 Gln Ala Glu Ile Ala Tyr Glu Glu Gly Glu Ile Pro Val Gly Ala Val 20 25 30 Val Val Cys Gln Lys Lys Ile Ile Ala Lys Ala Tyr Asn Gln Thr Glu 35 40 45 Arg Leu Asn Asp Val Thr Ala His Ala Glu Met Leu Ala Ile Thr Ser 50 55 60 Ala Ala Asn His Leu Gly Gly Lys Tyr Leu Thr Asp Cys Thr Leu Tyr 65 70 75 80 Val Ser Leu Glu Pro Cys Gly Met Cys Ala Gly Ala Leu Asn Trp Ser 85 90 95 Gln Ile Ser Glu Ile Val Tyr Ala Val Ala Asn Glu Lys Arg Gly Phe 100 105 110 Thr Lys Ile Asn Pro Asn Met Ile His Pro Lys Thr Lys Val Lys Ser 115 120 125 Gly Leu Met Ala Ala Glu Ser Lys Lys Leu Ile Asp Asp Phe Phe Ala 130 135 140 Lys Met Arg Asn Lys Lys Asn 145 150 <210> 44 <211> 281 <212> PRT <213> Artificial Sequence <400> 44 Pro Arg Pro Ser Tyr Gly Val Ser Gly Thr Thr Gly Ala Glu Gly Ala 1 5 10 15 Ala Thr Arg Ala Ala Gly Ala Asp Arg Gly Gly Asn Asp Phe Leu Thr 20 25 30 Ser Gly Met Val Trp Ala Cys Val Asp Trp Ile Val Tyr Ile Ser Tyr 35 40 45 Asn Ile Ser Trp Ala Gln Gly Cys Gly Leu Gly Glu Phe Val Gly Ser 50 55 60 Arg Leu Gly Ala Asn Ile Ser Asn Cys Thr Gln Lys Arg His Leu Gly 65 70 75 80 Ala Ile Pro Lys Asn Asp Lys Ala Ser Asp Thr Lys Gly Leu Gln Gly 85 90 95 Tyr Ala Asn Tyr Lys Lys Gly Val Phe His Ile Pro Lys Pro Arg Ala 100 105 110 Gly Gly Ser Ser Pro Ser Arg Arg Thr Ile Ile Phe Lys Gly Glu Pro 115 120 125 Leu Leu Asn Gln Ala Gly Tyr Met Arg Glu Ala Leu Ala Glu Ala Glu 130 135 140 Lys Ala Tyr Ala Leu Gly Glu Val Pro Val Gly Ala Val Val Val Leu 145 150 155 160 Asp Asp Lys Ile Ile Gly Arg Gly His Asn Leu Arg Glu Thr Leu Leu 165 170 175 Asp Ser Thr Ala His Ala Glu Ile Ile Ala Leu Arg Gln Ala Ala Arg 180 185 190 His Ile Gly Asp Trp Arg Leu Asn Gly Ser Val Leu Tyr Val Thr Leu 195 200 205 Glu Pro Cys Pro Met Cys Ala Gly Ala Met Ile Gln Phe Arg Val Gln 210 215 220 Thr Leu Val Tyr Gly Val Gln Asn Pro Lys Ala Gly Ala Val Asp Ser 225 230 235 240 Ile Met Asp Val Val Arg Glu Pro Arg Phe Asn His Gln Val Ala Val 245 250 255 Val Ser Gly Val Leu Glu Asp Glu Cys Arg Ala Ile Leu Lys Arg Phe 260 265 270 Phe Lys Glu Leu Arg Gly Asn Lys Lys 275 280 <210> 45 <211> 226 <212> PRT <213> Artificial Sequence <400> 45 Asn Val Pro Lys Glu Arg Val Lys Gln Asn Met Cys Met Glu Glu His 1 5 10 15 Lys Thr Gln Glu Glu Pro Val Arg Glu Glu Leu Arg Lys Lys Asp Thr 20 25 30 Gly Glu Glu Glu Ala Lys Lys Glu Thr Arg Glu Glu Lys Lys Glu Glu 35 40 45 Glu Ser Gln Val Pro Ala Phe Ser Arg Lys Asp Ile Lys Tyr Met Lys 50 55 60 Glu Ala Ile Arg Gln Ala Lys Lys Ala Lys Asp Leu Gly Glu Val Pro 65 70 75 80 Ile Gly Cys Val Ile Val Tyr Glu Asp Arg Ile Ile Gly Arg Gly Tyr 85 90 95 Asn Arg Arg Asn Thr Asp Arg Ser Thr Leu Ala His Ala Glu Leu Ala 100 105 110 Ala Ile Arg Lys Ala Cys Lys Lys Met Gly Asp Trp Arg Leu Glu Gly 115 120 125 Cys Thr Met Tyr Val Thr Leu Glu Pro Cys Gln Met Cys Ser Gly Ala 130 135 140 Leu Val Gln Ser Arg Ile Ser Lys Val Val Ile Gly Val Met Asn Pro 145 150 155 160 Lys Ala Gly Cys Ala Gly Ser Val Leu Asn Leu Leu Gln Met Lys Ala 165 170 175 Phe Asn His Gln Val Asp Val Glu Tyr Gly Leu Cys Lys Glu Met Cys 180 185 190 Ala Glu Ile Leu Arg Asp Phe Phe Arg Asp Leu Arg Arg Lys Asn Lys 195 200 205 Glu Ile Arg Leu Gln Glu Arg Lys Gln Lys Glu Ile Gln Ser Gln Glu 210 215 220 Leu Gly 225 <210> 46 <211> 171 <212> PRT <213> Artificial Sequence <400> 46 Asp Arg Pro Asp Leu Ser Ala Ser Asp Ala Asp Leu Glu Arg Trp Met 1 5 10 15 Asp His Ala Leu Gly Leu Ala Ser Met Ala Ala Arg Asn Gly Glu Val 20 25 30 Pro Val Gly Ala Val Leu Leu Ser Ala Thr Gly Gln Leu Ile Ala Glu 35 40 45 Ala Val Asn Thr Pro Ile Ala Gln Cys Asp Pro Thr Ala His Ala Glu 50 55 60 Leu Ala Val Leu Arg Lys Gly Ala Leu Ala Thr Gly Asn Tyr Arg Leu 65 70 75 80 Thr Gly Thr Thr Leu Leu Val Thr Leu Glu Pro Cys Ala Met Cys Ala 85 90 95 Gly Ala Ile Cys His Ala Arg Ile Gly His Leu Val Tyr Gly Val Asp 100 105 110 Asn Pro Lys Gly Gly Ala Val Arg His Gly Ala Thr Leu Phe Asp Gln 115 120 125 Val Thr Thr His His Arg Pro Arg Val Thr Ala Gly Ile Arg Ala Asp 130 135 140 Glu Ser Ala Ala Leu Leu Arg Ser Phe Phe Ala Glu Arg Arg Ala Met 145 150 155 160 Thr Arg Pro Arg Arg His Gly Glu Ser Gly Pro 165 170 <210> 47 <211> 170 <212> PRT <213> Artificial Sequence <400> 47 Ile Ile Glu Gln Lys Pro Ser Lys Asn Gln Leu Lys Lys Asp Phe Phe 1 5 10 15 Trp Met Asn Lys Ser Leu Asp Leu Ala Lys Lys Ser Glu Ile Leu Gly 20 25 30 Glu Ile Pro Ile Gly Ala Val Leu Ile Tyr Gln Asp Asn Ile Val Ala 35 40 45 Ser Ser Gly Asn Glu Val Ile Leu Arg Asn Asp Pro Ser Ala His Ala 50 55 60 Glu Ile Ile Val Ile Arg Glu Gly Ala Lys His Phe Lys Asn Tyr Arg 65 70 75 80 Leu Lys Glu Asn Leu Thr Ile Tyr Val Thr Ile Phe Pro Cys Ile Met 85 90 95 Cys Met Gly Ala Ile Phe Gln Ser Arg Ile Ser Arg Val Val Tyr Gly 100 105 110 Ser Glu Asn Tyr Lys Asn Asn Leu Ser Phe Phe Leu Phe Glu Lys Asn 115 120 125 Asn Thr Asn Ile Ser Met Asn Tyr Gly His Ile Thr Val Tyr Gly Gly 130 135 140 Ile Leu Ser Arg Ser Cys Ser Ser Ile Leu Lys Asn Phe Phe Lys Lys 145 150 155 160 Arg Arg Asn Leu Ile Gln Pro Lys Lys Phe 165 170 <210> 48 <211> 360 <212> PRT <213> Artificial Sequence <400> 48 Ser Glu Ser Asp Asp Ala His Trp Met Arg Glu Ala Ile Ala Gln Ala 1 5 10 15 Arg Ala Ala Gln Gln Ala Gly Glu Val Pro Val Gly Ala Val Leu Val 20 25 30 Arg Asp Gly Gln Val Ile Ala Thr Gly Arg Asn Ala Pro Ile Ala Gly 35 40 45 His Asp Pro Thr Ala His Ala Glu Met Ala Ala Leu Arg Ala Gly Ala 50 55 60 Ala Gln Leu Ser Asn Tyr Arg Leu Asp Gly Cys Thr Leu Tyr Val Thr 65 70 75 80 Leu Glu Pro Cys Ala Met Cys Ser Gly Ala Met Leu His Ala Arg Leu 85 90 95 Pro Arg Val Val Tyr Gly Val Ala Asn Ala Lys Thr Gly Ala Ala Gly 100 105 110 Ser Val Val Asn Leu Phe Ala Glu Pro Arg Leu Asn His Gln Thr Ala 115 120 125 Val Gln Gly Gly Val Leu Ala Asp Glu Cys Gly Ala Leu Leu Ser Asp 130 135 140 Phe Phe Arg Asp Arg Arg Arg Ala Gln Arg Ala Gln Gln Leu Ala Ala 145 150 155 160 His Pro Leu Arg Gln Asp Ala Leu Arg Thr Pro Asp Ala Ala Phe Ala 165 170 175 His Leu Asp Gly Pro Ala Pro His Tyr Val Ser Asp Leu Pro Ala Leu 180 185 190 Ala Gly Leu Arg Leu His Tyr Leu Asp Glu Gly Pro Arg Asp Ala Ala 195 200 205 Arg Thr Trp Leu Leu Leu His Ala Ser Pro Gly Trp Ser His Gly Trp 210 215 220 Gln Pro Met Leu Ala Ala Phe Ala Gln Ala Gly His Arg Val Val Ala 225 230 235 240 Pro Asp Leu Ile Gly Phe Gly Arg Ser Asp Lys Pro Lys Lys Glu Ala 245 250 255 Ala His Arg Leu Asp Trp His Arg Gln Val Leu Ala Glu Leu Val Gln 260 265 270 Arg Leu Ala Leu Arg Gly Val Val Gln Val Ala Gln Pro Gly Ala Pro 275 280 285 Leu Leu Pro Asp Ala Val Leu Ala Pro Leu Val Arg Val Leu His Val 290 295 300 Arg Gly Gly Ala Pro Cys Asp Ala Ala Pro Phe Pro Asp Ala Gly His 305 310 315 320 Arg Ala Gly Pro Arg Ala Phe Ala Arg Phe Ala Asp Ala Asp Ala Ala 325 330 335 Pro Leu Leu Thr Val Pro Asp Ala Ser Ala Ala Ser Ala Leu Arg Ala 340 345 350 Met Glu Tyr Phe Thr Arg Tyr Ala 355 360 <210> 49 <211> 248 <212> PRT <213> Artificial Sequence <400> 49 Asn Glu Pro Leu Ala Cys Thr Ala Ser Ile Gly Ser Ser Ala Gln Thr 1 5 10 15 Glu Asp Ser Glu Lys Ser Val Asp Ala Ser Ile Gly Ala Val Ser Ala 20 25 30 Pro Thr Ala Asp His Pro Val Ala Gly Pro Gly Val Pro Pro Gly Asn 35 40 45 Ser Glu Ala Pro Ile Ile Ser Glu Arg Asp Leu Arg Phe Met Ala Leu 50 55 60 Ala Gln Ala Ala Ala Glu Glu Ala Arg Ala Ala Gly Glu Val Pro Val 65 70 75 80 Gly Ala Val Leu Val Arg Gly Asp Glu Val Ile Ala Thr Gly Phe Asn 85 90 95 His Pro Ile Gly Ala His Asp Pro Ser Ala His Ala Glu Met Val Ala 100 105 110 Leu Arg Ala Ala Ala Gln Ser Leu Glu Asn Tyr Arg Leu Pro Gly Cys 115 120 125 Glu Leu Tyr Val Thr Leu Glu Pro Cys Leu Met Cys Ala Gly Ala Ile 130 135 140 Met His Ala Arg Ile Ala Arg Val Val Phe Gly Val Arg Asn Pro Lys 145 150 155 160 Thr Gly Ala Cys Gly Ser Val Val Asp Ala Phe Ala Asn Pro Arg Leu 165 170 175 Asn His His Thr Thr Val Ser Gly Gly Val Leu Glu Ala Glu Cys Gly 180 185 190 Ala Ala Leu Arg Ser Phe Phe Ala Glu Arg Arg Arg Ala Ser Arg Ala 195 200 205 Ala Arg Ala Ala Ala Arg Gly Glu Ala Thr Lys Ala Val Glu Val Ala 210 215 220 Glu Gly Ser Val Gly Thr Ala Thr Asp Ser Ala Thr Gln Pro Asn Ser 225 230 235 240 Glu Pro Pro Pro Thr Thr Pro Leu 245 <210> 50 <211> 186 <212> PRT <213> Artificial Sequence <400> 50 Thr Pro Thr Phe Ala Pro Asp Leu Glu Ala Asp Arg Ala Phe Met Arg 1 5 10 15 Leu Ala Leu Asp Gln Ala Gln Asn Ala Trp Leu Leu Gly Glu Val Pro 20 25 30 Val Gly Ala Val Ile Val Lys Asp Gly Lys Val Ile Ala Thr Gly Tyr 35 40 45 Asn Arg Pro Ile Gly Asp His Asp Pro Thr Ala His Ala Glu Ile Val 50 55 60 Ala Leu Arg Gln Ala Ala His Leu Leu Gly Asn Tyr Arg Leu Pro Glu 65 70 75 80 Cys Thr Leu Tyr Val Thr Leu Glu Pro Cys Ala Met Cys Ala Met Ala 85 90 95 Leu Leu His Ala Arg Phe Ala Arg Val Val Phe Gly Val Arg Asn Pro 100 105 110 Lys Thr Gly Ala Ala Gly Ser Val Val Asp Leu Phe Ala Glu Pro Arg 115 120 125 Leu Asn His His Cys Asp Ile Thr Pro Glu Ile Glu Gln Glu Ala Cys 130 135 140 Ser Ala Leu Leu Gln Asp Phe Phe Arg Ala Arg Arg Lys Glu Gln Lys 145 150 155 160 Arg Pro Glu Glu Ser Val His Asp Ala Cys Leu Ser Gly Ile Glu Val 165 170 175 Thr Glu Leu Asp Ile Glu Pro Pro Leu Ser 180 185 <210> 51 <211> 233 <212> PRT <213> Artificial Sequence <400> 51 Ala Lys Asp Phe Ser Ile Phe Asp Gln Lys Met Met Gln Leu Ala Leu 1 5 10 15 Glu Glu Ala Lys Leu Ala Phe Asn Lys Glu Glu Val Pro Val Gly Ala 20 25 30 Val Leu Thr Leu Gly Asp Gln Val Ile Ala Arg Ala His Asn Thr Met 35 40 45 Glu Thr Lys Gly Asp Pro Thr Ala His Ala Glu Ile Leu Cys Ile Arg 50 55 60 Lys Gly Ala Glu Ala Ile Gly Asp Trp Arg Leu Leu Gly Ala Thr Leu 65 70 75 80 Tyr Thr Thr Leu Glu Pro Cys Val Met Cys Gly Gly Ala Met Leu Leu 85 90 95 Ala Arg Ile Thr Arg Val Val Trp Gly Val Pro Asn Ile Arg His Gly 100 105 110 Ser Asn Gly Ser Trp Ile Asp Leu Phe Glu Lys Lys His Pro Thr His 115 120 125 Gln Leu Glu Ile Ala Gly Gly Leu Tyr Glu Glu Glu Ala Ala Asn Leu 130 135 140 Met Arg Leu Phe Phe Lys Asp Lys Gly Gln Asn Met Lys Lys Thr Asn 145 150 155 160 Phe Leu Leu Val Glu Leu Phe Asp Glu Leu Ile Ala Phe Gln Glu Thr 165 170 175 Lys Leu Leu Asn Tyr Ala Ala Glu Ile Ile Pro Asn Val Thr Ser Asp 180 185 190 Asp Ile Leu Gln Pro Asn Asp Tyr Asp Glu Leu Glu Asn His Pro Phe 195 200 205 Phe Arg Tyr Glu Glu Gly Val Leu Lys Gly Ile Gln Thr Ala Lys Met 210 215 220 Ala Val Leu Ala Lys Leu Arg Glu Asp 225 230 <210> 52 <211> 517 <212> PRT <213> Artificial Sequence <400> 52 Ala Val Gly Val Ser Gly Gly Ala Asp Ser Val Ala Leu Leu Arg Ala 1 5 10 15 Leu Val Leu Val Gly Ala Arg Pro Val Ala Ala His Leu Asp His Ala 20 25 30 Leu Arg Pro Glu Ser Ala Gln Asp Ala Ala Trp Val Gly Ala Leu Ala 35 40 45 Ala Asp Leu Gly Val Pro Phe Gly Thr Ala Arg Val Asp Val Gly Ala 50 55 60 Val Ala Gly Arg Arg Gly Trp Asn Val Glu Glu Ala Ala Arg Arg Val 65 70 75 80 Arg Tyr Asp Phe Leu Ala Arg Thr Ala Arg Ala His Gly Ala Gly Leu 85 90 95 Val Leu Thr Ala His Thr Arg Arg Asp Gln Ala Glu Thr Val Leu Trp 100 105 110 Gly Leu Leu Arg Gly Glu Ala Thr Leu Arg Gly Ile Ala Pro Val Trp 115 120 125 Gly Arg Val Arg Arg Pro Trp Leu Asp Ala Pro Arg Ala Asp Leu Glu 130 135 140 Thr Phe Leu Arg Ala Leu Gly Gln Asp Trp Arg Glu Asp Pro Thr Asn 145 150 155 160 Ala Asp Pro Ala Tyr Thr Arg Ala Trp Leu Arg Cys Glu Val Met Pro 165 170 175 Val Leu Arg Ala Arg Phe Pro Ala Val Glu Glu Ala Leu Ala His Phe 180 185 190 Gly Arg Leu Asn Ala Glu Asp Asp Asp Ala Leu Ser Ala Gln Ala Ala 195 200 205 Ala Leu Ser Ala His Ala Pro Leu Glu Arg Gln Ser Pro Ala Val Leu 210 215 220 Arg Arg His Val Ala Ala Glu Leu Arg Ala Ala Gly Leu Glu Tyr His 225 230 235 240 Gly Leu His Val Gly Ala Leu Ala Glu Gly Leu Arg Ala Gly Thr Thr 245 250 255 Arg His Leu Thr Leu Pro Gly Pro Arg Glu Val Thr Val Thr Gly Gly 260 265 270 Arg Leu His Leu Gly Pro Leu Ala Trp Pro Gly Pro Asp Phe Ala Leu 275 280 285 Pro Ser Gly Trp Thr Arg Arg Thr Arg Gln Pro Gly Asp Arg Leu Arg 290 295 300 Leu Pro Gly Gly Thr Arg Lys Leu Ser Asp Val Leu Thr Asp Ala Lys 305 310 315 320 Val Pro Arg Ala Glu Arg Asp Arg Val Pro Leu Ala Val Asp Ala Gly 325 330 335 Gly Ala Val Gln Trp Val Gly Leu Thr Ser Pro Leu Trp Ala Ala Gly 340 345 350 Ala Arg Glu Ala Ala Gly Ala Val Pro Asp Pro Leu His Ala Ala Met 355 360 365 Gly Glu Ala Leu Ala Leu Ala His Glu Ala Ala Gly Ala Gly Glu Val 370 375 380 Pro Val Gly Ala Val Val Leu Asp Ala Ala Gly Gly Val Val Gly Arg 385 390 395 400 Gly Arg Asn Thr Ser Arg Glu His Gly Asp Met Thr Arg His Ala Glu 405 410 415 Leu Ala Ala Leu Arg Glu Ala Ser Glu Ala Val Gly Ala Tyr Leu Gly 420 425 430 Asp Cys Thr Leu Val Val Thr Leu Glu Pro Cys Pro Met Cys Leu Gly 435 440 445 Ala Ala Ile Glu Ala Arg Val Gly His Val Val Tyr Gly Val Ala Asn 450 455 460 Pro Lys Ala Gly Ala Leu Gly Gly Val Ala Asp Val Leu Ala Ala His 465 470 475 480 Trp Gly His Ala Pro Arg Val Thr Pro Gly Val Arg Ala Ala Glu Ala 485 490 495 Gly Ala Leu Leu Arg Arg Ser Phe Gln Ala Ile Arg Gly Gln Gly Arg 500 505 510 Gly Glu Asp Gly Ala 515 <210> 53 <211> 290 <212> PRT <213> Artificial Sequence <400> 53 Asp Val Val Asp Ser Arg Ser Asp Gln Asp Trp Met Arg Leu Ala Leu 1 5 10 15 Thr Leu Ala Gln Arg Ala Ala Ala Ala Gly Glu Val Pro Val Gly Ala 20 25 30 Leu Leu Val Arg Asp Gly Val Ile Ile Gly Glu Gly Trp Asn Arg Pro 35 40 45 Ile Lys Thr His Asp Ala Ser Ala His Ala Glu Ile Gln Ala Leu Arg 50 55 60 Asp Ala Gly Gln Arg Val Gly Asn Tyr Arg Leu Pro Gly Thr Thr Leu 65 70 75 80 Tyr Val Thr Leu Glu Pro Cys Val Met Cys Ala Gly Ala Ile Val His 85 90 95 Ala Arg Val Gly Gln Val Ile Tyr Gly Val Pro Asn Pro Lys Ala Gly 100 105 110 Ala Cys Gly Ser Val Phe Asp Leu Leu Pro Ser Asp Ala Arg Phe Asn 115 120 125 His Arg Thr Asp Cys Lys Gly Gly Val Leu Thr Asp Asp Cys Ala Glu 130 135 140 Thr Leu Arg Ala Phe Phe Arg Ala Arg Arg Ser Thr Ala Phe Lys Ala 145 150 155 160 Ala Thr Ser Arg Pro Glu Thr Ser Ile Met Ser Ile Asp Asn Val Tyr 165 170 175 Ser Asp Asp Ala Ile Arg Asn Arg Leu Ala Thr Glu Leu Pro Arg Trp 180 185 190 Ser Leu Asp Ala Gly Cys Leu Gln Arg Thr Tyr Arg Thr Ser Gly Trp 195 200 205 Lys Gly Thr Leu Met Val Ile Asn Thr Val Gly His Leu Ala Glu Ala 210 215 220 Ala Trp His His Pro Asp Leu Thr Ala Ser Tyr Asp Arg Val Thr Val 225 230 235 240 Ser Leu Thr Thr His Ser Ala Lys Gly Val Thr Asp Lys Asp Phe Glu 245 250 255 Leu Ala Asn Arg Ile Glu Glu Thr Val Met Trp Arg Pro Ala Ser Gly 260 265 270 Ser Ala Leu Glu Gly Thr Pro Asp Asp Val Arg Tyr Ala Tyr Ile Gln 275 280 285 Tyr Asp 290 <210> 54 <211> 182 <212> PRT <213> Artificial Sequence <400> 54 Pro Pro Ala Phe Ile Thr Gly Val Thr Ser Leu Ser Asp Val Glu Leu 1 5 10 15 Asp His Glu Tyr Trp Met Arg His Ala Leu Thr Leu Ala Lys Arg Ala 20 25 30 Trp Asp Glu Arg Glu Val Pro Val Gly Ala Val Leu Val His Asn His 35 40 45 Arg Val Ile Gly Glu Gly Trp Asn Arg Pro Ile Gly Arg His Asp Pro 50 55 60 Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln Gly Gly Leu Val Leu 65 70 75 80 Gln Asn Tyr Arg Leu Leu Asp Thr Thr Leu Tyr Val Thr Phe Glu Pro 85 90 95 Cys Val Met Cys Ala Gly Ala Met Val His Ser Arg Ile Gly Arg Val 100 105 110 Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala Ala Gly Ser Leu Ile 115 120 125 Asp Val Leu His His Pro Gly Met Asn His Arg Val Glu Ile Ile Glu 130 135 140 Gly Val Leu Arg Asp Glu Cys Ala Thr Leu Leu Ser Asp Phe Phe Arg 145 150 155 160 Met Arg Arg Gln Glu Ile Lys Ala Leu Lys Lys Ala Asp Arg Ala Glu 165 170 175 Gly Ala Gly Pro Ala Val 180 <210> 55 <211> 155 <212> PRT <213> Artificial Sequence <400> 55 Thr Asn Asp Ile Tyr Phe Met Thr Leu Ala Ile Glu Glu Ala Lys Lys 1 5 10 15 Ala Ala Gln Leu Gly Glu Val Pro Ile Gly Ala Ile Ile Thr Lys Asp 20 25 30 Asp Glu Val Ile Ala Arg Ala His Asn Leu Arg Glu Thr Leu Gln Gln 35 40 45 Pro Thr Ala His Ala Glu His Ile Ala Ile Glu Arg Ala Ala Lys Val 50 55 60 Leu Gly Ser Trp Arg Leu Glu Gly Cys Thr Leu Tyr Val Thr Leu Glu 65 70 75 80 Pro Cys Val Met Cys Ala Gly Thr Ile Val Met Ser Arg Ile Pro Arg 85 90 95 Val Val Tyr Gly Val Asp Asn Pro Lys Gly Gly Cys Ser Gly Ser Leu 100 105 110 Met Asn Leu Leu Gln Gln Ser Asn Phe Asn His Arg Ala Ile Val Asp 115 120 125 Lys Gly Val Leu Lys Glu Ala Cys Ser Thr Leu Leu Thr Thr Phe Phe 130 135 140 Lys Asn Leu Arg Ala Asn Lys Lys Ser Thr Asn 145 150 155 <210> 56 <211> 178 <212> PRT <213> Artificial Sequence <400> 56 Glu Leu Gly Glu Ser Phe Leu Met Pro Tyr Ser Leu Glu Glu Gln Thr 1 5 10 15 Tyr Phe Met Gln Glu Ala Leu Lys Glu Ser Glu Lys Ser Leu Gln Lys 20 25 30 Ala Glu Ile Pro Ile Gly Cys Val Ile Val Lys Asp Gly Glu Ile Ile 35 40 45 Gly Arg Gly His Asn Ala Arg Glu Glu Ser Asn Gln Ala Ile Met His 50 55 60 Ala Glu Met Met Ala Ile Asn Glu Ala Asn Ala His Glu Gly Asn Trp 65 70 75 80 Arg Leu Leu Asp Thr Thr Leu Phe Val Thr Ile Glu Pro Cys Val Met 85 90 95 Cys Ser Gly Ala Ile Gly Leu Ala Arg Ile Pro His Val Ile Tyr Gly 100 105 110 Val Ser Asn Gln Lys Phe Gly Gly Val Asp Ser Leu Tyr Gln Ile Leu 115 120 125 Thr Asp Glu Arg Leu Asn His Arg Val Gln Val Glu Arg Gly Leu Leu 130 135 140 Ala Ala Asp Cys Ala Asn Ile Met Gln Thr Phe Phe Arg Gln Gly Arg 145 150 155 160 Glu Arg Lys Lys Ile Ala Lys His Leu Ile Lys Glu Gln Ser Asp Pro 165 170 175 Phe Asp <210> 57 <211> 349 <212> PRT <213> Artificial Sequence <400> 57 Ser Val Pro Ala Asn Pro Cys Gly Ala Pro Leu Ala Asp Ala Asp Arg 1 5 10 15 Leu Glu Ala Gly Lys Ala Ser Ala Ala Pro Leu Glu Gly Ala Ser Gly 20 25 30 Val Asp Leu Ile Gly Gly Asp Ala Ala Cys Gly Thr Ala Gly Ala Gly 35 40 45 Phe Ala Ala Thr Thr Gln Ala Ala Arg Thr Ser Lys Val Pro Ala Ala 50 55 60 Thr Ala Ser Asp Pro Ala Ala Gln Ala Ser Val Ala His Thr Ala Ser 65 70 75 80 Ala Pro Thr Thr Ala Glu His Thr Ala Thr Gly Arg Thr Pro Ala Ala 85 90 95 His Ala Tyr Ala Thr Gln Thr Pro Ala His His Thr Pro Ala Glu Pro 100 105 110 Thr Pro Ala Glu Pro Thr Pro Ala Gln Pro Thr Pro Ala Gln Pro Thr 115 120 125 Pro Ala Gln Pro Thr Pro Ala Gln Pro Thr Pro Ala Gln Pro Thr Pro 130 135 140 Ala Glu Pro Thr Pro Ala Glu Pro Thr Pro Ala Glu Pro Thr Pro Ala 145 150 155 160 Glu Pro Thr Pro Ala Glu Pro Thr Pro Thr Thr Pro Ala Pro Thr Val 165 170 175 Ser Glu Arg Asp Leu Arg Phe Met Ala Leu Ala Gln Ala Ala Ala Glu 180 185 190 Glu Ala Arg Ala Ala Gly Glu Val Pro Val Gly Ala Val Leu Val Arg 195 200 205 Gly Asp Glu Val Ile Ala Lys Gly Phe Asn His Pro Ile Ser Ala His 210 215 220 Asp Pro Ser Ala His Ala Glu Met Val Ala Leu Arg Ala Ala Ala Gln 225 230 235 240 Val Val Glu Asn Tyr Arg Leu Pro Gly Cys Glu Leu Tyr Val Thr Leu 245 250 255 Glu Pro Cys Leu Met Cys Ala Gly Ala Ile Met His Ala Arg Ile Ala 260 265 270 Arg Val Val Phe Gly Val Arg Asn Pro Lys Thr Gly Ala Cys Gly Ser 275 280 285 Val Val Asp Ala Phe Ala Asn Pro Gln Leu Asn His His Thr Glu Val 290 295 300 Thr Gly Gly Val Leu Glu Asn Glu Cys Gly Ala Ala Leu Lys Ser Phe 305 310 315 320 Phe Ala Glu Arg Arg Arg Ala Ser Arg Asp Ala Arg Ala Ala Ala Arg 325 330 335 Ala Gly Asn Gly Ala Gln Ala Glu Pro Asn Glu Pro Arg 340 345 <210> 58 <211> 165 <212> PRT <213> Artificial Sequence <400> 58 Glu Val Glu Phe Ser His Glu Tyr Trp Met Arg His Ala Leu Thr Leu 1 5 10 15 Ala Lys Arg Ala Trp Asp Glu Arg Glu Val Pro Val Gly Ala Val Leu 20 25 30 Val His Asn Asn Arg Val Ile Gly Glu Gly Trp Asn Arg Pro Ile Gly 35 40 45 Arg His Asp Pro Thr Ala His Ala Glu Ile Met Ala Leu Arg Gln Gly 50 55 60 Gly Leu Val Met Gln Asn Tyr Arg Leu Ile Asp Ala Thr Leu Tyr Val 65 70 75 80 Thr Leu Glu Pro Cys Val Met Cys Ala Gly Ala Met Ile His Ser Arg 85 90 95 Ile Gly Arg Val Val Phe Gly Val Arg Asn Ala Lys Thr Gly Ala Ala 100 105 110 Gly Ser Leu Met Asp Val Leu His His Pro Gly Met Asn His Arg Val 115 120 125 Glu Ile Thr Glu Gly Ile Leu Ala Asp Glu Cys Ala Ala Leu Leu Ser 130 135 140 Asp Phe Phe Arg Met Arg Arg Gln Glu Ile Lys Ala Gln Lys Lys Ala 145 150 155 160 Gln Ser Ser Thr Asp 165

Claims

1. A base editor, characterized in that After adding NLS sequence and linker sequence to 5' and 3' of mutant TadA-8e, respectively, NLS-mutant TadA-8e-linker is obtained, and NLS-mutant TadA-8e-linker is placed at the N-terminus, C-terminus or internal fusion site of Cas nuclease to form a fusion protein; Wherein, NLS-mutant TadA-8e-linker means that one or more of the amino acids in TadA-8e are mutated relative to NLS-TadA-8e-linker, the amino acid sequence of NLS-TadA-8e-linker is shown in SEQ ID NO.4, and the amino acid sequence of NLS-mutant TadA-8e-linker is the amino acid sequence obtained by replacing TadA-8e with mutant TadA-8e in the amino acid sequence of NLS-TadA-8e-linker; The mutant TadA-8e is selected from one of the following deaminases obtained by mutation in any one of (1) to (2): (1) Deaminases obtained by making the following single-point mutations in the amino acids of TadA-8e: N46L, N46P, N46C, N46Q, N46D; (2) Deaminase obtained by making the following double-point mutations in the amino acids of TadA-8e: V28G-N46L, V28G-N46C, V28G-N46P, V28W-N46L, V28W-N46C, V28W-N46P, N46P-N108Y, N46P-N108S , N46P-N108Q, N46P-N108D, N46P-N108C, N46P-N108H, N46P-F84M, N46P-I49A, N46P-I49G, N46P-A4 8G, N46C-N108Y, N46C-N108S, N46C-N108Q, N46C-N108M, N46C-N108C, N46C-N108H, N46L-N108Y, N4 6L-N108Q, N46L-N108D, N46L-N108M, N46L-N108H, N46L-F84M, N46L-I49A, N46L-I49G, N46L-V82G, N46C-V82G, N46C-V82T, N46C-F84M, N46L-V82T, N46P-F84M, N46P-N108M.

2. The base editor according to claim 1, characterized in that The Cas nuclease is selected as nSpCas9, and the internal fusion sites are the 113th, 203rd, 312th, 459th, 535th, 583th, 687th, 701st, 715th, 730th, 770th, 793th, 801st, 895th, 905th, 919th, 946th, 1010th, 1029th, 1047th, 1117th, 1154th, 1249th, and 1282nd fusion sites.

3. The method for constructing the base editor according to claim 1, characterized in that: The following steps are involved: The mutant TadA-8e and Cas nuclease were fused at different sites to construct a base editor. The amino acid sequence of TadA-8e is shown in SEQ ID NO.

1.

4. Application of base editor CBE for non-disease diagnosis and treatment purposes, characterized in that: The base editor CBE mediates C·G--T·A mutation; The base editor CBE refers to a fusion protein formed by fusion of the deaminase obtained by performing the following mutations on the amino acids in TadA-8e and placing it at the N-terminus of nSpCas9 and the 1249th fusion site. The amino acid sequence of TadA-8e is shown in SEQ ID NO.

1. Single point mutation: N46P Double point mutations: V28W-N46L, V28W-N46C, V28W-N46P, N46P-N108Y, N46P-N108S, N46P-N108Q, N46P-N108D, N46P-N108C, N46P-N108H, N46P-F84M, N46P-I49A, N46P-I49G, N46P-A48G, N46C-N108Q, N46C-N108M, N46 C-N108C, N46C-N108H, N46L-N108Y, N46L-N108Q, N46L-N108D, N46L-N108M, N46L-N108H, N46L-F84M , N46L-I49A, N46L-I49G, N46L-V82G, V28G-N46L, N46C-N108S, N46C-N108Y, V28G-N46P, V28G-N46C.

5. Application of base editor ACBE for non-disease diagnosis and treatment purposes, characterized in that: The base editor ACBE mediates A·T--G·C and C·G--T·A mutations; Base editor ACBE refers to a fusion protein formed by fusion of the deaminase obtained by point mutation of amino acids in TadA-8e to the N-terminus and the 1249th fusion site of nSpCas9. This type of fusion protein has the ability to mediate A·T--G·C and C·G--T·A mutations. The amino acid sequence of TadA-8e is shown in SEQ ID NO.1; Among them, the deaminase obtained by making the following single-point mutation in the amino acid in TadA-8e: N46C.

6. A polynucleotide, characterized in that Encoding the base editor according to any one of claims 1-2.

7. A carrier, characterized in that Containing the polynucleotide according to claim 6.

8. A host cell, characterized in that Contains the base editor according to any one of claims 1-2, or contains the vector according to claim 7.